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ABSTRACT 
Platelet-derived eicosanoids play important signalling roles in haemostasis and 
innate immunity and have major medical implications in cardiovascular disease, 
inflammation and cancer. Therefore, identification and characterisation of novel 
platelet lipids is an important goal. Prior to my PhD, our group identified a novel 
cyclooxygenase-1 (COX-1) product generated by platelets upon agonist activation in 
an aspirin–sensitive manner. Preliminary structural data suggested this lipid to be 8-
hydroxy-9,11-dioxolane eicosatrienoic acid (DXA3) (Aldrovandi, unpublished). 
However, this required further investigation and its biology was unknown. In this 
study, I undertook a detailed structural characterisation of DXA3. Using GC/MS, high 
resolution LC/MSn and UV enabled structural characterisation of the lipid. Through 
pharmacological studies on isolated platelets and using mutant COX-2 enzymes, I 
revealed a distinct enzymatic mechanism of COX where the dioxolane forms within 
the COX catalytic site, then a radical escapes from the enzyme to form DXA3 possibly 
via a peroxidase. I developed a quantitative assay and showed that DXA3 is generated 
in ng amounts by thrombin-activated platelets (human and murine) with 77% of 
DXA3 esterified to phosphatidylethanolamine (PE). In addition to platelets, I detected 
the lipid in human serum derived from whole blood following clot formation in vitro 
and the macrophage cell line RAW246.7 in response to calcium ionophore A23187 
stimulation. Last, DXA3 stimulated expression of the integrin Mac-1 on human 
neutrophils. In conclusion, DXA3 represents a novel eicosanoid, generated by 
activated platelets that activates neutrophils and may play a role in early immune 
responses.  
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1.1 EICOSANOIDS 
Eicosanoids are oxidation products of 20 carbon polyunsaturated fatty acids such as 
arachidonate that play an important signalling role in haemostasis and innate 
immunity (Smith & Murphy 2002; Fahy 2005). They are generated via three 
enzymatic pathways, namely cyclooxygenases (COXs) (described in 1.3), 
lipoxygenases (LOXs) and epoxygenases (Scheme 1.1) (Smith 1989; O’Donnell & 
Murphy 2012; Wolfe 1982; Hammond & O’Donnell 2012; Smith & Murphy 2002).  
COXs oxidise arachidonate to PGH2, which subsequently form prostanoids, e.g. 
thromboxane (Tx) and Prostaglandin E2 (PGE2) (Smith & Murphy 2002). The 
structures, signalling receptors and functions of the mayor prostanoids are shown in 
Table 1.1. In this thesis I will characterise a novel lipid generated by cyclooxygenase-
1 (COX-1). Therefore, COX biology and prostanoid function will be described in more 
detail in 1.3. 
LOXs mediate synthesis of hydroperoxy eicosatetraenoic acids (HpETEs) from 
arachidonate. These unstable intermediates act as precursors for formation of 
hydroxy eicosatetraenoic acids (HETEs), dihydroxyeicosatetraenoic acids (DIHETEs), 
lipoxins and leukotrienes (Rådmark 2002; Borgeat et al. 1976; Serhan et al. 1986; 
Goetzl & Sun 1979; Lindgren 1981). LOX products are generated by several tissues 
and cell types such as platelets and leukocytes, and play an important role in  
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Scheme 1.1. Eicosanoid generation via cyclooxygenases (COXs), Lipoxygenases 
(LOXs) and Epoxygenases. Modified from Smith & Murphy 2002; Hammond & 
O’Donnell 2012. 
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Table 1.1 Chemical structures, generating enzymes, signalling receptors, and 
mediated functions of the major COX products. 
Chemical structures drawn using Chemsketch (ACD labs). Matsunobu et al. 2013; 
Okuno et al 2008,2015; Hirata and Narumiya 2011; Yuhki et al. 2011; Takahashi et al. 
2002; Nagao et al. 2003; Zhou et al. 2007; Nakajima et al. 2010; Sugimoto et al. 1997; 
Alexander, et al. 2002; Liu et al. 2014 
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inflammation, for example by acting as chemoattractants (Goetzl et al. 1980; Bryant 
et al. 1982; Rabinovitch et al. 1981; Hamberg & Samuelsson 1974; Jakschik et al. 
1980; Samuelsson 1983; Kühn & O’Donnell 2006; Smith & Murphy 2002; Bray et al. 
1981). 
Epoxygenases synthesise 5,6-, 8,9-, 11,12- and 14,15-epoxy eicosatrienoic acids 
(EETs) from arachidonate (Capdevila et al. 2000; Zeldin 2001; Daikh et al. 1994). EETs 
are generated by several tissues and cells including liver, heart or endothelial cells 
(Rosolowsky & Campbell 1996; Zeldin et al. 1996). They mediate a wide range of 
biological functions including vasodilation, inhibiting calcium mobilization, and 
decreasing ischemic and/or reperfusion injury (Pratt et al. 2002; Node et al. 1999; 
Rosolowsky & Campbell 1993; Chen et al. 1999; Gross et al. 2005). 
In addition to their physiological roles, eicosanoids are associated with a range of 
diseases including cancer, artherosclerosis and Alzheimer’s disease suggesting that 
they mediate important roles in both health and disease (Manev et al. 2011; McGeer 
& McGeer 1999; Greene et al. 2011; Sheng et al. 1997; Levy 1997; Theken et al. 2012; 
Smith et al. 1984; Willis et al. 1986). Consequently, studies characterising eicosanoid 
signalling and function and moreover, the identification of novel eicosanoids are 
essential for furthering our understanding of the biological significance of this lipid 
family.  
 
1.2 PLATELETS 
Platelets are anucleate circulating cells that play important roles in haemostasis, 
inflammation, wound healing and immune responses (Machlus & Italiano 2013). 
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After erythrocytes, platelets are the most abundant blood cell. In an adult human the 
normal platelet count is 150-350 x 109 L-1 and approximately 100 billion are generated 
per day (Thon et al. 2012; George 2000).  
 
1.2.1 PLATELET LIFECYCLE: FROM PRODUCTION TO DESTRUCTION 
The progenitors for platelets, megakaryocytes (MKs), are large (50-100 μm) bone 
marrow resident cells (Wright 1906, Pease 1956; Nakeff & Floeh 1976). During the 
first stage of platelet formation, MKs undergo maturation and become polyploid in 
shape with an enlarged cytoplasm. Simultaneously, they become filled with 
cytoskeletal proteins and platelet-specific granules (Bartley et al. 1994; de Sauvage 
et al. 1994; Kaushansky et al. 1994). During the second stage of platelet formation, 
residual cell bodies and nuclear material are degraded and 10-20 proplatelets are 
packed within each MK (Richardson et al. 2005). MKs migrate to the vascular niche 
and release the proplatelets into sinusoidal blood vessels (Zhang et al. 2012) During 
the final stage proplatelets elongate, thin and branch, forming platelets at their tips, 
that subsequently fragment into individual cells (Richardson et al. 2005; Thon et al. 
2010).  
Human platelets circulate in the bloodstream with a typical life span of 7 - 10 days 
(Mustard et al. 1966; Murphy & Francis 1971). After this time, they are selectively 
removed by the reticuloendothelial system. This is regulated by anti- and pro-
apoptotic BcL-2 family proteins (Bcl-XL, Bak, and Bax) and a proteasome, multiprotein 
complex  (Nayak et al. 2013; Mason et al. 2007; Nussbaum et al. 1998). A fine balance 
between platelet synthesis and destruction maintains the number of mature 
platelets in the circulation (Kaushansky 2005; Mason et al. 2007). 
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1.2.2 PLATELET STRUCTURE 
Resting platelets are discoid with a smooth, undulating surface (Feder et al. 1985). 
As the smallest component of the blood, they range between 1 - 2 μm in diameter 
(Nayak et al. 2013; Kamath 2001). They contain a large surface area due to an open 
canalicular system that connects the surface with the cytoplasm along with α-
granules, dense granules and lysosomes. Upon activation granules fuse with the 
membrane and release their contents into the extracellular space. Platelets also 
contain a dense tubular system, which is a derivative of the smooth endoplasmic 
reticulum derived from the megakaryocyte. This sequesters calcium and is important 
during platelet activation (Ebbeling et al. 1992; White 1972). 
The well-defined cytoskeleton maintains the platelet’s disc shape and integrity when 
they are exposed to shear forces in the circulation (Semple et al. 2011). Following 
activation, calcium is mobilized leading to the formation of filopodia and pseusopods, 
and enabling the disc shaped platelet to change into spiny spheres (Hartwig 1992).  
 
1.2.3 PLATELETS IN HAEMOSTASIS AND IMMUNE RESPONSES 
Platelets play a central role in haemostasis and immune responses through direct 
interaction with other cells or via the mediators they release. They store bioactive 
mediators in their granules that are released on activation, including small molecules 
such as adenosine diphosphate (ADP) and calcium, and proteins, e.g. growth factors, 
cytokines and haemostatic factors (Marcus et al. 1966; Martin et al. 1974; 
Whiteheart 2011; Coppinger et al. 2004). Furthermore, platelets contain mRNA and 
all the translational machinery to generate proteins (Denis et al. 2005; Lindemann & 
Gawaz 2007; Shashkin et al. 2008). Proteomic analysis revealed that thrombin-
 27 
 
activated platelets release approxmately 300 proteins that are involved in both 
haemostasis and immune responses (Coppinger et al. 2004). A major early event 
during platelet activation is the generation of eicosanoids. During this, 
phospholipases are activated that cleave fatty acids from the sn2 position of 
phospholipids (further description see 1.3.3.1). Arachidonate is the most abundant 
fatty acid released and is oxidised by LOX and COX enzymes as a substrate to generate 
eicosanoids such as thromboxane A2 (TxA2) and 12-HETE (O’Donnell et al. 2014). The 
proaggregatory TxA2 represents a major product generated by COX and 
thromboxane synthase (TxS). Following generation in ng amounts, this is quickly 
converted to TxB2. TxA2 binds to G-protein coupled receptors (TPα and β), mainly 
expressed by platelets and smooth muscle cells (Raychowdhury et al. 1994). 
Activation of TP receptors results in intracellular activation of phospholipase C and 
calcium release from intracellular stores (Dorn & Becker 1993). This induces platelet 
aggregation and smooth muscle contraction, highlighting a key role for TxA2 during 
haemostasis (Chiyotani et al. 1992; Spurney et al. 1993). 
 
1.2.3.1 PLATELETS IN HAEMOSTASIS 
Following injury to the blood vessel, circulating platelets bind to matrix proteins such 
as the collagen substratum that becomes exposed on the endothelium. This enables 
platelet activation, and shape change, with release of granule contents and newly 
synthesised mediators such as TxA2. Consequently, as more platelets become 
recruited and activated, the cycle continues with binding to fibrinogen and formation 
of a clot that seals the damaged vessel (Scheme 1.2)  
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Scheme 1.2. Platelets in haemostasis. In the event of vascular injury, collagen and 
other membrane proteins become exposed at the vessel lumen. This leads to 
adhesion and activation of circulating platelets (A). Consequently, activated platelets 
release mediators such as ADP and TxA2 resulting in further platelet activation (B). 
Simultaneously, the coagulation cascade is activated leading to the formation of 
thrombin, which causes the further activation of platelets and the enhanced 
formation of fibrin. Fibrin forms stands, which stabilize the platelet plaque to prevent 
bleeding (C). Modified from Semple et al. 2011. 
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(Richardson et al. 2005; Semple et al. 2011). Platelet activation by TxA2 is 
counteracted by prostacyclin (PGI2) and PGE2, which are synthesised by endothelial 
cells and inhibit platelet aggregation and induce vasodilatation (Van Hinsbergh 2012; 
Shankarraman et al. 2012). The regulation of clot formation by pro- and anti-
aggregatory stimuli maintains a balance between coagulation and bleeding in healthy 
individuals. An imbalance can either lead to elongated bleeding or thrombosis, which 
is often a consequence of cardiovascular diseases (CVD). For example, 
atherosclerosis and its thrombotic complications are the largest cause of morbidity 
and mortality in the industrialized world. Atherosclerosis is an inflammatory multi-
factorial disease characterised by thickening and hardening of arteries (Zaman et al. 
2000). This disease is further characterised by accumulation of primarily leukocytes, 
endothelial cells, lipids and smooth muscle cells forming an atherosclerotic lesion 
within the intima of arteries (Swirski & Nahrendorf 2013; Elneihoum 1997; de Korte 
2002; Jonasson et al. 1985). Most atherosclerotic lesions remain asymptomatic until 
the lesion ruptures resulting in exposure of collagen that can interact with circulating 
platelets causing their adhesion and activation (Penz 2005). Simultaneously, tissue 
factor is released by smooth muscle cells and monocytes resulting in further 
recruitment and activation of platelets and subsequently formation of a thrombotic 
clot on the lesion surface (Libby 2005). Rupture of these clots leads to acute 
myocardial infarction and/or stroke. To prevent thrombus formation, CVD patients 
are administered antithrombotic therapies that can include the inhibition of the 
proaggregatory TxA2 by either aspirin that targets COX-1 (1.3.7) or by thromboxane 
receptor antagonists  
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such as terutroban (S18886) that targets TxA2 signalling (Viles-Gonzalez et al. 2005; 
Lesault et al. 2011).  
 
1.2.3.2 PLATELETS IN IMMUNE RESPONSES AND THE INTERACTION WITH LEUKOCYTES 
In addition to their essential role in haemostasis, platelets also participate in immune 
responses through their interactions with leukocytes via receptor cross-talk or the 
secretion of eicosanoids. At the site of injury platelets induce both haemostasis and 
leukocyte recruitment. The circulating platelets adhere to exposed subendothelial 
matrix through interaction with matrix proteins and then become activated.  
Following activation, several platelet receptors become externalised, including P-
selectin, which interacts with the P-selectin glycoprotein ligand-1 (PSGL-1) present 
on the surface of polymorphonuclear leukocytes (PMNs) and Mac-1 on dendritic cells 
(DCs) and neutrophils. This induces rolling and adhesion of the PMNs and activation 
(Weyrich & Zimmerman 2004; V Sreeramkumar et al. 2014; Langer et al. 2007). 
Secretion of platelet-activating factor (PAF) and platelet derived cytokines such as 
platelet factor 4 (CXCL4), leads to the expression of β2 integrins on the PMN surface, 
which are essential for their adhesion and migration (Weyrich & Zimmerman 2004; 
Gleissner et al. 2008; Brandt et al. 2000). Platelet-neutrophil interactions aid 
neutrophil adhesion to the endothelium and induce neutrophil extracellular trap 
(NET) release that results in increased bacterial clearance in vivo. These interactions 
are not only mediated by P-selectin but also toll like receptor 4 (TLR4) (Sreeramkumar 
et al. 2014; Clark et al. 2007; Andonegui et al. 2005). Platelets also express TLRs 1, 2, 
6 and 9 on their surface following activation suggesting an active role in immune 
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reactions (Shiraki et al. 2004; Andonegui et al. 2005; Cognasse et al. 2005; Aslam et 
al. 2006). Furthermore, they express CD40 ligand (CD40L), a transmembrane protein 
structurally related to the cytokine TNF-α, in response to activation (Henn et al. 
1998). Platelet CD40L enables interaction with T-cells and endothelial cells, resulting 
in increased T-cell recruitment, chemokine and adhesion molecule secretion, and 
inhibiting endothelial cell migration (Danese et al. 2004; Henn et al. 1998; Henn et al. 
2001).  
Circulating platelets can also interact with leukocytes to form aggregates. Platelet-
leukocyte aggregates are detected in patients with inflammatory or thrombotic 
conditions (Schrottmaier et al. 2015). P-selectin mediated platelet-leukocyte 
interactions are greatest for monocytes and neutrophils (Rinder et al. 1991). Platelet-
monocyte and -neutrophil interactions can result in either pro- or anti-inflammatory 
responses. For example, platelet-neutrophil clusters generate lipoxin A4 (LXA4), 
which regulates downstream vascular inflammatory responses. Platelet-monocyte 
interactions enhance the number of activated monocytes in the circulation 
suggesting pro-inflammatory properties (Passacquale et al. 2011; Gudbrandsdottir et 
al. 2013; Corken et al. 2014; Zarbock et al. 2007; Schrottmaier et al. 2015; 
Brancaleone et al. 2013). Of relevance, increased levels of platelet-leukocyte 
aggregates have been detected in patients with acute thrombotic events, such as 
myocardial infarction or stroke suggesting an involvement of these aggregates in 
disease (Mickelson et al. 1996; Michelson et al. 2001; Htun et al. 2006). Although 
several signalling molecules that trigger platelet-leukocyte interaction have been 
identified, the roles of platelet-derived lipid mediators in immune responses remain 
unclear. A notable example of a platelet derived lipid that leads to neutrophil 
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recruitment is platelet-activating factor (PAF), which is a pro-inflammatory 
phosphoglyceride (Kulkarni et al. 2007; Hanahan 1986; Prescott et al. 2000). 
However, the role of platelet-derived eicosanoids in immune responses remains 
poorly understood. Inhibition of COX-1 by aspirin reduces the formation of platelet-
leukocyte aggregates, inhibits the release of platelet derived CD40L, and reduces 
platelet-induced formation of reactive oxygen species (ROS) by monocytes 
(Miedzobrodzki et al. 2010; Santilli et al. 2006; Nannizzi-Alaimo et al. 2003). These 
studies indicate that platelet COX-1 products affect platelet-leukocyte interactions 
and platelet mediated leukocyte function. However, it is unknown whether these 
effects occur because of reduced platelet activation as a consequence of reduced 
TxA2 levels or whether COX-1-derived lipids mediate these interaction and functions. 
Therefore, the identification and characterisation of platelet derived mediators and 
their effects upon haemostasis and immunity warrant detailed study. 
 
1.3 CYCLOOXYGENASES 
Cyclooxygenases-1 and -2 (COX-1 and -2) are the generic names for prostaglandin 
endoperoxide H synthases-1 and 2 and so the term COX will be used from here on. 
COXs catalyse the first committed step in prostanoid synthesis, namely the 
conversion of arachidonate and oxygen to prostaglandin H2 (PGH2). PGH2 is the 
precursor for PGs and Tx. COX-1 and COX-2 are homodimeric, membrane-bound, 
glycosylated proteins that contain a heme group and two catalytic sites (1.3.2). 
Pharmacologically, they are important targets of NSAIDs such as aspirin and 
ibuprofen (1.3.7).  
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Prior to my PhD, our group discovered a new lipid generated by COX-1 in activated 
platelets. Preliminary structural analysis suggested that the lipid is a novel COX 
product. Based on this data, this lipid was proposed to be 8-hydroxyl, 9,11-dioxolane 
eicosatrienoic acid (DXA3). However, its structure was not fully established, and its 
cellular biology, including synthetic pathway of generation and biological actions 
were unknown. Therefore, in this thesis I undertook a detailed structural and 
functional analysis of this novel lipid. A full description of the discovery of DXA3 will 
be shown in 1.5. 
 
1.3.1 HISTORY AND CLASSIFICATION OF COX AND ITS PRODUCTS 
Goldblatt and Euler independently discovered prostaglandins in the 1930s. The 
purified “substances” from prostate gland extracts and seminal vesicles lowered 
blood pressure and caused contraction of smooth muscle cells. In reference to the 
tissue in which these substances were first discovered, Euler named them 
prostaglandins (Goldblatt 1935; Euler 1935; Euler 1936). In the 1960s, several 
researchers attempted to purify prostaglandins and reveal their structure, and these 
later were identified and named as PGE 1, 2, 3, PGF 1α, and 2α (Structures of PGE2 
and PGF2α shown in Table 1.1) (Bergstroem et al. 1963; Samuelsson 1963; 
Bergstroem & Sjoevall 1960). Bergstroem & Sjoevall were the first to propose a 
chemical formula of C20H34O5 for prostaglandins and in 1964, the 20-carbon long 
chain fatty acid arachidonate was identified as the substrate for prostaglandin 
synthesis (Bergstroem et al. 1964; van Dorp et al. 1964). In 1967, the enzymatic 
pathway responsible for the conversion of arachidonate to prostaglandins was 
discovered (Hamberg & Samuelsson 1967). Subsequently, Smith and Willis (1969, 
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1973) demonstrated that platelets generate prostaglandins during clotting. Aspirin 
had already been marketed for 74 years but its biological function remained 
unknown until 1971, when Sir John Vane discovered that aspirin blocked 
prostaglandin synthesis. This Nobel prize winning discovery led to an enormous 
increase in prostaglandin research. In 1973, an endoperoxide product (PGG2) was 
postulated as an intermediate in the prostaglandin synthesis pathway (Hamberg & 
Samuelsson 1973; Mats Hamberg & Samuelsson 1974). Soon after, the enzyme 
responsible for prostaglandin synthesis was purified from bovine seminal vesicles 
and termed prostaglandin H synthase or prostaglandin endoperoxide synthase (E.C. 
1.14.99.1), typically referred to as COX (Hemler et al. 1976; van der Ouderaa et al. 
1977; Miyamoto et al. 1976). The identification of the gene encoding COX-1 then led 
to the cloning of the COX-1 enzyme in the 1980s (DeWitt & Smith 1988; Merlie et al. 
1988). Functionally, researchers had already proposed in the 1970s that COX elicited 
both cyclooxygenase and peroxidase activity, but only 12 years later, in 1988, was it 
demonstrated that the enzyme has two distinct enzymatic sites (O’Brian &Rahimtula 
1976; Marshall & Kulmacz 1988). 
In the 1970s, researchers began to speculate whether there was more than one COX 
isoform. In 1972, Smith and Lands (1972) proposed two distinct prostaglandin 
synthase activities in acetone powder extracts of sheep vesicular glands. During the 
1980s, studies investigating NSAID inhibition and time course profiles of PGE2 and 
PGF2α synthesis provided further evidence that more than one COX enzyme existed 
(Lysz 1982, 1988). These findings were supported by a study conducted by Habenicht 
et al. who showed that the human platelet-derived growth factor induces early 
(within minutes) and late (after 2-4 hrs) prostaglandin generation in Swiss 3T3 cells, 
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suggesting a constitutive (COX-1) and inducible (COX-2) isoform of COX enzymes 
(Habenicht et al. 1985). Four years later, in 1989, Rosen et al. further demonstrated 
that there are two mRNAs for COX present within seminal vesicles, and LPS 
stimulation of monocytes resulted in prostaglandin and Tx synthesis in a time- and 
dose-dependent manner. These findings led to the proposal that these cells contain 
two pools of COX enzymes (Fu et al 1990). Indeed, this was confirmed in the 1990s 
when the gene encoding for COX-2 was found and overexpression of this gene 
resulted in increased COX activity, which was inhibited by NSAIDs (O’Banion et al. 
1991; Meade et al. 1993; Hla & Neilson 1992). In 2002, a third cyclooxygenase, COX-
3, was discovered which is encoded by the same gene as COX-1 but is retaining an 
intron that is not retained COX-1 during translation. COX-3 is inhibited by N-(4-
hydroxyphenyl) ethanamide N-(4-hydroxyphenyl) acetamide (paracetamol), 
however, its biological function warrants further investigation (Chandrasekharan et 
al. 2002; Botting 2003). 
To date, COX and prostanoids have been of significant pharmacological interest and 
consequently, targeted NSAIDs (1.3.7) or drugs targeting prostanoid synthesis 
downstream of COX have been developed, as well as selective COX-2 inhibitors, used 
for inflammatory disease. 
 
1.3.2 STRUCTURE OF COX 
The genes encoding COX-1 and COX-2 consist of about 600 base pairs and both 
isomers have a similar primary structure (Michael Garavito et al. 2002). The x-ray 
crystal membrane structure of ovine COX-1 was first shown in 1994 by Picot et al. 
(1994). COX-1 is a homodimer with the two monomers connected by a non-
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crystallographic two-fold symmetry axis (Figure 1.1). The polypeptide chain has a 
high content of α-helices (40%) and almost no β-pleated sheets. The tertiary 
structure of COX reveals three units. The first is an epidermal growth factor (EGF) 
module at the C-terminal end (amino terminal residues 34-72), followed by a series 
of four amphipathic helices forming the membrane binding motif (residues 73-116), 
which represents the second unit, allowing insertion of the enzyme into the lipid 
bilayer. The third unit is a catalytic domain, which contains the cyclooxygenase (COX) 
and the peroxide (POX) active sites. The first catalytic domain, POX, is located at the 
interface between the large and small lobes of this catalytic domain, furthest from 
the membrane. This site is solvent accessible and contains the Fe(III)-protoporphyrin 
IX prosthetic group (heme group). POX is structurally homologous to other 
mammalian peroxidase sequences (MPO, 70% sequence homolog), as well as 
cytochrome c peroxidase (CCP) and fungal lignin peroxidase (LiP) (18 % sequence 
homolog each). However, the EGF module and membrane binding motif are not seen 
in other MPOs (Picot et al. 1994). The second catalytic domain, COX, is a narrow 
tunnel (8 Å wide and 25 Å long) that is highly hydrophobic and opens to the 
membrane binding domain. This enables arachidonate to enter the COX site after the 
lipid is cleaved from intracellular membranes (Picot et al. 1994).  
In 2000, Malkowski et al. determined the x-ray crystal structure of apo-COX-1 with 
Co3+ bound to the endogenous substrate arachidonate at the catalytic site (Figure 
1.2). A resolution of 3Å allowed the identification of 49 amino acid residues of COX 
that interact with arachidonate (Malkowski et al. 2000). Subsequently, Thuresson et 
al. (2001) identified five functional categories of these residues that mediate the 
arachidonate-COX interaction: 
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Figure 1.1. X-ray crystal structure of COX-1 complex with fluriprofen. The 
homodimer COX-1 shown along the dimer interface with the molecular two-fold axis 
vertical. Protein data bank (PDB), identification number 1CQE, Picot et al. 1994. 
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Figure 1.2. Schematic interaction between arachidonate and COX channel residues. 
The carbon backbone of arachidonate is shown in yellow and oxygen atoms in red. 
The 13 pro (S) hydrogen is depicted in blue. The 49 interactions are shown as dashed 
lines indicating a distance within 4.0Å between the side chain atom of COX and 
arachidonate (Malkowski et al. 2000). 
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 Tyr-385 that mediates hydrogen abstraction from carbon 13 (C13) of 
arachidonate 
 Gly-533 and Tyr-348 are critical to position C13 of arachidonate for hydrogen 
abstraction 
 Arg-120 is essential for high affinity binding of arachidonate to COX 
 Val-349, Trp-387, and Leu- 534 position arachidonate following hydrogen 
abstraction within the active site in order to yield PGG2 rather than mono- 
hydroperoxy acid products (11(R)-HETE and 15(S,R)-HETE)  
 Other residues contribute to an optimal catalytic efficiency 
 
Arachidonate is positioned in a L-shaped conformation in the active site of COX-1 or 
COX-2 (Malkowski et al. 2000; Rowlinson et al. 1999). The active sites in both 
isoforms are identical apart from minor amino acid changes (Gierse et al. 1996). 
These increase the size of the COX-2 channel and explain the isoform specific 
substrate tolerance (Laneuville et al. 1995). The increased size also accounts for COX-
2 specific inhibitors and clarifies why aspirin fully inhibits COX-1 but allows turnover 
of arachidonate by COX-2 to 15-HETE (Lecomte et al. 1994; Gierse et al. 1996).  
 
1.3.3 PROSTANOID GENERATION 
Prostanoids are generated de novo in response to extracellular hormonal stimuli, e.g. 
in platelets in response to thrombin. Their generation requires three steps: First, 
arachidonate is mobilised from membrane phospholipids by phospholipases 
(described in 1.3.3.1). Second, COX enzymes oxidise arachidonate to PGH2 (described 
in 1.3.3.2), which is then converted to prostanoids via cell specific synthases 
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downstream of COXs (described in 1.3.3.5) (Smith et al. 2000). Finally, they are either 
released from the cell as free fatty acids or in the case of PGE2 esterified to 
phospholipids (Aldrovandi et al. 2013). Aside from the enzymatic oxidation of 
arachidonate, prostanoid-like structures are produced in vivo independently of COX, 
primarily by free radical-induced peroxidation of arachidonic acid. These so called 
isoprostanes are measured to assess the oxidative stress status in vivo (Montuschi et 
al. 2004). 
 
1.3.3.1 MOBILISATION OF ARACHIDONATE 
Engagement of cell surface receptors including PAR1/PAR4 causes the activation of 
phospholipases and subsequently the hydrolysis of arachidonate (Holinstat 2006; RM 
et al. 1995; Henriksen & Hanks 2002). Five main groups of phospholipases including 
30 different enzymes have been identified (Burke & Dennis 2009; Six & Dennis 2000; 
M. Murakami et al. 2011). However, cytosolic phospholipase A2 (cPLA2) is the key 
player in eicosanoid generation since cells lacking this are unable to generate these 
lipids (Tramposch et al. 1994; Brooke et al. 2014; Riendeau et al. 1994; Bartoli et al. 
1994). During prostanoid generation, two phases are described: the immediate 
phase and the delayed phase. In the immediate phase, receptor activation, e.g. 
PAR1/4 receptor stimulation by thrombin in platelets, leads to intracellular calcium 
mobilisation (Coughlin 2000). The calcium-dependent cPLA2, which is located in the 
cytoplasm in resting cells, translocates to the endoplasmic reticulum and the nuclear 
envelope. Calcium binds to the N-terminal CalB domain of cPLA2. This interaction 
enables the cPLA2 to bind to intracellular membranes and to hydrolyse the sn2 ester 
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bond of phospholipids yielding arachidonate. Arachidonate is released within 
seconds of receptor activation. Therefore, the constitutively expressed COX-1, and 
not the inducible COX-2, is believed to be responsible for prostanoid generation 
during the immediate phase (Clark et al. 1991; Evans et al. 2001).  
The delayed phase is characterised by long term cell stimulation (2-3 hrs), e.g. 
cytokine or growth factor stimulation of macrophages or mast cells, and results in 
increased activity of calcium-dependent secretory PLA2s (sPLA2) and expression of 
COX-2 (Reddy & Herschman 1997; Balsinde & Dennis 1996). sPLA2s can be subdivided 
into five isoforms and are secreted by cells such as mast cells (Fonteh et al. 1994; M. 
Murakami et al. 2011). sPLA2s show less substrate specificity than cPLA2 and interact 
with heparin sulphate containing proteoglycans present on the cell surfaces, where 
they hydrolyse phospholipids at the sn2 position (Murakami et al. 2001; Murakami 
et al. 2010). Several transgenic or knockout studies have demonstrated that sPLA2s 
mediate an array of homeostatic roles, including those involved in coagulation and 
cellular proliferation and have been implicated in diseases including asthma, 
atherosclerosis and cancer (Murakami et al. 2011; Murakami et al. 2010; Shridas et 
al. 2014). 
In vitro studies have demonstrated that sPLA2 expression in the macrophage cell line 
P33D1 depends on previous activation of cPLA2. Therefore, cPLA2 also acts as a 
regulator of PG generation in the delayed phase (Shinohara et al. 1999; Balsinde et 
al. 1998). 
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1.3.3.2 GENERATION OF PGH2 BY COX 
Once arachidonate is hydrolysed from phospholipids, COXs catalyse its oxidation to 
PGH2. In contrast to COX-1, which exclusively utilises arachidonate as its substrate, 
COX-2 can also oxidise 2-arachidonylglycerol, dihomo-gamma-linolenic acid (DGLA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), (Kozak et al. 2000; 
Chen 2010; Levin et al. 2002). Both enzymes perform two semi-independent 
reactions: the oxygenation of arachidonate using two oxygen molecules at the COX 
active site and the two electron reduction of the product PGG2 to PGH2 at the POX 
active site. As shown in 1.3.2, the two reactions occur at different sites within the 
enzyme, but these are structurally and functionally connected. 
The COX enzymatic cycle is based on a co-ordinated series of radical reactions 
summarised in Scheme 1.3 (Hamberg & Samulsson 1967; Mason et al. 1980; Hecker 
et al. 1987; Elizabeth D Thuresson et al. 2001; Wu et al. 2011). COX turnover is 
initiated by a two-electron oxidation of the heme group to an oxo-ferryl porphyrin 
cation radical at the POX active site (A). This radical then oxidises a tyrosine (Tyr-385) 
to a tyrosyl radical at the COX active site (D). When arachidonate enters the active 
site of the enzyme, Tyr-385. mediates the abstraction of the 13-pro(S)-hydrogen from 
arachidonate, representing the rate limiting step of the COX reaction, then 
isomerisation leads to a carbon-centred radical at C11 (E). Oxygen traps this radical 
as the 11-hydroperoxyl radical (F). This then attacks the double bond at C9 forming 
an endoperoxide. The carbon-centred radical relocates to C8, which attacks at C12 
forming the prostanoid ring, with the radical migrating to C15. At this position the 
radical is trapped by a second oxygen forming a 15 -(S)-hydroperoxyl radical (G). In 
the last step this is reduced to a hydroperoxide at C15 forming PGG2 (H). PGG2 moves  
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Scheme 1.3. Oxidation of arachidonate to PGH2 by COX. Redox reactions at the POX 
active site (A-C) lead to radical formation of Tyr-385 at the COX active site (D). This 
radical attacks arachidonate forming a carbon centred radical at C13 (E). 
Subsequently, the C13 radical is oxidised resulting in PGG2 (F-H). At the POX active 
site PGG2 is reduced to PGH2, then the cycle continues (I). A detailed description of 
this pathway is shown in 1.3.3.2. Modified from Marnett 2000. 
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to the POX active site of the enzymes where the hydroperoxide at C15 is reduced to 
a hydroxide to form PGH2 by 2-electron oxidation of the heme group (Scheme 1.3) 
(Marnett 2000; Elizabeth D. Thuresson et al. 2001; Smith & Murphy 2002; Rouzer & 
Marnett 2003; Lassmann et al. 1991). The POX site acts independently of COX 
function and can also reduce long chain fatty acids other than PGG2 (Lambeir et al. 
1985; Koshkin & Dunford 1999). COX activity is initiated at 10-fold lower 
concentrations of hydroperoxides for COX-2 than for COX-1 suggesting that COX-1 
and COX-2 can act independently when expressed in the same cell (Kulmacz 1998; 
Kulmacz & Wang 1995). 
 
1.3.3.3 SUICIDE INACTIVATION OF COXS 
Arachidonate oxidation by COXs is an enzymatic reaction initiated by the generation 
of radicals at the POX catalytic site which activates COX function. This perpetuates 
further POX and COX activation in a continual amplification cycle, which is terminated 
when the amplifying radicals cause damage to the catalytic sites. This leads to a 
suicide inactivation of the enzyme that irreversibly terminates COX turnover within 
1-2 min even if sufficient substrate is available (Wu et al. 1999; Tsai & Kulmacz 2010). 
Inactivation of POX can be studied independently of COX function and is thought to 
originate from oxidative damage due to increasing hydroperoxide levels and the high 
oxidation state of the oxoferryl heme (Rouzer & Marnett 2003). POX-derived 
oxidants then cause distinct types of damage at the COX active site, however, their 
identity remains unknown (Wu et al. 2003). In addition, the Tyr radical itself causes 
COX inactivation (Song et al. 2001; Tsai & Kulmacz 2010). Whether there are 
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differences between inactivation mechanisms of COX-1 vs. COX-2 also remains 
undetermined. 
 
1.3.3.4 COXS GENERATE 11-AND 15-HETE IN ADDITION TO PGH2 
COX oxidises arachidonate to generate PGH2, the precursor for PGE2, PGD2, PGF2α, 
TxA2 and PGI2 (Smith et al. 2000). However, COX also exhibits “lipoxygenase activity” 
generating small amounts of 11 (S)- and 15 (S) and (R)-HETEs (Xiao et al. 1997). These 
products form when the 11- and 15-hydroperoxyl radicals escape from the COX 
active site, instead of finishing the catalytic cycle. Indeed, mutations in the COX 
domain of COX-1 lead to enhanced formation of PGG2 and both 15(S)– and 15(R)-
HETE (mutant V349L) or 11(R)-HETE (mutant V349A/W387F) (Thuresson et al. 2000; 
Harman et al. 2004a). The latter forms after the 11-hydroperoxyl radical escapes 
from the COX site and is subsequently reduced twice, first to 11-HpETE and then to 
11(R)-HETE independently of COX (Harman et al. 2004a).  
 
1.3.3.5 CELL SPECIFIC PROSTANOID GENERATION VIA SPECIFIC SYNTHASES  
COX-derived PGH2 is the precursor for prostanoids that are generated via specific 
synthases PGE synthase (PGES), PGD synthase (PGDS), PGF2α synthase, PGI synthase 
(PGIS), and TxA synthase (TxS), which catalyse the conversion of PGH2 to PGE2, PGD2, 
PGF2α, PGI2 and TxA2, respectively. All these reactions involve isomerisation of PGH2, 
except PGF2α formation, which is a two-electron reduction of PGH2 or reduction of 
PGE2 or PGD2  (Moriuchi et al. 2008). Prostanoid synthesis is regulated at different 
levels including expression, activation and tissue distribution of the enzymes 
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involved. Constitutively COX-1 plays a role in several physiological processes 
including platelet aggregation and renal function. The inducible form, COX-2, is 
expressed in cells in response to stimuli such as cytokines and growth factors 
(Chandrasekharan & Simmons 2004). Consequently, COX-2 is associated with 
inflammatory events. However, the co-ordinated action of COXs along with 
prostanoid synthases downstream of COX leads to a cell specific generation of 
prostanoids. For example, TxS is highly abundant in platelets whilst PGIS is present in 
endothelial cells (Bos et al. 2004; Caughey et al. 2001). Such cell specific generation 
indicates that prostanoid generation is tightly controlled within each cell type. In 
addition, several studies suggest that these synthases are selectively coupled to the 
upstream enzymes, COX-1 and COX-2 (Ueno et al. 2001). For example, COX-2 couples 
preferentially to either PGE synthase or PGI synthase depending on the cell type and 
stimulus used. For example, IL-1α and TNF stimulation of human lung carcinoma cells 
(A549 cells) or bone marrow-derived mast cells (BMMC) results in PGE synthase 
coupling, whereas LPS stimulation of peritoneal macrophages results in PGI synthase 
coupling (Chen et al. 1997; Matsumoto et al. 1997; Smith et al. 2000). These coupling 
mechanisms promote specific biological activities and differential signalling of COX-1 
and COX-2 leading to a diverse range of important biological functions mediated by 
prostanoids (Bos et al. 2004; Naraba et al. 1998). 
 
1.3.4 PROSTANOID RECEPTORS AND FUNCTIONS 
Prostanoids represent a large group of bioactive oxidised lipids. Following their 
generation and release, they interact with seven-transmembrane receptors that 
belong to the G-protein-coupled, rhodopsin-type family (Bos et al. 2004). The 
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nomenclature of these receptors follows the name of the binding ligand. PGD2 binds 
to the DP receptors (DP1 and DP2), TxA2 to TP (TPα and TPβ), PGI2 to IP, PGF2α to FP 
and PGE2 to the EP receptor (EP1-4) (Kennedy et al. 1982; Bos et al. 2004; Hirata & 
Narumiya 2011). In 1989, the first prostanoid receptor was structurally identified as 
the TP receptor (Ushikubi et al. 1989). This was followed by homology based 
screening, which enabled structural identification of the other prostanoid receptors 
(Nakagawa et al. 1994; Hirata et al. 1994; Regan et al. 1994; Abramovitz et al. 1994). 
Since then subtypes of these receptors have been identified.  
Receptor signalling induces several functions, including platelet aggregation and 
smooth muscle contraction via TxA2, platelet inhibition and smooth muscle 
contraction via PGI2 and generation of fever and suppression of type I allergic 
reactions via PGE2 (Ushikubi et al. 1998; Kunikata et al. 2005; Spurney et al. 1993; 
Hamberg et al. 1975; Dorn & Becker 1993). Therapeutically, prostanoids are targeted 
by inhibition of either COX through NSAIDs (described in 1.3.7) or the prostanoid 
receptor. For example, the inhibition of the TP receptor by terutroban (S18886) is 
used in atherosclerotic therapy and causes a regression of advanced atherosclerotic 
lesions (Viles-Gonzalez et al. 2005; Lesault et al. 2011).  
 
1.3.5 CLASSIFICATION OF PROSTANOIDS 
Prostanoids can be subdivided into PGs, which contain a five-membered ring 
encompassing carbons 8 to 12 and TXs, which contain a heterocyclic six-membered 
ring. Prostanoids contain a trans double bond between C13 and C14 and a hydroxyl 
group at C15 (Simmons et al. 2004; Smith & Murphy 2002). The nomenclature of 
prostaglandins contains the abbreviation PG plus letters A-I that indicate the nature 
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and location of oxygen substituent present in the ring. Likewise, thromboxanes are 
classified in TxA and TxB (Samuelsson & Hamberg 1978). Numerical subscripts 
indicate the number of carbon-carbon double bonds such as PGE2, which has two 
double bonds (Nelson 1974). Based on the number of double bonds prostanoids can 
be further classified into series 1, 2 and 3, where class 2 is the most abundant in 
mammals (Bos et al. 2004). Greek subscripts, e.g. PGF2α, symbolise the orientation 
of hydroxyl groups attached to the cyclopentane ring.  
 
1.3.6 PHOSPHOLIPID-ESTERIFIED PROSTANOIDS 
During 1980-90s, exogenously-added eicosanoids were shown to be incorporated 
into phospholipids in cultured cells. For example, 15-HETE was esterified to 
phosphatidylinositol (PI) in human airway epithelial cells (Alpert & Walenga 1993). 
More recent studies demonstrated that esterified eicosanoids are acutely generated 
in human and murine platelets, neutrophils and monocytes/macrophages using 
endogenous substrate and that they can play a role in inflammation and coagulation 
(Thomas et al. 2010; Maskrey et al. 2007; Morgan et al. 2009; Clark et al. 2011; 
Aldrovandi et al. 2013).  
Whereas esterified eicosanoids such as HETE-PLs are well studied regarding their 
generation and biological activity, little is known about prostanoids that attach to 
PLs. In 2013, Androvandi et al. revealed that thrombin activated platelets generate 
PGE2 esterified to PE. Mechanistically, PGE2, synthesised by COX, is immediately 
incorporated into PE by esterification enzymes including CoA-synthetases and 
lysophospholipid acyltransferases. In contrast to free PGE2, esterified PGE2 remains 
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cell associated following its generation suggesting a role in membrane-associated 
functions (Aldrovandi et al. 2013).  
Recent studies from our group demonstrated that the novel COX-product, DXA3, 
which is characterised as a free fatty acid in this study, is esterified to PE and PC upon 
thrombin activation of platelets and both the pathway of generation and localisation 
are identical to PGE2-PEs (Aldrovandi et al, unpublished). However, as for PGE2-PE, 
the function of DXA3-PE remains unknown and warrants further study. 
 
1.3.7 INHIBITION OF COXS BY ASPIRIN 
NSAIDs such as acetylsalicylic acid (aspirin) or 2-(4-Isobutylphenyl) propanoic acid 
(ibuprofen) inhibit COX functions and therefore prostanoid generation. There are 
two families that include the classical NSAIDs and COX-2 inhibitors. Classical NSAIDs 
such as aspirin inhibit both COX-1 and COX-2. In contrast, COX-2 inhibitors such as 4-
[5-(4-Methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide 
(celecoxib) or 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one (rofecoxib) block 
COX-2 due to the structural difference of the active sites of COXs. All NSAIDs except 
aspirin compete with arachidonate for binding to the COX active site. However, there 
are three classes of NSAIDs differing in their kinetic inhibitory properties (Smith et al. 
2000; Marnett et al. 1999). The first group that includes ibuprofen exhibits rapid, 
reversible binding. The second type binds to the enzyme in two stages, first the drug 
binds rapidly but reversibly with low affinity, then the affinity is increased reducing 
the reversibility. A drug belonging to this second class is (RS)-2-(2-fluorobiphenyl-4-
yl) propanoic acid (fluriprofen). The third group that includes aspirin, binds rapidly 
and reversibly in the first instance but time-dependently acetylates the Ser-530 
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residue at the COX site and irreversibly inhibits the enzyme (Smith et al. 2000; 
Marnett et al. 1999). NSAIDs are commonly used as anti-platelet therapy in 
cardiovascular disease, in cancer therapy, and to target inflammation, pain and fever 
(Cook et al. 2013; Chan et al. 2012; Cuzick et al. 2009; Seibert et al. 1994; DeWitt 
1999; Cao et al. 1997; Gladding et al. 2008; May et al. 1982). 
Aspirin was first discovered in 1935 by Felix Hoffman and represents the most 
popular classic NSAID with a worldwide consumption of 100 billion tablets per year 
(Vane & Botting 2003). It mediates broad pharmacological actions that include anti-
inflammatory, anti-pyretic and analgesic effects. 
Aspirin is 170-fold more potent in its inhibition of COX-1 than COX-2 (Vane et al. 
1998). Thus, COX-2 can still oxidise arachidonate to 15-HETE following aspirinisation, 
whereas COX-1 function is completely abolished (O’Neill et al. 1994; Mancini et al. 
1994). This is due to the larger active site present in COX-2 which allows arachidonate 
to enter even if aspirin is already bound (Vane et al. 1998). Mechanistically, aspirin 
enters the COX active site and interacts with Arg-120, which is located close to the 
opening of the catalytic channel, through a weak iconic bond. Aspirin then covalently 
modifies COX via acetylation of Ser-530 in COX-1 and Ser-516 in COX-2 (Lecomte et 
al. 1994; Loll et al. 1995). This causes inactivation of COX and prevents arachidonate 
from accessing the active site. In contrast, aspirin does not inhibit POX (Shimokawa 
& Smith 1992; DeWitt et al. 1990).  
 
1.3.8 INHIBITION OF PLATELETS BY ASPIRIN 
Aspirin has been used for many years to combat a broad range of pathophysiological 
processes due to its anti-inflammatory and pain relieving properties. A major 
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pharmacological target of aspirin is platelet COX-1. This leads to inhibition of TxA2 
formation and subsequently prevents blood clotting (Hata & Breyer 2004). 
Therefore, low dose aspirin (<75 mg per day) is used as an antithrombotic therapy in 
acute or secondary prevention of myocardial infarction, atherosclerosis or 
cerebrovascular disease such as ischemic stroke (Patrono & Baigent 2009; 
Antithrombotic Trialists’ (ATT) Collaboration 2009; Patrono 2004; Warner et al. 
2011). 
When administered orally, aspirin is rapidly absorbed in the upper gastrointestinal 
(GI) tract and inhibits platelet function within 60 min (Jimenez et al. 1992). As 
platelets circulate in the portal system, they are exposed to aspirin. Thus, inhibition 
occurs pre-systemically before the drug is metabolised by the liver. Consequently, 
low dose aspirin is sufficient to inhibit COX-1 in platelets in vivo. A repeated daily 
aspirin intake lower than 100 mg causes a dose-dependent and cumulative inhibition 
of platelet TxA2 production explaining the drugs clinical efficiency as an 
antithrombotic agent at low doses (Patrignani et al. 1982; Tohgi et al. 1992). Despite 
its rapid clearance, aspirin inhibits TxA2 production for the lifetime of the platelet. 
This is due to irreversible COX-1 inhibition by aspirin and the inability of platelets to 
induce COX-1. Therefore, TxA2 generation is suppressed for 7-10 days post aspirin 
consumption (Patrono & Baigent 2009; Warner et al. 2011). 
Higher single doses of aspirin (> 100 mg) can lead to inhibition of COX-2, which is 
upregulated during inflammation. Therefore, aspirin can be used at higher doses for 
analgesia and during inflammation (Patrono 2004). 
Aspirin also inhibits COX-1 expressed by the gastric mucosa, where PGE2 and PGI2 are 
cytoprotective (Jackson et al. 2000). Consequently, the inhibition of PGE2/PGI2 
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mediated gastric cytoprotection can result in dose dependent GI bleeding (Patrignani 
& Patrono 2015; Rodriguez et al. 2001). Long-term, this can lead to GI complications, 
including gastric ulcers, but also renal failure and an increased risk of hemorrhagic 
stroke (Awtry & Loscalzo 2000). However, low-dose aspirin therapy remains the drug 
regime of choice for anti-platelet therapy in the prevention of cardiovascular events. 
Recent studies have examined the use of aspirin in the treatment of other diseases, 
such as cancer, and suggest that low-doses can reduce metastasis and overall 
mortality (Algra & Rothwell 2012; Peter M. Rothwell et al. 2012). However, the effect 
of aspirin upon different cancer types and its long term effects still warrants further 
study. 
 
1.4 DISCOVERY OF DXA3 
Recent studies from our group aiming to identify PL-esterified prostaglandins 
demonstrated that platelets generate a novel lipid (Hinz and Aldrovandi, 
unpublished). This is formed during platelet activation and corresponds to an 
arachidonate-based structure containing three additional oxygen atoms. With a 
parent ion mass of m/z 351.2175, this fatty acid is the same molecular mass as 
prostaglandins with an elemental composition of C20O5H32. The LC/MS/MS spectrum 
(Figure 1.3, Panel B) of this lipid did not match any known eicosanoid spectrum listed 
on LipidMaps or other databases.  
Based on preliminary structural work using GC/MS in collaboration with Dr. Robert 
Murphy (University of Colorado, Denver) prior to my PhD, this lipid was initially 
proposed to contain a dioxolane ring. Dioxolanes are heterocyclic acetals formed 
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during oxidation of alkanes. They can form as oxidation products of arachidonate-
cholesteryl esters in vitro with 11-HpETE as an intermediate (Havrilla et al. 2000). The 
proposed lipid products generated during this reaction are depicted in Scheme 1.. 
Furthermore, arachidonate-derived dioxolanes were recently shown to be generated 
enzymatically by LOX isoforms in vitro (Teder et al. 2014). However, to date 
dioxolanes have not been described in any cell type and are not known to be 
biologically active. Therefore, DXA3 represents the first dioxolane generated in 
platelets in response to a physiological agonist. A detailed description of the 
proposed structure and further structural characterisation will be shown in Chapter 
3. 
Prior to my PhD, DXA3 was shown to be generated by platelets as both a free acid 
eicosanoid and esterified to PE (Figure 1.3, Panels A-D) (Aldrovandi et al., 
unpublished). Moreover, the lipid was found to be generated by recombinant COX-1 
(Figure 1.3, Panels E and F) and COX-2 in vitro (Aldrovandi, unpublished). DXA3 and 
DXA3-PE generation was also found to be coordinated by the same signalling pathway 
as COX-1-derived prostanoids. Specifically, PAR1/PAR4 receptors activated a 
signalling cascade that involves the activation of Src tyrosine kinases, p38 MAPK, PLC 
and cPLA2. COX-1 then formed free DXA3, which was subsequently re-esterified to 
DXA3-PE via LPAT enzymes (Aldrovandi et al., unpublished). However, up to now the 
enzymatic mechanism of formation of DXA3 by COX, amounts of the lipid generated 
by platelets and its biological functions have not been characterised.  
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Scheme 1.4. Structures of lipid products derived from a two-step oxidation of 
arachidonate-cholesterol ester in vitro via cholesterol-11-HpETE. Oxidation of 
cholesterol-arachidonate and subsequently cholesterol-11-HpETE results in the 
formation of isoprostanes, monocyclic and serial cyclic products. Dioxolanes are 
marked in red. R = cholesteryl. Modified from Havrilla et al. (2000). 
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Figure 1.3. DXA3 is esterified at sn2 position in DXA3-PE and is generated as free 
acid by thrombin activated platelets and recombinant COX-1 in vitro. LC/MS/MS 
chromatograms monitoring DXA3 m/z 351.2 to 165.1 derived from (A) purified 
platelet PE, (C) thrombin activated platelets and (E) in vitro COX-1 reaction utilizing 
arachidonate. The product ion spectra of all three approaches are identical (Panel B, 
D and F). Modified from Aldrovandi et al., unpublished. 
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1.5  CHROMATOGRAPHY COUPLED MASS SPECTROMETRY OF LIPIDS 
Mass spectrometry (MS) is an important and powerful analytical technique that has 
enabled quantification and structural characterisation of eicosanoids since the 1960s 
(Bergström & Samuelsson 1962). MS analysis requires lipids to be ionised. 
Historically, electron ionisation in combination with gas chromatography (GC) was 
used for eicosanoid characterisation. For GC the lipids are derivatised to convert 
them into a volatile state in order to pass into the gas chromatograph. However, not 
all lipids are suitable for GC/MS. Leukotriene C4 (LTC4) cannot be made volatile for 
GC and therefore, a different approach was necessary for structural characterisation 
(Murphy et al. 1979). In contrast, electrospray ionisation (ESI) represents a more 
recent and rapid technique that generates gas-phase ions and allows analysis of 
negatively ([M-H]-) and positively ([M-H]+) charged lipids (Yamashita & Fenn 1984). 
These molecular ions (parent ions) of the eicosanoid reveal important structural 
information, for example about the number of oxygen atoms within the oxidised 
arachidonate, when analysed using high resolution instruments. Full structural 
characterisation and identification of eicosanoids requires collision induced 
dissociation (CID) of the parent ion with an inert gas such as N2. This enables the 
formation of unique fragments (fragment ions) to give a specific fragmentation 
pattern (MS/MS spectrum) (Murphy et al. 2005). In general, there are two principles 
of lipid analysis using ESI-MS that include shotgun MS and liquid-chromatography 
(LC)-MS. 
1.  “Shotgun” lipidomics analyses lipid extracts without on-line chromatography. 
Separation of lipids is achieved “in source” according to the lipid’s specific 
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ionisation and adduct formation properties. Shotgun lipidomics allows detection 
of the most abundant lipids. This approach is high throughput and large amounts 
of lipidomic data can be generated within a relatively short time frame. 
However, it is not generally quantitative and can miss low abundant lipids 
(O’Donnell et al. 2014). Ion suppression is one of the major challenges during 
shotgun analysis. For example, when classes of lipids are present at high 
abundance, they dominate the spectrum. Consequently, lipids that are present 
at a much lower abundance can be missed (Yang & Han 2011). 
2. LC/MS is a robust and reliable quantitative and qualitative analytical tool that is 
routinely used in lipid research (O’Donnell et al. 2014). Coupling LC to MS allows 
analysis of single lipids within a lipid mixture, for example in biological samples 
(Bylund et al. 1998; Nithipatikom et al. 2001; Kita et al. 2005; Kempen et al. 
2001). In addition, lipids are kept in solution during LC and are not exposed to 
atmospheric oxygen. This prevents lipid oxidation and subsequently formation 
and detection of artefacts (Pulfer & Murphy 2003).  
 
1.5.1 TRIPLE QUADRUPOLE MASS SPECTROMETRY FOR LIPID ANALYSIS 
Mass spectrometric analysis consists of three general steps: ionisation, mass analysis 
and detection. The direct coupling of high performance liquid chromatography 
(HPLC) to MS yielded a breakthrough in analysis of biological samples. However, lipids 
need to be in the gas phase for MS analysis, and this is commonly achieved by ESI 
(Murphy et al. 2005). Briefly, lipids elute from the LC column and reach the MS source 
in solution through a thin stainless steel or quartz silica capillary, which is maintained 
at a high voltage. This results in formation of an aerosol of highly charged droplets, 
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which have the same polarity as the capillary voltage. Within a nebulising gas (N2), 
which shears around the droplets and increases the sample flow rate, they pass down 
a pressure and potential gradient towards the MS. High source temperatures (heated 
ESI, hESI) lead to solvent evaporation and subsequently result in a decreased droplet 
size. Simultaneously, the same amount of charge remains on their surface leading to 
an increased surface charge density. Then, the electric field strength reaches a critical 
point causing a coulombic repulsion and explosion and consequently, the ejection of 
ions from these highly charged droplets. The ions are collected in a sampling skimmer 
before they enter the MS (illustrated in Scheme 1.4) (Ho et al. 2003; Bruins 1998). 
The ions travel through an oscillating electric field applied between quadrupoles, 
which consist of four cyclindrical rods that are allocated parallel to each other (e.g. 
Q1, Scheme 1.). The principle of separating these ions within the MS is based on their 
mass to charge (m/z) ratio, which affects their movement through the quadrupoles 
towards the detector. For example, when a specific m/z is selected, ions with a 
different m/z are not stable in their flight path, and will be discharged and 
consequently, fail to reach the detector. For lipid identification and quantification, 
CID is applied using a triple quadrupole instrument, which consists of three linear 
assembled quadrupoles (Q1, Q2 and Q3), thus, this system is also known as a 
“tandem-MS”. Whereas Q1 and Q3 represent mass analysers, Q2 is the collision cell. 
When the ion of interest (parent ion) enters the MS it is mass-selected by its m/z 
ratio in Q1 and travels towards Q2. In Q2, the parent ion is fragmented into fragment 
ions through CID with an inert gas such as N2. The fragment ions generated in Q2 are 
monitored in Q3. The MS can be set for a static parent m/z (in Q1) and static fragment 
m/z (in Q3). For example, PGE2 is monitored using the transition m/z 351.2 (parent  
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Scheme 1.5. Principle of Triple Quadrupole mass spectrometry. Parent ions are 
introduced to the mass spectrometer either through direct injection or 
chromatography. The parent ion m/z is detected in Q1 and parent ions fragmented 
in the collision cell, e.g. through collision with N2. Specific fragment ions are detected 
in Q3. Modified from O’Donnell et al. 2014. 
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ion) to 271.1 (fragment ion) (LipidMaps.org). Ions with different m/z ratios will be 
filtered out and will not reach the detector. This mode of data acquisition is called 
multiple reaction monitoring (MRM), allows a high degree of specificity and 
sensitivity, and is commonly used for quantification (O’Donnell et al. 2014; Ho et al. 
2003). For identification, the MRM is coupled to an enhanced product ion (EPI) 
analysis that generates a spectrum of the MRM for the selected transition. Parent 
and fragment ions reaching the detector generate signals that are transmitted by a 
computer system and displayed graphically as chromatograms (intensity of signals 
over time) and spectra (relative abundance of parent and fragment signals according 
to their m/z ratio) (Ho et al. 2003). 
 
1.5.2 DISCOVERY OF NOVEL LIPIDS USING LC/MS/MS 
Eicosanoids were first discovered in the 1960s and research in this area dramatically 
increased in the 1970s following the discovery of the biological function of aspirin (as 
described in 1.3.1). GC/MS, HPLC-UV and thin layer chromatography (TLC) were 
employed for quantitative and qualitative lipid analyses whilst NMR and UV 
techniques were used for structural characterisation. Data from these analytical 
methods were combined to yield the structure of unknown lipids. Although GC/MS 
was applied for structural elucidation of novel lipids such as the PGs, very few lipids 
could be characterised in detail using these approaches. This is due to the 
requirement of the lipid to be volatile to enter as a gas into the MS as well as the 
relative insensitivity of NMR (Granström & Samuelsson 1669; Murphy & Gaskell 
2011). Structural lipid analysis using MS significantly increased with the development 
of fast atom bombardment ionization and ESI (Barber et al. 1982; Murphy et al. 1982; 
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Fenn et al. 1989, Wheelan et al. 1993). Combined with CID and MS/MS this enabled 
the structural elucidation of several lipids including arachidonate-derived oxidation 
products (Murphy 1993; Fruteau de Laclos et al. 1993, Zirrolli & Murphy 1993). Due 
to the continuing evolution of LC/MS/MS, increased precision, sensitivity, selectivity 
and accuracy now allow the study of femtomole quantities of non-volatile and 
thermally labile molecules (Murphy et al. 2005; Ho et al. 2003). Furthermore, high 
resolution instruments such as the Orbitrap platform allow accurate mass analysis of 
parent and product ions to be determined (O’Donnell et al. 2014; Perry et al. 2008). 
These advantages allowed the identification and structural analysis of novel lipid 
classes such as protectins and resolvins, which are generated in picomolar 
concentrations (Hong et al. 2007; Masoodi et al. 2008; Serhan et al. 2002; Schwab et 
al. 2007). In our laboratory many phospholipid-esterified eicosanoids were 
structurally identified (Thomas et al. 2010; Maskrey et al. 2007; Morgan et al. 2009; 
Clark et al. 2011; Aldrovandi et al. 2013). This work utilised precursor scanning 
tandem-MS, where a particular fragment ion is selected in Q3 and the precursor 
masses are scanned in Q1. For example, Aldrovandi et al. (2013) identified PGE2 
attached to four species of PE generated by activated platelets when scanning for 
PGE2 ([M-H]- 351.2) in Q3. Alongside PGE2-PE another lipid with an identical parent 
mass was discovered and later identified as DXA3-PE. This will be further discribed in 
1.5.  
LC/MS/MS has fast become an essential analytical tool in lipid research that enables 
detailed analyses of platelet-derived lipids to be undertaken, leading to significantly 
improved understanding of their role in platelet biology (O’Donnell et al. 2014).  
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1.6 GENERAL AIM 
Prior to this study, DXA3 as novel COX product was discovered using LC/MS/MS. To 
classify a novel lipid as a physiological mediator, it is crucial to undertake a detailed 
structural and functional characterisation of the lipid. Specifically, for any new lipid 
mediator, this should include studies on the following: 
 
 Tissue/cell distribution 
 The lipid amount generated by cells and tissues 
 Lipid generation in response to a physiological agonist 
 Bioactivity of the lipid   
 
Therefore, in this thesis I will obtain further structural characterisation, examine the 
generation of DXA3 at a cellular and enzymatic level, then I will quantify DXA3 in 
biological samples and determine its biological activity towards neutrophils. 
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2 CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 ANTIBODIES 
IgG1 mouse anti-human isotype control Alexa Fluor 647 and anti-human CD11b Alexa 
Fluor 647 were supplied from eBioscience (CA, USA). 
 
2.1.2 CHEMICALS 
All chemicals were from Sigma Aldrich (MO, USA) unless otherwise stated. 
 
2.1.3 DERIVATISATION AND HYDROGENATION CHEMICALS 
2,3,4,5,6-pentaflourobenzyl bromide (PFB) and palladium on carbon (Pd-C) were 
from Sigma Aldrich (MO, USA), Methyloxime (MOX) from biomedicals (France) and 
BSTFA from Supleco (PA USA). 
 
2.1.4 ENZYMES 
Purified ovine or human recombinant COX-1 and COX-2 as well as the COX-2 mutants 
were a kind gift from Prof. Larry Marnett (Vanderbilt University, TE, USA) or from 
Cayman Chemicals (MI, USA). Snake venom cPLA2 was from Calbiochem (UK). 
Thrombin was supplied by Sigma Aldrich (MO, USA). 
 
2.1.5 LIPID STANDARDS 
[14C]-Arachidonate was from Perkin Elmer (MA, USA) and 1,2-Dimyristoyl-sn-glycero-
3-phosphoethanolamine (DMPE) from Avanti Polar Lipids (AL, USA), all other lipid 
standards were from Cayman Chemicals (MI, USA) 
 65 
 
2.1.6 SOLVENTS 
All solvents were HPLC-grade and from Thermo Fisher (MA, USA). 
 
2.1.7 BUFFERS AND SOLUTIONS 
Acid Citrate Dextrose (ACD) buffer 
85 mmol/L trisodium citrate, 65 mmol/L citric acid and 100 mmol/L glucose. 
 
Flow Cytometry buffer 
0.5 % BSA, 5 mM EDTA, 2 mM sodium azide in phosphate buffer saline (PBS) pH 7.4 
(Gibco, Thermo Fisher Scientific). 
 
HEPES buffer 
100 mM NaCl, 5 mM KCl, 1 mM NaH2PO4 x 2 H2O, 2 mM glucose at pH 7.4. 
 
Kreb’s buffer 
50 mM HEPES, 100 mM NaCl, 5 mM KCl, 1 mM NaH2PO4*2H2O, 2 mM Glucose. After 
adjusting the pH to 7.4, 2.5 mM CaCl2 was added. 
 
Phosphate buffer  
100 mM potassium phosphate, pH 7.4 
 
Tyrode’s buffer 
134 mmol/L NaCl, 12 mmol/L NaHCO3, 2.9 mmol/L KCl, 0.34 mmol/L Na2HPO4, 1.0 
mmol/L MgCl2, 10 mmol/L HEPES and 5 mmol/L glucose at pH 7.4 
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2.1.8 SOFTWARE 
Analyst 1.6 (Applied Biosystems, CA, USA), ChemSketch (ACD labs, MO, USA), FlowJo 
(FlowJo, LLC, OR, USA), Microsoft Office (Microsoft corporation, WA, USA), and 
XCalibur (Thermo Scientific, MA, USA). 
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2.2 METHODS 
2.2.1 CELL BIOLOGY 
2.2.1.1 ISOLATION OF HUMAN PLATELETS FROM BLOOD 
Whole blood was collected from healthy donors with informed consent (SMREC 
12/37, SMREC 12/10). This study was approved by the Cardiff University School of 
Medicine Ethics Committee and conducted in accordance with the Declaration of 
Helsinki. For blood samples relating to cPLA2-deficient studies, blood was collected 
as follows: healthy volunteer samples; approved by St Thomas’s Hospital Research 
Ethics Committee, reference 07/Q0702/24: cPLA2-deficient patient samples; 
approved by South East NHS Research Ethics Committee. 
For platelet purification, 50 ml of fresh human blood was obtained and mixed with 
ACD buffer at a ratio 8.1:1.9 (v/v blood: ACD) and slowly transferred into two 50 ml 
falcon tubes. The blood:ACD was centrifuged at 250 g (1500 rpm, 12 cm rotor) for 10 
min at room temperature (RT) with no brake. The platelet rich plasma (PRP) was 
collected and transferred into a fresh tube, then centrifuged at 900 g (2900 rpm, 12 
cm rotor) for 10 min at RT with the brake switched off. The supernatant was 
discarded and the pellet resuspended in 10 ml of calcium free Tyrode’s buffer 
containing ACD (9:1, v/v Tyrodes:ACD) and centrifuged at 800 g (2800 rpm, 12 cm 
rotor) for 10 min at RT with no brake. The pellet was resuspended in 2 ml of calcium 
free Tyrode’s, before diluting the platelets 1:100 using Tyrode’s and trypan blue. 
Platelets were counted using a haemocytometer and the count adjusted using 
Tyrode’s to the required concentration and the platelets used within 2 h. 
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2.2.1.2 PURIFICATION OF MURINE PLATELETS 
All animal experiments were performed in accordance with the United Kingdom 
Home Office Animals (Scientific Procedures) Act of 1986. 12/15-LOX knockout mice 
generated as described previously (Cyrus et al. 1999) and wild-type male C57BL/6 
mice (25–30 g) from Charles River, UK, were kept in constant temperature cages (20 
–22 °C) and given access to water and standard chow ad libitum. 
For studies on isolated murine platelets whole blood was collected via cardiac 
puncture (all mice were 28 weeks old) into 150 μl ACD buffer. 150 μl 3.8 % sodium 
citrate and 300 μl Tyrode’s buffer were added and the blood centrifuged at 150 g for 
5 min at RT. PRP was collected and 400 μl Tyrode’s buffer added to the red cells and 
centrifuged again at 150 g for 5 min at RT. PRPs were combined and centrifuged at 
530 g for 5 min at room temperature. Platelets were resuspended in Tyrode’s buffer 
at 2 x 108 ml-1. 
 
2.2.1.3 ACTIVATION OF WASHED PLATELETS 
1 mM CaCl2 was added 5 min prior to activation and platelets incubated at 37 oC. 0.2 
units ml-1 thrombin was added and platelets incubated at 37 °C for 0 min to 2 h. In 
some experiments, platelets were treated with 50 μM picotamide or 1-10 mM 
iodoacetate for 10 min at 37 oC prior to CaCl2 and thrombin. Lipids were extracted as 
described in 2.2.5.1.  
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2.2.1.4 CPLA2 HYDROLYSIS OF ESTERIFIED LIPIDS 
Lipids were extracted (2.2.5.1) and dried under N2, then were resuspended in 1 ml 
Tris buffer (150 mmol/l NaCl, 5 mmol/l CaCl2, 10 mmol/l Trizma base at pH 8.9) and 
hydrolysed using 100 μg snake venom cPLA2 for 60 min at 37 oC. Lipids were extracted 
as described in 2.2.5.1. 
 
2.2.1.5 SERUM AND CLOT ISOLATION 
5 ml whole blood was collected without anti-coagulant and allowed to clot for 15 min 
at 37 oC. Clots and serum were separated by centrifugation at 1,730 g for 10 min at 
RT. Lipids were extracted from serum as described in 2.2.5.1. 500 mg (wet weight) 
clot was placed in a pre-frozen mortar and pestle on dry ice and further cooled with 
liquid N2. The clot was ground up and added to 3 ml PBS pH 7.4 containing 10 mM 
diethylene triamine pentaacetic acid (DTPA). Lipids were extracted from 1 ml 
samples as described in 2.2.5.1. 
 
2.2.1.6 ISOLATION OF HUMAN NEUTROPHILS FROM WHOLE BLOOD 
For neutrophil isolation, human blood was drawn into a 20 ml syringe and mixed with 
HetaSep: 2 % sodium citrate (1:2) at a ratio of 3.3:1. The syringe was placed upright 
on its base to allow erythrocytes to sediment at room temperature for 45 – 60 min. 
The plasma layer was removed by slowly ejecting the layer into a fresh, chilled 
centrifugation tube using a butterfly needle tube with the needle removed. The 
plasma layer was slowly underlayered with Lymphoprep at a ratio 1:3 (v:v) by ejecting 
Lymphoprep into the bottom of the tube using a 3 ml plastic pasteur pipette. This 
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was centrifuged at 800 g (2000 rpm, 12 cm rotor) for 20 min at 4 C with no brake. 
The supernatant was removed using a pasteur pipette drawing the supernatant up 
from the Lymphoprep interface. The pellet was resuspended into 10 ml of 0.4 % (w/v) 
Na-tricitrate/PBS and decanted into a new chilled tube. Neutrophils were centrifuged 
at 4 C, 400 g (1400 rpm, 12 cm rotor) for 5 min and the supernatant discarded.  
To remove contaminating erythrocytes a hypertonic shock was performed by adding 
3 ml of ice cold 0.2 % (w/v) NaCl, then 3 ml of ice cold 1.6 % (w/v) NaCl and slowly 
mixing using a pasteur pipette for 35 – 50 s. 6ml of PBS was added and the 
neutrophils centrifuged at 4 C, 400 g (1400 rpm, 12 cm rotor) for 5 min. The 
supernatant was discarded and the hypertonic shock repeated once or twice again 
as required. The pellet was resuspended in 1 ml of Kreb’s buffer. Neutrophil numbers 
were adjusted to the required cell number using Kreb’s buffer and kept on ice till 
used. 
 
2.2.1.7 NEUTROPHIL ACTIVATION AND ANTIBODY STAINING 
For flow cytometry experiments, purified neutrophils (2.2.1.6) were diluted to a 
concentration of 2 x 106 ml-1. Cells were activated using 1 μM fMLP or 10 μM DXA3 
and incubated at 37 oC for 20 min. In some experiments, neutrophils were incubated 
with 10 nM- 10 μM DXA3 for 10 min at 37 oC prior to fMLP treatment. Cells were 
centrifuged at 1330 rpm for 5 min at 4 oC, the supernatant was removed and 50 μl 
flow cytometry buffer containing 5 % mouse serum added. Neutrophils were 
incubated for 1 h on ice, then centrifuged again and the supernatant removed. 
0.0625 μg anti-human CD11b Alexa Flour647 antibody or isotype control was added 
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to each sample and incubated for 30 min on ice. Neutrophils were washed twice with 
flow cytometry buffer and cells resuspended in 700 μl flow cytometry buffer prior to 
analysis. 
 
2.2.1.8 CULTURING AND ACTIVATION OF RAW246 CELLS 
RAW246 cells were cultured in DMEM (10 % FBS, 1 x Pen/Strep) at 37 oC and 5 % CO2. 
Cells were defrosted, added to 9 ml of media and centrifuged at 400 g (1200 rpm) for 
5 min at RT with no brake. The supernatant was discarded and the cells resuspended 
in 1 ml of medium. The cells were added to 50 ml of media into a T175 cell culture 
flask. 
Upon reaching a confluency of 80 - 90 % the medium was removed and the cells 
washed twice using PBS. 10 ml trypsin was added and the cells incubated at 37 oC for 
3 - 5 min. In order to stop the reaction, medium was added and the cell suspension 
transferred into a 50 ml falcon tube and centrifuged at 400 g (1200 rpm) for 5 min at 
RT without brake. The supernatant was discarded and the cells resuspended in 10 ml. 
Cells were diluted into a new flask at required ratios and incubated at 37 oC and 5 % 
CO2. 
 
2.2.1.9 ACTIVATION OF RAW246 CELLS 
Upon reaching a confluency of 80 - 90 % the medium was removed and cells washed 
twice using PBS. Serum free DMEM (1 x Pen/Strep) was added and the cells incubated 
for 1 h at 37 oC and 5 % CO2. For some experiments, 200 ng/ml LPS was added and 
cells incubated for 24 hrs at 37 oC and 5 % CO2. The cells were counted using a 
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disposable haemocytometer (Immune Systems). The cell concentration was adjusted 
to 8 x 106 ml-1. In some experiments cells were incubated for 30 min with 10 μM 
calcium ionophore A23187 at 37 oC. Lipids were extracted according to 2.2.5.1 
following addition of PGE2-d4 as internal standard (IS). 
 
2.2.2 GENERATION OF DXA3 USING RECOMBINANT OR PURIFIED CYCLOOXYGENASES 
For enzyme reconstitution, COX-1 purified from sheep seminal vesicles, recombinant 
ovine COX-1, COX-2 or the COX-2 mutants V349A or W387F were incubated with two 
molar equivalents of hematin in 100 mM phosphate buffer for 20 min on ice. A final 
amount of 3.4 μg COX-1 was incubated with 150 μM arachidonate or deuterated 
arachidonate (arachidonate-d8) and 500 μM phenol in 100 mM phosphate buffer for 
3 min at 37 °C under oxygen atmosphere. For COX-2, V349A or W387F 30 μM 
arachidonate was oxidised using 10.2 μg enzyme and 500 μM phenol in 100 mM 
phosphate buffer for 5 min at 37 oC under O2 atmosphere. Lipids were extracted 
using the hexane-isopropanol-extraction method (2.2.5.1). 
 
2.2.3 IN VITRO OXIDATION OF ARACHIDONATE 
3.5 eq. N-methyl benzohydroxamic acid (NMBHA) and 0.1 eq. 2,2'-azobis(4-methoxy-
2,4,dimethyl valeronitrile) (MeOAMVN) were added to a 6.5 mM arachidonate 
solution in chlorobenzene and the mixture was stirred at 37 °C for 5 h under O2 
atmosphere. Both NMBHA and MeOAMVN were a gift from Prof. Ned A. Porter 
(Vanderbilt University, TN,USA). The sample was dried under N2 and dissolved in 
methanol. Purification of the free hydroperoxide positional isomers was 
accomplished using reverse phase HPLC using a Spherisorb ODS2 column (5 μm, 150 
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mm x 4.6 mm; Waters) with a solvent gradient of 50 - 90 % solvent B (acetonitrile, 
0.1 % formic acid) in solvent A (water, 0.1 % formic acid) over 60 min, 90 % solvent B 
60 - 64.5 min, 50 % solvent B 65.5 - 75 min and a flow rate of 1 ml min-1. Lipids were 
monitored at 205 nm (unoxidized lipid) and 235 nm (HpETE) and fractions were 
collected at 30 second intervals. HpETEs were identified in these fractions using 
MS/MS: m/z 317.2 to 115.1 (5-HpETE); m/z 317.2 to 155.1 (8-HpETE); m/z 317.2 to 
151.1 (9-HpETE); m/z 317.2 to 167.1 (11-HpETE), m/z 317.2 to 179.1 (12-HpETE); m/z 
317.2 to 219.1 (15-HpETE). The fraction containing 11-HpETE was purified using Sep 
Pak purification as described in 2.2.5.2. 
 
2.2.4 GENERATION OF DXA3 VIA OXIDATION OF ISOLATED 11-HPETE 
The purified 11-HpETE was oxidised using 0.1 eq. MeOAMVN in 5 ml chlorobenzene 
stirring at 37 °C for 5 h under O2 atmosphere. Hydroperoxides generated via 
oxidation of 11-HpETE were reduced using 95 μg SnCl2 in water for 10 min at RT. 
Lipids were extracted using hexane-isopropanol-extraction (2.2.5.1) and analysed by 
LC/MS/MS (2.2.7.3).  
 
2.2.5 LIPID PURIFICATION 
2.2.5.1 ISOPROPANOL-HEXANE LIPID EXTRACTION 
For all experiments 5 - 10 ng deuterated standards PGE2-d4, 12-HETE-d8, TxB2-d4, 
DMPE (IS) were added to samples prior to extraction. Lipids were extracted using a 
solvent mixture (1 mol/L acetic acid, isopropyl alcohol, hexane (2:20:30, v/v/v)) at a 
ratio of 2.5 ml to 1 ml sample. The sample was vortexed, and 2.5 ml of hexane added. 
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Following vortexing and centrifugation at 1500 rpm for 5 min at 4 oC, lipids were 
recovered from the upper hexane layer. The samples were then re-extracted by 
addition of an equal volume of hexane. The combined hexane layers were dried 
under vacuum and analysed using LC-MS/MS (2.2.7).  
 
2.2.5.2 LIPID PURIFICATION USING SOLID PHASE EXTRACTION COLUMNS 
Silica-based solid phase extraction columns (Sep Pak, Waters, MA, USA) were 
equilibrated with 5 ml of water pH 3.0 followed by 5 ml of methanol. Samples for 
purification were diluted with water to an organic content of 15 % and purified over 
the column. The column was washed with 20 ml water at pH 3.0 and lipids extracted 
using 5 ml of methanol. The mixture was dried using nitrogen flow and the lipids 
dissolved in 100 - 200 μL of methanol. 
 
 
2.2.6 LIPID DERIVATISATION AND HYDROGENATION 
2.2.6.1 METHYLOXIME (MOX) DERIVATISATION OF CARBONYL GROUPS. 
Lipids were dried under nitrogen flow in a glass vial. In a second vial, 1 mL of 1 N 
NaOH was combined with a few grains of MOX. The tubes were connected with the 
dry lipid uppermost to prevent solvation, and incubated for 2 h at 60 °C.  
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2.2.6.2 2,3,4,5,6-PENTAFLOUROBENZYL BROMIDE (PFB)-DERIVATISATION OF 
CARBOXYLS. 
Lipid was dried under N2 and 25 μl of 1 % PFB and 25 μl of n,n-diisopropylethylamine 
(DIEA), both in acetonitrile, added. The mixture was vortexed and incubated for 30 
min at 20 °C. The sample was dried under N2. 
 
2.2.6.3 TRIMETHYLSILANE (TMS)-DERIVATISATION OF HYDROXYL GROUPS. 
Lipid was dissolved in 50 μl of N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and 
50 μl of acetonitrile, vortexed and incubated for 1 h at 60 °C. The lipid was dried 
under N2 and 2 mL of ethylacetate and 1 mL of H2O added. The sample was vortexed 
and the ethylacetate layer recovered, dried, then dissolved in acetonitrile for GC/MS 
(2.2.9).  
 
2.2.6.4 CATALYTIC HYDROGENATION USING PALLADIUM ON CARBON (PD-C). 
Purified DXA3 was incubated with 731 μM Pd-C (10 wt. % loading) in methanol for 2.5 
h at 20 °C in a C18 solid phase extraction cartridge under hydrogen flow. The solution 
was centrifuged through the column and used for derivatisation according to 2.2.6.1, 
2.2.6.2, 2.2.6.3 and analysed using GC/MS (2.2.9). 
 
2.2.7 ANALYTICAL METHODS 
2.2.7.1 HPLC-PURIFICATION OF DXA3 FROM LIPID EXTRACT  
Lipid extracts were separated using reverse-phase HPLC (Agilent) employing a 
Spherisorb ODS2 column (5 μm, 150 mm x 4.6 mm; Waters) with a gradient of 20-
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42.5 % solvent B (100 % acetonitrile, 0.1 % formic acid) in solvent A (100 % water, 0.1 
% formic acid) over 50 min, 42.5 - 90 % solvent B 50 - 60 min, 90 % solvent B 60 - 64.5 
min, 90 - 20 % 64.5 - 65.5 min and 20 % solvent B 65.5 - 75 min with a flow rate of 1 
ml min-1. 30 sec fractions were collected and analysed using MS/MS monitoring m/z 
351.2 to 165.1. Water was removed from DXA3 containing fractions using Sep-Pak 
C18 cartridge purification as described in 2.2.5.2. Simultaneously, absorbance was 
monitored at 210, 235 and 270 nm. 
In some experiments, [14C]-labelled lipids were monitored using a radioflow detector 
(Berthold Technologies). 
 
2.2.7.2 Q1 SCAN 
Lipid extracts were injected directly without LC separation at a flow rate of 10 μl/min 
and analysed in full scan mode (Q1) in a mass range of m/z 100 - 400 on the 4000 Q-
Trap (AB Sciex, Canada). 
  
2.2.7.3 REVERSE-PHASE LC/MS/MS OF FREE FATTY ACIDS (75 MIN) 
Lipid extracts were separated using reverse-phase HPLC as described in 2.2.7.1. 
LC/MS/MS was performed using a HPLC (Shimadzu, Japan) and 4000 Q-Trap (AB 
Sciex, Canada). Analysis was performed in negative MRM mode monitoring the 
parent to fragment m/z listed in Table 2.. Lipid spectra were monitored in Enhanced 
Product Ion (EPI) mode. For further explanations please see 1.5.1. 
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2.2.7.4 REVERSE PHASE LC/MS/MS  OF FREE FATTY ACIDS (30 MIN) 
Lipid extracts were separated using a Spherisorb ODS2 column (5 μm, 150 mm x 4.6 
mm; Waters) with a gradient of 50 - 90 % solvent B (60 % methanol, 40 % acetonitrile, 
0.1 % glacial acetic acid) in solvent A (75 % water, 25 % acetonitrile, 0.1 % glacial 
acetic acid) over 20 min, 90 % solvent B over 5 min, 90 - 50 % solvent B from 25 – 
25.1 min and 50 % solvent B from 25.1 - 30 min with a flow rate of 1 ml.min-1. 
LC/MS/MS was performed with a HPLC (Shimadzu, Japan) and 4000 Q-Trap (AB Sciex, 
Canada), using negative MRM or EPI mode monitoring the lipids listed in Table 2.. 
 
2.2.7.5 REVERSE PHASE LC/MS/MS  OF PHOSPHOLIPIDS 
Lipid extracts were analysed using a Luna column (3 μm, 150 x 2.0 mm) with a 
gradient of 50 - 100% solvent B (100 % methanol, 1 mM ammonium acetate) in 
solvent A (60 % methanol, 20 % water, 20 % acetonitrile, 1 mM ammonium acetate) 
over 10 min, 100 % solvent B from 10 - 40 min, 100 - 50 % solvent B from 40.0-42.0 
min and 42.1 to 50 min 50 % solvent B with a flow rate of 0.2 ml min-1. DXA3-PE was 
identified using LC/MS/MS on the HPLC (Shimadzu, Japan) coupled 4000 Qtrap (AB  
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Table 2.1. MS/MS parameters monitoring eicosanoids. 
DP: declustering potential [mV], CE: collision energy [mV] 
Lipid 
Q1  
[m/z] 
Q3 
[m/z] 
DP 
[mV] 
CE 
[mV] 
DXA3 351.2 165.1 -55 -26 
[14C] DXA3 353.2 165.1 -55 -26 
PGE2 351.2 271.1 -55 -26 
TxB2 396.2 169.1 -50 -22 
12-HETE 319.2 179.1 -85 -20 
PGE2-d4 355.2 271.1 -55 -26 
TxB2-d4 373.2 173.1 -95 -36 
12-HETE-d8 327.2 184.1 -85 -20 
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Sciex, Canada) employing negative MRM mode monitoring the transitions shown 
in Table 2.. 
 
2.2.8 REVERSE PHASE LC/MS3 
To determine the accurate mass of lipids of interest and their MS3 fragmentation 
spectra, a reverse phase HLPC approach was employed on an Orbitrap Elite 
instrument (Thermo Fisher, MA, USA) with a Spherisorb ODS2 column (5 μm, 150 
mm x 4.6 mm, Waters) and a solvent gradient described in 2.2.7.1. Analysis was 
performed using h-ESI in negative ion mode at sheet, auxillary and sweep gas 
flows of 70, 20, and 0. Capillary and source heater temperatures were set to 300 
and 350 oC, respectively. MS/MS analysis of DXA3 (m/z 351.2177) or DXA3-d8 (m/z 
359.2679) was undertaken in negative FTMS mode using CIDwith a resolving 
power of 30,000. Data dependent MS3 monitoring DXA3 or DXA3-d8 was carried 
out in negative FTMS mode with resolving power of 15,000.  
 
2.2.9 GC-MS 
GC/MS was carried out on a DSQ Finnigan (Thermo Fisher, MA, USA) at the 
laboratory of Dr. Robert Murphy (University of Denver, USA). Samples were 
analysed using a Phenomenex 30M ZB-1 column in negative polarity mode with a 
source temperature of 200 °C and methane as reagent gas applying a gas flow of 
1.8 ml min-1. 
 
 
 
 80 
 
Table 2.2. MS/MS parameters monitoring DXA3-PEs. 
DP: declustering potential [mV], CE: collision energy [mV] 
Lipid Q1  
m/z 
Q3  
m/z 
DP 
 [mV] 
CE 
 [mV] 
DXA3-PE 
18:0a 
814.7 351.1 -140 -45 
DXA3-PE 
18:0p 
798.6 351.1 -140 -45 
DXA3-PE 
18:1p 
796.6 351.2 -140 -45 
DXA3-PE 
16:0p 
770.6 351.2 -140 -45 
DMPE 634.4 227.2 -140 -45 
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2.2.10 FLOW CYTOMETRY ANALYSIS OF NEUTROPHILS 
Flow cytometric analysis was performed using a Cyan ADP analyser (Beckman 
Counter, CA, USA). The forward scatter (FSC), side scatter (SSC) and Alexa Fluor 
647 voltage parameters were determined using unstained purified neutrophils 
prior to acquisition of the experimental samples. Data was analysed using flowjo 
software (FlowJo, LLC, OR, USA). 
 
2.2.11 STATISTICS 
Statistical significance was assessed using one way ANOVA followed by Bonferroni 
multiple comparisons test, as indicated on legends. * p  0.05 was considered 
statistically significant and *** indicated p  0.005. 
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3 CHAPTER THREE 
STRUCTURAL CHARACTERISATION OF A NOVEL PLATELET 
LIPID 
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3.1 INTRODUCTION 
Preliminary structural studies performed by members of the O’Donnell group in 
collaboration with Prof. Robert Murphy (University of Colorado, Denver) revealed 
that DXA3 contains three double bonds and five oxygen atoms in total. Three of those 
form a carboxyl and one hydroxyl group. These studies also demonstrated that DXA3 
contains no carbonyl group and is acid stable, effectively excluding epoxides 
(unpublished). DXA3 elutes later than PGE2 on reverse phase chromatography 
indicating it to be less polar than PGE2. Hence, for the two remaining oxygen atoms 
a dioxolane ring structure and three double bonds were proposed yielding m/z 
351.2175 and a elemental composition of C20O5H32. 
As described in Chapter 1 (1.4), arachidonate - derived dioxolanes have been 
demonstrated previously to form in chemical reactions. Havrilla et al. proposed a 
structure for the mono-cyclic product (Scheme 1.) that contains a dioxolane ring and 
three double bonds and calculation of its ion mass as a free fatty acid form reveals 
m/z 351.2177, which is identical to that of DXA3. Therefore, the free fatty acid 
structure of the monocyclic product we found in platelets was initially proposed to 
be 8-hydroxy-9,11-dioxolane eicosatrienoic acid (DXA3) (Scheme 3.1).  
 
Scheme 3.1.Proposed structure of DXA3. 
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However, Havrilla et al. (2000) analysed dioxolanes that were esterified to 
cholesterol using positive ion mode. Thus, their data cannot be compared with our 
MS/MS of DXA3 obtained in negative ion mode. Therefore, in this chapter I will 
structurally characterise HPLC -purified DXA3 generated by COX-1 in vitro. In order to 
open the chemically-stable dioxolane ring and to determine the number of double 
bonds, I will hydrogenate DXA3 using palladium on carbon (Pd-C) as catalyst (as 
shown by Yin et al. 2004), then derivatise and analyse using GC/MS. In addition, high 
resolution LC/MSn of DXA3 and its deuterated analogue DXA3-d8 derived from 
oxidation of arachidonate and arachidonate-d8 by COX-1 in vitro will be undertaken.  
The proposed structure for DXA3 contains a conjugated diene (Scheme 3.1). 
Structurally similar dioxolanes derived from LOX in vitro were shown to be UV active 
with an absorbance max of λ 238 nm (Teder et al. 2014). Therefore, DXA3 should 
absorb at similar wavelength. To provide further evidence for our proposed 
structure, I will determine whether COX-derived DXA3 is UV-active. 
 
3.1.1 AIMS 
 Elucidate the functional groups of the two remaining oxygen atoms in DXA3 
through hydrogenation using Pd-C. 
 Determine the fragmentation pathway of DXA3 by employing high resolution 
MSn analysis using lipid generated from either arachidonate or arachidonate-
d8, to further support the proposed structure of DXA3. 
 Investigate whether DXA3 contains a conjugated diene by using LC/UV.  
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3.2 RESULTS 
To confirm the proposed structure of DXA3 derived from COX-1 in vitro (2.2.2), I 
utilised GC/MS at the University of Denver (3.2.1), high resolution MS (3.2.2) and 
LC/UV (3.2.5). These studies were carried out in collaboration with Prof. Robert 
Murphy (University of Colorado, USA). 
 
3.2.1 HYDROGENATION OF HPLC-PURIFIED DXA3 REVEALS A DIOXOLANE RING AND THREE 
DOUBLE BONDS 
Yin et al (2004) demonstrated that dioxolanes can be hydrogenated using Pd-C as 
catalyst leading to ring opening and hydrogenation of double bonds. Therefore, in 
this study, HPLC-purified DXA3 generated by purified COX-1 in vitro was 
hydrogenated using the same catalyst. 
Following hydrogenation, DXA3 was derivatised using methoxyamine hydrochloride 
(MOX), N,O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA) and /or pentafluorbenzyl 
bromide (PFB) as described in 2.2.6. MOX derivatises carbonyl groups leading to a 
mass increase of +29 amu. Derivatisation with BSTFA results in addition of 
trimethylsilyl (TMS) to hydroxyl groups and a mass increase of +72 amu. The carboxyl 
group, common to all eicosanoids, is derivatised using PFB. This enables lipids to 
become sufficiently volatile for GC/MS. During ionisation, electrons generated are 
captured by the electrophilic PFB leading to cleavage of this group from the lipid, and 
resulting in regeneration of the carboxylate anion, which is detected in negative ion 
mode (termed negative chemical ionisation, NICI). 
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The proposed lipid structures were drawn in ChemSketch (ACD Labs), allowing 
calculation of masses of DXA3, its hydrogenated analogue, and following 
derivatisation using BSTFA (Scheme 3.2). 
 
 
Scheme 3.2. Hydrogenation and derivatisation of DXA3. 
Hydrogenation of DXA3 with m/z 351.2 should result in ring opening and hydrolysis 
of double bonds to m/z 359.2. Thus, derivatisation using BSTFA reagent should lead 
to the addition of three TMS groups resulting in m/z 575.4. 
 
 
Hydrogenation of DXA3 is expected to open the dioxolane ring, forming two hydroxyl 
groups. Along with reduction of the three double bonds this would lead to m/z 359.2. 
The hydroxyl groups can then be derivatised using BSTFA resulting in m/z 575.4. 
Indeed, when extracting this mass from a GC/MS full scan, four peaks (1-4) elute 
(Figure 3.1). As expected, the mass spectra for all four peaks show m/z 575.4 (Figure 
3.2). This data is consistent with the presence of three hydroxyl groups and three 
double bonds. Alongside DXA3, several unknown ions appear in the spectra including 
m/z 427.3, 501.3 and 517.4. However, when extracting them from the TIC, it was 
seen that none of those coeluted with DXA3. Therefore, these ions remain 
unidentified but do not originate from DXA3 itself (data not shown).  
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Figure 3.1. Four products are detected when monitoring m/z 575.4 in HPLC-
purified DXA3 generated by COX-1 in vitro following hydrogenation. DXA3 was 
generated by COX-1 in vitro, then purified as described in 2.2.2 and 2.2.7.1. HPLC-
purified DXA3 was hydrogenated and derivatised using TMS (2.2.6) and analysed 
using GC/MS (2.2.6, 2.2.9). (A) Total ion current (TIC). (B) The extracted ion m/z 
575-576 shows four peaks eluting at 10.35 min (Peak 1), 10.54 min (Peak 2), 10.62 
min (Peak 3) and 10.74 min (Peak 4).  
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Figure 3.2. GC/MS of DXA3 is consistent with three double bonds and a dioxolane 
ring. DXA3 was generated by COX-1 in vitro, purified, then hydrogenated and 
derivatised using BSTFA as described in 2.2.2, 2.2.7.1 and 2.2.6. GC/MS spectrum 
of (A) Peak 1, (B) Peak 2, (C) Peak 3 and (D) Peak 4 eluting in 3.1. For all peaks a 
background spectrum was subtracted. m/z 575.4 represents the m/z for 
hydrogenated DXA3 + 3x TMS groups.  
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3.2.2 THE FRAGMENTATION PATHWAY FOR DXA3 SUPPORTS THE PREVIOUS PROPOSED 
STRUCTURE 
To determine the CID fragmentation pattern of DXA3, I generated data dependent 
MSn utilizing high resolution Orbitrap MS, which allows a mass accuracy down to 1 
ppm.  
In this approach, MSn data are used to generate a fragmentation pathway, as 
illustrated in Scheme 3.3: A parent ion is detected in an MS experiment and 
fragmented in MS/MS mode generating several product ions (Scheme 3.3, 1-3). 
These can then be fragmented again in a data dependent MS3 experiment to 
determine which ion originates from which parent. Utilizing high resolution MS 
allows calculation of the chemical composition of parent and fragment ions, thus 
enabling the structural elucidation of both. 
In this study I analysed DXA3 and its deuterated analogue (DXA3 -d8) generated by 
COX-1 in vitro as described in 2.2.2. Both were analysed using LC/MS/MS to generate 
a fragmentation spectrum of the parent ions (3.2.2.1). This was followed by MSn of 
the most abundant fragment ions (3.2.2.2, 3.2.2.3). Based on the data obtained, I 
propose two fragmentation pathways including structures for the parent and 
fragment ions (3.2.3, 3.2.4). 
 
3.2.2.1 GENERATION OF A MS/MS SPECTRUM OF BOTH DXA3 AND DXA3-D8 USING 
HIGH RESOLUTION ORBITRAP MASS SPECTROMETRY 
Due to the different pump system on the Orbitrap platform, DXA3 and DXA3-d8 elute 
slightly later than on the 4000 QTrap system, at 47.61 min (Figure 3.3, Panel A) and 
47.18 min (Figure 3.4, Panel A) respectively. DXA3 was identified based on its MS/MS  
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Scheme 3.3. Building a pathway of fragmentation based on MSn experiments. A 
parent ion, which is observed in an MS spectrum, is fragmented in a MS/MS 
experiment generating fragment ions 1-3. These ions can be fragmented again in a 
MS3 experiment to determine the relationship between fragment ions and 
consequently develop a fragmentation pathway. 
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Figure 3.3. DXA3 generated by COX-1 in vitro elutes at 47.61 min on the Orbitrap 
Elite platform. DXA3 was generated by COX-1 in vitro and analysed using high 
resolution LC/MS as described in 2.2.2 and 2.2.7.3. (A) DXA3 elutes at 47.61 min 
in the MS chromatogram monitoring the parent ion m/z 351.2175. (B) MS 
spectrum of DXA3 eluting at 47.61 min in (A). m/z 351.2182 is the most abundant 
ion. (C) MS/MS spectrum of DXA3. 
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Figure 3.4. DXA3-d8 derived from COX-1 in vitro elutes at 47.18 min on the 
Orbitrap platform. LC/MS analysis of DXA3 generated by oxidation of 
arachidonate-d8 using COX-1 in vitro as described in 2.2.2 and 2.2.7.3. (A) LC/MS 
chromatogram monitoring m/z 359.2675 for DXA3-d8 reveals one major peak 
eluting at 47.18 min. (B) MS spectrum of this peak shows m/z 359.2679 as the 
most abundant ion. (C) MS/MS spectrum of ion m/z 359.27. 
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spectrum and retention time in regard to that of PGE2, which elutes at 30.03 min 
on the Orbitrap system. Therefore, shifts in retention time of both lipids would be 
identical. DXA3 with m/z 351.2182 (Figure 3.3, Panel B) is within the acceptable 5 
ppm range for ion identification compared to a theoretical ion mass of DXA3 m/z 
351.2177, which I calculated using ChemSketch. LC/MS/MS analysis of this ion 
(Figure 3.3, Panel C) shows an identical fragment spectrum as detected prior to 
this study for DXA3 attached to PE (Aldrovandi et al, unpublished). The MS 
spectrum of DXA3-d8 reveals m/z 359.2679 as the most abundant ion (Figure 3.4, 
Panel B), which is only 1.1 ppm different from the theoretical calculated ion mass 
for DXA3-d8. As a consequence of deuteration, the MS/MS spectrum of this lipid 
is expected to reveal fragment ions differing by up to 8 Da from those of the 
undeuterated lipid (Figure 3.4, Panel C). 
 
3.2.2.2 MSN DATA OF DXA3 
The ten most abundant fragment ions generated during DXA3 MS/MS 
fragmentation (Figure 3.3, Panel C) were selected for further LC/MS3 analysis 
(Figure 3.5). The fragmentation spectrum of m/z 333.2078 shows the ions m/z 
315.1968, m/z 289.2166 and m/z 271.2077 (Figure 3.5, Panel A). As described in 
3.2.2.1, this indicates that m/z 315.1968 and m/z 271.2077 originate from m/z 
333.2078. Following fragmentation of m/z 315.1971 the ion m/z 271.2068 is 
detected (Figure 3.5, Panel B). Hence, this ion originates from m/z 315.1971. MS3 
of m/z 271.2171 reveals minor ions (Figure 3.5, Panel C), which are not detected 
in MS/MS spectra (Figure 3.3, Panel C). Therefore these will not be considered in  
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Figure 3.5. Data dependent MS3spectra of DXA3. LC/MSn of DXA3 derived from 
COX-1 in vitro as described in 2.2.2 and 2.2.8. MS3spectra of (A) m/z 333.21, (B) 
m/z 315.20, (C) m/z 271.21, (D) m/z 225.11, (E) m/z 207.10, (F) m/z 195.10, (G) 
m/z 177.09, (H) m/z 165.09, (I) m/z 163.11 and (J) m/z 149.10. Data obtained on 
high resolution Orbitrap MS. 
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this fragmentation pathway. The spectra indicate that m/z 271.2077 originates 
from m/z 315.1968, which itself originates from m/z 333.2078. The ions m/z 
225.1136, m/z 207.1031 and m/z 163.1133 belong to an additional fragmentation 
pathway. The ion m/z 163.1133 originates from m/z 207.1031 (Figure 3.5, Panel 
I), which itself is a result of fragmentation of m/z 225.1136 (Figure 3.5, Panel D). 
Fragmentation of m/z 163.1133 results in minor ions not considered in this 
pathway.  
MS3 spectra for the remaining ions m/z 195.1031 (Figure 3.5, Panel F), m/z 
177.0925 (Figure 3.5, Panel G), m/z 165.0915 (Figure 3.5, Panel H), and m/z 
149.0976 (Figure 3.5, Panel J) suggest that m/z 177.0925 is a product ion of m/z 
195.1031. The mass difference of 18 Da between these ions indicates the loss of 
a water molecule. However, the ions m/z 195.1031, m/z 165.0915 and m/z 
149.0976 show no relation to each other or other ions investigated. This suggests 
that these ions are fragments of either the parent ion m/z 351.2177 or ions not 
chosen for MS3 experiments. Therefore, these ions were neither structurally 
identified nor considered in the fragmentation pathway presented herein. 
 
3.2.2.3 MSN DATA OF DXA3-D8 
To determine the fragmentation pathway of DXA3-d8, the same analytical process 
was employed as described for DXA3 (3.2.2.2). The MS/MS spectrum of the parent 
ion m/z 359.2667 is depicted in Figure 3.4, Panel C. From this spectrum the ten 
most abundant fragment ions were selected for data  
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dependent MS3 analysis (Figure 3.6). The parent ion m/z 359.2667 is fragmented 
into m/z 341.2574 and m/z 340.251 (Figure 3.4, Panel C). MS3 spectra of both ions 
show the product ion m/z 322.2405 (Figure 3.6, Panels A and B) and 
fragmentation of this results in m/z 278.2522 (Figure 3.6, Panel C), which could 
not be further fragmented (Figure 3.6, Panel D). Therefore, m/z 278.2522 is 
considered to be the end of the fragmentation pathway. 
As for DXA3, also MS3 for DXA3-d8 indicates a second pathway of fragmentation in 
which m/z 168.14 is a fragment of m/z 212.13 (Figure 3.6, Panel F). The latter 
originates from m/z 231.15 (Figure 3.6, Panel E). The fragment ions of DXA3-d8 
are consistent with deuterium atoms on the carbon backbone of DXA3. 
MS3 spectra of the remaining ions m/z 200.13 (Figure 3.6, Panel G), m/z 181.12 
(Figure 3.6, Panel H) and m/z 169.15 (Figure 3.6, Panel I) do not indicate a 
relationship to each other or the other ions investigated. Thus, these ions were 
not considered further. 
 
3.2.3 FRAGMENTATION PATHWAY OF DXA3 M/Z 351.2177 TO M/Z 271.2067 
All MSn results are summarised in Table .1 for DXA3 and Table 3.2 for DXA3-d8. 
Both demonstrate that all MS/MS and MS3 fragment ions are generated through 
fragmentation of the parent ion m/z 351.2182 or m/z 359.2667. Additional MS3 
fragment ions generated from their corresponding MS/MS fragments, formed as 
a result of m/z 351.2182 or m/z 359.2667 parent ion fragmentation are also 
described. 
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Figure 3.6. Data dependent MS3 spectra of DXA3-d8. LC/MSn of DXA3-d8 
generated by COX-1 in vitro as described in 2.2.2 and 2.2.8. MS3 spectra of (A) m/z 
341.26, (B) m/z 340.25, (C) m/z 322.24, (D) m/z 278.25, (E) m/z 231.15, (F) m/z 
212.13, (G) m/z 200.13, (H) m/z 181.12, (I) m/z 169.15 and (J) m/z 168.14. Data 
obtained on high resolution Orbitrap MS. 
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Table 3.1 Fragmentation of DXA3 m/z 351.2182 using MS/MS and 
MS3performed using the Orbitrap Elite. 
 
DXA3 parent 
mass 
MS/MS 
fragments 
MS3 
fragments 
m/z m/z m/z 
351.2182 333.2078 315.1969 289.2173 271.2072 219.1664 
351.2182 315.1971 297.1971 271.2069   
351.2182 271.2071 253.1983 217.1599   
351.2182 225.1136 207.1031 163.1128   
351.2182 207.1031 189.0924 163.1132 109.0662  
351.2182 195.1031 177.0925 151.1132   
351.2182 177.0925 159.0821    
351.2182 165.0915 121.1023    
351.2182 163.1133 145.1023 121.0662 109.0662  
351.2182 149.0976     
 
 
Table 3.2 Fragmentation of DXA3-d8 m/z 359.2667 using MS/MS and 
MS3experiments using the Orbitrap Elite. 
 
DXA3-d8 
parent 
mass 
MS/MS 
fragments  
MS3 
fragments 
m/z m/z  m/z  
359.2667 341.2573 323.2483 322.2409 297.2668   
359.2667 340.251 321.2348 322.2397 296.2589 277.243  
359.2667 322.2406 278.2511     
359.2667 278.2508      
359.2667 231.1511 213.1405 212.1344 211.1283 168.1441 165.1505 
359.2667 212.1342 168.1451 113.0907    
359.2667 200.1343 181.1177 156.1445 182.1235   
359.2667 181.1174 163.1066 162.1067    
359.2667 169.1175 150.1343 125.1281    
359.2667 168.1443      
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Notably, in addition to a parent mass of m/z 359.2681, m/z 358.2621 was 
detected in the LC/MS spectrum of DXA3-d8. This mass corresponds to an open 
ring structure as shown in Figure 3.7, Panel B. In contrast, ring opening of 
undeuterated DXA3 does not result in a mass change and remains at m/z 351.2177 
(Figure 3.7, Panel A). Consequently, this cannot be detected in the spectrum. 
However, as ring opening is detected for DXA3-d8, it will be considered in the 
fragmentation pathway.  
Some MSn spectra of DXA3-d8 contain additional ions not found for DXA3. As 
demonstrated on m/z 341.2575 and m/z 340.2513 (Figure 3.8, Panel A), these ions 
differ by approximately 1 Da from one another and appear with similar abundance 
in the MS/MS spectra. This is due to the deuterium atoms within DXA3-d8, since 
the substrate for COX-1, arachidonate-d8, contains eight deuterium atoms at 
positions 5, 6, 8, 9, 11, 12, 14, and 15. Consequently, DXA3-d8 contains deuterium 
at the same positions: 
O
O
CH3
ODD
D
D
D
D
D
OH
OH
D
1
2
3
4
56
7
8
9
10
11
12
13
14
15
16
17
18
19
20  
 
As a result of deuteration, fragmentation or the loss of a water molecule from 
DXA3-d8 leads to the abstraction of either hydrogen (H) or deuterium (D) atoms. 
Consequently, additional DXA3-d8 fragments are formed that are not seen for 
DXA3. For example, the loss of a water molecule from DXA3-d8 will result in m/z 
341.2 and m/z 340.2 (Figure 3.8, Panel B): 
m/z 359.2679 
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Figure 3.7. Ring opening is detected during DXA3-d8 fragmentation. MS spectra 
obtained on high resolution Orbitrap MS of DXA3 and DXA3-d8 derived from COX-
1 in vitro as described in 2.2.2 and 2.2.8. Extraction of the parent ion masses of 
(A) DXA3 m/z 351.2177 and (B) DXA3-d8 m/z 359.2979.  
 
 
 
 101 
 
 
Figure 3.8. Loss of water from DXA3-d8 results in several product ions. DXA3-d8 
derived from COX-1 in vitro was analysed using high resolution LC/MS/MS as 
described in 2.2.2 and 2.2.8. (A) MS/MS spectrum of DXA3-d8 shown within the 
range m/z 335-360. During fragmentation a water molecule can be abstracted 
either as H2O or DHO from position C8 or C11. This results in (B) the ions m/z 
341.2573 or m/z 340.2511, (C) m/z 340.2511 or m/z 339.2448 or (D) m/z 340.2511 
or m/z339.2448. Structures were drawn using Chemsketch.  
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 359.2 Da -18 Da (H2O) = 341.2 Da, resulting from loss of H at position C7 
and a hydroxyl group (OH) at position C8 
 359.2 Da -19 Da (DHO) = 340.2 Da, resulting from loss of D at C8 and OH 
at C8. 
If ring opening occurs first (resulting in m/z 358.2), a carbonyl group is either 
formed at C9 or C11 and loss of a water molecule leads to m/z 340.2 and m/z 
339.2 (Figure 3.8, Panels C and D): 
 358.2 Da -18 Da= 340.2 Da, resulting from loss of H at C7 and OH at C8 or 
H at C10 and OH at C11.  
 358.2 Da – 19 Da (DHO) = 339.2 Da, resulting from loss of D at C8 and OH 
at C8 or D at C11 and OH at C11. 
To compare the MSn data for DXA3-d8 and DXA3, the ion mass differences of both 
lipids were calculated shown as Δ m/z in Table 3.3. These differences correlate 
with the number of remaining deuterium atoms in the ion following 
fragmentation. This provides information regarding deuterium or hydrogen 
abstraction during fragmentation. 
Based on the data shown in Table 3.2 and Table 3.3 and opening of the dioxolane 
ring (Figure 3.7), I propose two fragmentation pathways for DXA3 (m/z 351.2177) 
leading to m/z 271.2067 and m/z 163.1132. This is supported by data obtained on 
DXA3-d8 fragmentation.  
The fragmentation pattern of DXA3 to m/z 271.2067 is shown in the MS/MS 
spectrum (Figure 3.9). Parent and fragment ion structures for this pathway are 
depicted in Figure 3.10 and Figure 3.11. I propose that fragmentation commences 
with the loss of a water molecule from the parent ion  
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Table 3.3 DXA3 and DXA3-d8 parent and product ion masses differ by up to 8 
Da. 
Ion masses of DXA3 and DXA3 d-8 were subtracted giving 𝜟m/z. This value 
correlates with the number of deuterium atoms in the ion. 
 
 DXA3  
m/z 
DXA3-d8 
m/z 
𝜟m/z  
(DXA3/ DXA3 d-8) 
Parent ion mass 351.2177 359.2667 8 
Product ion mass 333.2075 340.251 7 
  341.2573 8 
 315.1971 322.2405 7 
  323.2469 8 
 271.2069 278.2508 7 
 225.1135 231.1511 6 
 207.1029 212.1342 5 
 195.103 200.1343 5 
 165.0924 169.1175 4 
 163.1132 168.1443 5 
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Figure 3.9. Fragmentation pathway of m/z 351.2182 to m/z 271.2071. LC/MS/MS 
spectrum of DXA3 monitoring the fragmentation of m/z 351.2182 as described in 
2.2.2 and 2.2.8. Data dependent MSn experiments enabled the determination of 
the relationship between fragment ions marked in red.  
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Figure 3.10. Fragmentation pathway of DXA3 from m/z 351.2177 to m/z 
271.2067. Fragmentation pathway based on MSn data of DXA3 performed on the 
Orbitrap Elite instrument as described in 2.2.8. The fragmentation of the parent 
ion m/z 351.2177 to m/z 271.2067 is shown. The pathway shows abstraction of 
both water and CO2 alongside rearrangements of double bonds and neutral 
carbon atoms. 
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Figure 3.11. Fragmentation pathway of DXA3-d8 from m/z 359.2679 to m/z 
278.2507. Fragmentation pathway based on MSn data of DXA3 performed on the 
Orbitrap Elite instrument as described in 2.2.8. The fragmentation of the parent 
ion m/z 359.2679 to m/z 278.2507 is shown. The pathway shows both abstraction 
of water and CO2 alongside rearrangements of double bonds and neutral carbon 
atoms. 
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m/z 351.2177. Then, the dioxolane ring opens resulting in a carbonyl group at C9 
leading to m/z 333.2071. The loss of both a water and a carbon dioxide molecule 
from this ion results in m/z 271.2067 via m/z 315.1967 (Figure 3.10). This 
proposed fragmentation pathway was supported by LC/MS3 data of DXA3-d8 as 
shown in Figure 3.11. In particular, examining both m/z 341.2573 and m/z 
340.2511 in the LC/MSn spectra of DXA3-d8 led to the proposed ring opening as 
shown in Figure 3.11. As for DXA3, DXA3-d8 fragmentation continues through loss 
of both a water and a carbon dioxide molecule leading to m/z 278.2507 via m/z 
322.2405 (Figure 3.11). 
 
3.2.4 FRAGMENTATION PATHWAY OF DXA3 M/Z 351.2177 TO M/Z 163.1128 
The second pathway of fragmentation of m/z 351.2177 to m/z 163.1132 is shown 
in the MS/MS spectrum (Figure 3.12). The structures of parent and fragment ions 
are depicted in Figure 3.13, Figure 3.14, and Figure 3.15. I propose that the 
dioxolane ring opening occurs first resulting in a carbonyl group at position C9 
(Figure 3.13) or C11 (Figure 3.14). Sigmatrophic shifts and loss of one water 
molecule result in m/z 333.2071 and further loss of alkyl chains lead to m/z 
225.1132. With the loss of a water molecule, m/z 207.1027 is generated, which 
then fragments to m/z 163.1128 due to loss of carbon dioxide and molecular 
rearrangement. This pathway is supported by fragmentation of DXA3-d8 (Figure 
3.15). 
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Figure 3.12. Pathway of fragmentation of DXA3 from m/z 351.2182 to m/z 
163.113. MS/MS spectrum of DXA3 m/z 351.2182 as described in 2.2.7.6. Data 
dependent MSn experiments enabled the determination of the relationship 
between all fragment ions marked in red.  
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Figure 3.13. Fragmentation pathway of DXA3 from m/z 351.2177 to m/z 
163.1128 with dioxolane ring opening via 9-carbonyl. Fragmentation pathway 
based on MSn data of DXA3 performed on the Orbitrap Elite instrument as 
described in 2.2.2 and 2.2.8. The fragmentation of the parent ion m/z 351.2177 
to m/z 163.1128 is shown. The pathway shows abstraction of both water and CO2 
and rearrangements of double bonds and neutral carbon atoms. 
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Figure 3.14. Fragmentation pathway of DXA3 from m/z 351.2177 to m/z 
163.1128 with dioxolane ring opening via 11-carbonyl. Fragmentation pathway 
based on MSn data of DXA3 performed on the Orbitrap Elite instrument as 
described in2.2.2 and 2.2.8. The fragmentation of the parent ion m/z 351.2177 to 
m/z 163.1128 is shown. The pathway shows abstraction of both a water and CO2 
molecule and rearrangements of double bonds and neutral carbon atoms. 
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Figure 3.15. Pathway of fragmentation of DXA3-d8 from m/z 359.2679 to m/z 
168.1442. Fragmentation pathway based on MSn data of DXA3 performed on the 
Orbitrap Elite instrument as described in 2.2.2 and 2.2.8. Depicted is the fragmentation 
of the parent ion m/z 359.2679 to m/z 168.1442. The pathway shows both abstraction 
of water and CO2 and rearrangements of double bonds and neutral carbon atoms. 
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3.2.1 DXA3 IS UV ACTIVE 
DXA3 was generated using COX-1 in vitro as described in 2.2.2. Lipid extract was analysed 
using LC/UV at 235 nm and fractions collected every 30 sec. MS analysis monitoring m/z 
351.2 to 165.1 demonstrated that DXA3 elutes at 47 min (Figure 3.16, Panel A). A lipid 
eluting at this retention time showed a UV spectrum (Figure 3.16, Panel B) similar to that 
for previous described dioxolanes, with a λmax at 238 nm (Figure 3.16, Panel C, Teder 
et al. 2015). Although this spectrum is weak, due to the low ng levels of DXA3 present, it 
is strong evidence for the presence of the conjugated diene at C12-C15. 
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Figure 3.16. DXA3 is UV active. DXA3 was generated using COX-1 in vitro as described in 
2.2.2. The lipid extract was analysed using LC-UV. DXA3 was identified using MS (2.2.7.1). 
(A) DXA3 elutes at 47 min in the UV chromatogram monitoring 235 nm. (B) UV spectrum 
of DXA3. (C) UV spectrum of conjugated dienes and monocyclic peroxides (Teder et al. 
2014).  
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3.3 DISCUSSION 
In this chapter I further confirmed the proposed structure of DXA3 to be 8-hydroxy, 9, 
11-dioxolane eicosatrienoic acid using two different MS approaches; GC/MS and 
LC/MSn.  
GC/MS analysis represents a traditional analytical tool for structural characterisation of 
lipids (Murphy & Gaskell 2011). To confirm the proposed structure, DXA3 was 
hydrogenated using Pd-C as shown for previously described dioxolanes (Roza & Francke 
1978; Yin et al. 2004). However, due to the extremely small amounts available, analysis 
was challenging. For studies presented herein, DXA3 derived from COX-1 in vitro was 
used. Although this approach yielded greater amounts of lipid than that generated by 
activated platelets derived from several donors (Chapter 7), additional isomers are 
formed during this reaction as shown in detail in Chapter 4. Therefore, the four peaks 
detected in the GC/MS chromatogram may be due to small amounts of contaminating 
isomers that were not separated during our chromatography. Additional ions observed 
in GC/MS spectra were detected throughout the entire chromatogram and are 
considered as background. The ions m/z 427, m/z 501 and m/z 517 appear with relative 
high abundance. As our synthetic protocol only yields low amounts of DXA3, background 
ions appear with high abundance relative to the hydrogenated and derivatised DXA3 m/z 
575.  
High resolution Orbitrap MS allow accurate mass analysis down to 1 ppm (O’Donnell et 
al. 2014; Perry et al. 2008). However, a mass range of 5 ppm is commonly used for ion 
identification, thus detecting DXA3 at m/z 351.2177 ± 0.002 Da. In combination with LC, 
this enabled the separation of this lipid from other COX-1 -derived lipids and generation 
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of MS/MS spectra, without prior purification. This was crucial as a pure DXA3 standard 
is not yet commercially available. Together with GC/MS analysis of hydrogenated DXA3, 
the fragmentation patterns of DXA3 and DXA3-d8 I developed from my high resolution 
dataset support the proposed lipid structure (Scheme 6). However, the stereochemistry 
of the three stereocentres (C8, C9 and C11) within DXA3 and positions of double bonds 
are yet to be determined and require further investigation. Therefore, ongoing 
collaborations aim to synthesise larger amounts of pure DXA3, which can then be used 
to further confirm our proposed structure. This will be further discussed in Chapter 9.1. 
The use of deuterated DXA3 was essential for this analysis. However, some details of 
fragmentation still remain unclear. For example, for one of the pathways it could not be 
determined whether a carbonyl group forms at C9 or C11 since the masses of the 
resulting fragment ion masses are identical for both (Figure 3.13, Figure 3.14). Using a 
deuterated arachidonate analogue with fewer deuterium atoms at fixed positions could 
clarify this but this is not currently commercially available.  
Herein, I showed that DXA3 derived from COX-1 in vitro has a similar UV spectrum as 
that of a structurally related dioxolane (Teder et al 2014). This indicates the presence of 
a UV chromophore, and thus, further supports our proposed conjugated diene at C12-
C15. In addition, the MS/MS spectrum of DXA3 shows m/z 155.1 as low abundant ion 
consistent with the product ion spectrum of 8-HETE (LipidMaps). This eicosanoid 
contains a hydroxyl group at C8, identical to the proposed structure for DXA3, and 
fragmentation between C8 and C9 results in generation of m/z 155.1. Therefore, this 
provides further evidence for our hypothesis that the hydroxyl group is located at C8. 
DXA3 represents a novel COX-1-derived lipid, which is structurally distinct to other COX 
products described previously and has never been shown to be generated by any cell 
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type to date. However, other studies have shown dioxolanes in vitro, variably identifying 
them as cyclic peroxides, monocyclic and serial cyclic dioxolanes, dioxolane isoprostanes 
or hydroxy-endoperoxides (Teder et al. 2014; Roza & Francke 1978; Havrilla et al. 2000; 
Yin et al. 2004). To date, no common nomenclature for this lipid class exists. Therefore, 
we proposed a name following the existing nomenclature system for prostaglandins 
described by Nelson (1974). The lipid stem name should be related to characteristic 
structural feature, e.g. dioxolane. As this lipid is the first described in its class it belongs 
to family A. Additionally, a numeric subscript was added indicating the number of double 
bonds resulting in dioxolane A3, abbreviated to DXA3. 
  
In conclusion, data presented in this chapter fully support the proposed covalent 
structure of DXA3. This is identical to a dioxolane previously shown to be generated in 
vitro through oxidation of 11-HpETE esterified to cholesterol (Havrilla et al., 2000). 
Therefore, in the next chapter I will investigate whether DXA3 forms via this in vitro 
oxidation reaction, using the free acid, and will compare this to DXA3 formed by human 
platelets and COX isoforms. 
. 
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4 CHAPTER FOUR 
GENERATION OF DXA3 BY PLATELETS, COX-1 AND 11-
HPETE OXIDATION IN VITRO 
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4.1 INTRODUCTION 
In Chapter 3, further evidence for the structure of a novel platelet COX product was 
obtained. This lipid is identical to the free fatty acid form of monocyclic oxidation 
products of cholesteryl -arachidonate esters, previously shown (Havrilla et al., 2000). 
However, to date no comparable data of both approaches exists. Havrilla et al. oxidised 
cholesteryl -arachidonate, purified the resulting cholesteryl -11-HpETE and oxidised this, 
leading to cholesteryl esters of mono and serial cyclic products (dioxolanes), and 
isoprostanes (Chapter 1, Scheme 1.3, Havrilla et al. 2000). For oxidation, a free radical 
initiator was used leading to an 11-hydroperoxyl radical (Scheme 1.). This indicates that 
the 11-hydroperoxyl radical is an essential intermediate in the resulting arachidonate 
derived dioxolane formation in vitro.  
The 11-hydroperoxyl radical also forms as an intermediate of COX reactions (Marnett et 
al. 1984). Briefly, during the COX cycle, arachidonate is oxidized forming the 11-
hydroperoxyl radical, which can either form PGG2 or be released from the catalytic site 
and reduced to first 11(R)-HpETE, then 11(R)-HETE, a well-known and abundant side 
product of COX reactions (Hamberg & Samuelsson 1967; Harman et al. 2004).  
In summary, the 11-hydroperoxyl radical is an intermediate of both, enzymatic and non-
enzymatic arachidonate oxidation, either of which can lead to dioxolane formation 
(Havrilla et al. 2000; Marnett et al. 1984). Therefore, in this chapter I will investigate 
whether DXA3 is formed during 11-HpETE oxidation in vitro and compare this data to 
that of DXA3 derived from arachidonate oxidation by COX-1 in vitro and activated 
platelets. This will further our understanding of its enzymatic generation pathway in 
platelets. 
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4.1.1 AIMS 
 Characterise DXA3 generation by COX-1 in vitro 
 Characterising DXA3 formation by oxidation of 11-HpETE as shown by Havrilla et 
al., 2000 
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4.2 RESULTS 
In this chapter, I used LC/MS/MS to compare MS/MS spectra from DXA3 generated by 
platelets (4.2.1), purified COX-1 (4.2.2) and oxidation of 11-HpETE in vitro (4.2.3).  
 
4.2.1 GENERATION OF DXA3 BY THROMBIN ACTIVATED PLATELETS 
Prior to my PhD, it was demonstrated that activated platelets generate DXA3 
(Aldrovandi, unpublished). Thus, platelet-derived lipid was compared with DXA3 
generated either by COX-1 or by 11-HpETE oxidation in vitro. For this, I isolated platelets 
from healthy human donors, activated them using 0.2 U/ml thrombin for 1 h followed 
by lipid extraction as described in 2.2.1.1, 2.2.1.3 and 2.2.5.1. LC/MS analysis 
demonstrated that four ions elute when monitoring the parent m/z of DXA3 at 351.2 
([M-H]-) (Figure 4.1, Panel A). PGE2 elutes at 32.2 min. A single peak was observed eluting 
at 49.67 min when monitoring DXA3 (Figure 4.1, Panel B). The product ion spectrum of 
this ion is shown in Figure 4.1, Panel C. Both retention time and spectra were used for 
identification of DXA3 generated by COX-1 and 11-HpETE oxidation in vitro. 
 
4.2.2 GENERATION OF DXA3 USING COX-1 IN VITRO 
To generate DXA3 by COX-1, I incubated the purified or recombinant holo enzyme and 
arachidonate substrate for 3 min at 37 oC. This was followed by lipid extraction as 
described in 2.2.2 and 2.2.5.1.  
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Figure 4.1. DXA3 generated by thrombin activated platelets. LC/MS/MS analysis of a 
lipid extract derived from thrombin activated platelets as described in 2.2.1.1, 2.2.1.3, 
2.2.5.1 and 2.2.7.3. (A) Chromatogram of lipids with a parent ion mass of m/z 351.2. 
PGE2 elutes at 32.2 min and DXA3 at 49.71 min. (B) Chromatogram of DXA3 monitoring 
m/z 351.2 to 165.1. A single peak elutes at 49.67 min. (C) MS/MS spectrum of DXA3 
eluting at 49.67 min in (A). 
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Several peaks eluted in the chromatogram when monitoring the parent ion mass (Figure 
4.2, Panel A). PGE2 was identified eluting at 32.18 min and DXA3 at 49.66 min (Figure 4.2, 
Panels B and C). However, when monitoring m/z 351.2 to 165.1 for DXA3, two additional 
peaks were seen, eluting at 47.76 min and 51.18 min (Figure 4.2, Panels B and C). These 
will be discussed in 4.2.4. 
 
4.2.3 IN VITRO OXIDATION OF 11-HPETE FORMS DXA3 
Havrilla et al. (2000) demonstrated that isoprostanes and mono and serial cyclic 
products are formed by a two-step oxidation of cholesteryl-arachidonate. To investigate 
whether DXA3 forms during this reaction, arachidonate was oxidised using the free 
radical initiator NMBHA and MeOAMVN under oxygen atmosphere as described in 2.2.3. 
The resulting 11-HpETE was HPLC purified and oxidized again using the same approach 
(2.2.4). Unsaturated fatty acids such as arachidonate are likely to oxidise under oxygen 
as used in this reaction. However, to fasten this reaction, a free radical initiator was 
used. Therefore, a reaction blank without initiator was not monitored. 
LC/MS/MS analysis demonstrated that several ions with similar abundance elute when 
monitoring the parent m/z of DXA3 (Figure 4.3, Panel A). Based on retention time and 
MS/MS, DXA3 was identified eluting at 49.56 min (Figure 4.3, Panels B and C). Two 
additional ions that elute at 47.70 min and 51.20 min were also detected (Figure 4.3, 
Panel B), identical to DXA3 derived from COX-1 in vitro (Figure 4.2, Panel B). These will 
be described in 4.2.4. 
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Figure 4.2. DXA3 is generated using COX-1 in vitro. LC/MS/MS analysis of lipid extract 
of an in vitro COX-1 reaction as described in 2.2.2, 2.2.1.3, 2.2.5.1 and 2.2.7.3. (A) 
Chromatogram of lipids monitoring the parent mass of m/z 351.2. PGE2 elutes at 32.18 
min and DXA3 at 49.65 min. (B) Chromatogram of DXA3 monitoring m/z 351.2 to 165.1 
showing three peaks eluting at 47.76 min, 49.66 min and 51.18 min. (C) MS/MS spectrum 
of peak eluting at 49.66 min in (panel B). LC/MS/MS analysis using an MRM experiment 
on the 4000 QTrap platform as described in 2.2.7.3. 
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Figure 4.3. DXA3 is generated using an oxidation of arachidonate followed by oxidation 
of HPLC-purified 11-HpETE in vitro. LC/MS/MS analysis of lipid extract of in vitro 
arachidonate oxidation. (A) Chromatogram of lipids monitoring a parent mass of 
m/z351.2. (B) Chromatogram of DXA3 monitoring m/z 351.2 to 165.1 displaying three 
peaks eluting at 47.70 min, 49.56 min and 51.20 min. (C) Spectrum of peak eluting at 
49.56 min (panel B). LC/MS/MS using MRM experiment on the 4000QTrap platform as 
described in2.2.7.3
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4.2.4 ISOMER FORMATION OF DXA3 IN IN VITRO APPROACHES 
DXA3 was generated by platelets, COX-1 and oxidation of 11-HpETE in vitro (4.2.1, 4.2.2 
and 4.2.3). However, two additional peaks, which elute close to DXA3, are observed in 
both in vitro approaches (Figure 4.4). The spectra of these additional peaks are identical 
to DXA3 and differ only in ion intensities (Figure 4.5, Figure 4.6). Identical spectra and 
close retention times indicate that these products are likely to be isomers, which are 
formed during the in vitro reactions. These are not seen in platelet lipid extracts. 
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Figure 4.4. DXA3 is generated by thrombin activated platelets, COX-1 and oxidation of 
arachidonate in vitro. Overlay of chromatograms monitoring m/z 351.2 to 165.1 shows 
only one peak eluting in lipid extract of thrombin activated platelets, Peak 2 (scattered 
line), whereas two additional peaks (Peak 1 and 3) elute in lipid extract of COX-1 (grey, 
solid line) and oxidation of arachidonate (black, solid line). Reversed phase LC/MS/MS 
analysis using MRM experiment on the 4000 QTrap platform as described in 2.2.7.3. 
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Figure 4.5. Two additional isoforms of DXA3 are formed using COX-1 in vitro. Shown 
are LC/MS/MS spectra of Peak 1 and Peak 3 in Figure 4.2 derived from COX-1 in vitro as 
described in 2.2.2. (A) Spectrum of Peak 1 eluting at 47.76 min. (B) Spectrum of Peak 3 
eluting at 51.18 min. Both spectra display identical product ions compared to DXA3 
(Figure 4.2, Panel C). LC/MS/MS using the 4000 QTrap platform as described in 2.2.7.3. 
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Figure 4.6. Two additional isomers of DXA3 are formed during oxidation of 11-HpETE 
in vitro. LC/MS/MS spectra of Peak 1 and Peak 3 eluting in Figure 4.3. (A) Spectrum of 
Peak 1. (B) Spectrum of Peak 3. Both spectra display identical product ions compared to 
DXA3 (Figure 4.3, Panel C). Sample preparation and LC/MS/MS analysis using the 4000 
QTrap platform as described in 2.2.3, 2.2.4 and 2.2.7.3. 
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4.3 DISCUSSION 
Studies presented herein demonstrate that DXA3 can be formed using three 
approaches: by thrombin activated platelets, oxidation of arachidonate using COX-1 
in vitro or 11-HpETE oxidation in vitro. Its formation via 11-HpETE oxidation indicates 
the 11- hydroperoxyl lipid radical is an essential intermediate. Thus, this lipid may 
also be an intermediate during COX-1 generation of DXA3 in platelets or by purified 
enzyme. While a single isomer is generated in platelets, two additional isomers are 
formed in vitro by COX-1 and 11-HpETE oxidation. This suggests an uncontrolled 
reaction often observed during autoxidation processes, that is absent in cells. Indeed, 
Aldrovandi et al. (unpublished) demonstrated that small amounts of DXA3-PEs are 
formed spontaneously in vitro using arachidonate and hematin but no enzyme 
suggesting an oxidative effect of hematin. This reagent was used for enzyme 
reconstitution in this study. Therefore, this might promote isomer formation during 
COX reactions.  
Isomer formation has also been described by Havrilla et al. (2000) during the two 
step oxidation of cholesteryl-arachidonate. Their monocyclic product, which has the 
same structure as DXA3, contains three stereocentres (Havrilla et al. 2000). These are 
shown in Scheme 4.1 for DXA3.  
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Scheme 4.1. Stereocentres in DXA3. 
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These stereocentres can give rise to four possible pairs of enantiomers (eight 
stereoisomers: RRR, RRS, RSR, RSS, SSS, SSR, SRS and SRR) of DXA3 (Havrilla et al. 
2000). As enantiomers cannot be distinguished using our LC/MS/MS, four peaks 
would be expected in the chromatogram. In reality, however, only three peaks were 
detected following in vitro generation of DXA3 (Figure 4.2, Figure 4.3). This 
observation may be explained if we consider the conformation of the stereocentres 
within the lipid which are present at positions C8, C9 and C11 with the dioxolane ring 
formed between C9 and C11 (Scheme 4.1). Applying the Cahn–Ingold–Prelog (CIP) 
sequence rules and considering the steric efficiency of dioxolane formation, the 
conformation of the stereocentres at C9 and C11 are likely to be the same (RRR, SSS, 
RSS, SRR) giving rise to two out of three peaks we observe in our chromatogram. In 
contrast, the less likely formed isomers (RRS, SSR, SRS, RSR) will appear with lower 
intensities or may not reach the limit of detection explaining why only three out of 
four pairs of enantiomers are detected. Alternatively, two pairs of enantiomers could 
coelute in our chromatography and appear as one peak, also potentially explaining 
the observation of three instead of four separate peaks. To investigate this further 
LC/MS/MS analysis in combination with a chiral HPLC-column could be used which 
enables differentiation between enantiomers. However, this methodology requires 
greater amounts of substrate than the LC/MS/MS techniques used herein. Therefore, 
this methodology may not be suitable for DXA3 analysis as only small amounts of 
lipids are available.  
As several products are formed in in vitro approaches which may coelute, a second 
transition in addition to m/z 351.2 to 165.1 could be added to the LC/MS/MS method 
allowing a more accurate identification when no MS/MS spectrum is monitored 
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alongside the MS/MS chromatogram. For example, m/z 351.2 to 271.1 as another 
very abundant fragment ion in the DXA3 spectrum (Figure 4.2, Panel C) could be used. 
 
In conclusion, my data suggests a 11-hydroperoxyl radical is an intermediate during 
DXA3 formation and that its generation in platelets occurs in a controlled manner. 
Other prostanoids are generated from PGH2 by specific synthases such as TxS 
downstream of COX (Haurand & Ullrich 1985; Shen & Tai 1986). To further investigate 
the enzymatic pathway by which DXA3 is generated in platelets, the role of three 
enzymes upstream (cPLA2) and downstream (TxS and peroxidase) of COX will be 
determined in the following chapter. Also, to further investigate whether 11-
hydroperoxyl radical escape from the active site plays a role in enzymatic DXA3 
formation, I will study two recombinant COX-2 mutants, which were a kind gift of Dr 
Larry Marnett (Vanderbilt University, Nashville, USA). These allow greater escape of 
the 11-hydroperoxyl radical from the active site, and consequently generate more 
11(R)-HETE but less PGH2 than wildtype COX-2. Thus, I will use these enzymes to 
determine whether DXA3 is generated as a result of 11-hydroperoxyl radical escape 
from the active site. 
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5 CHAPTER FIVE 
ENZYMATIC PATHWAY OF DXA3 FORMATION 
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5.1 INTRODUCTION 
Prostanoid synthesis is regulated by the expression, tissue distribution and activity of 
PLA2s, COXs, and additional specific synthases that act downstream of COXs. PLA2s 
control the availability of arachidonate, which is hydrolysed from phospholipids of 
the intracellular membrane (Harizi et al. 2008; Makoto Murakami et al. 2011). In 
particular, cPLA2 is the key player in eicosanoid generation since cells lacking this are 
unable to generate these lipids (Tramposch et al. 1994; Brooke et al. 2014; Riendeau 
et al. 1994; Bartoli et al. 1994). Inhibition of cPLA2 in vitro using a pharmacological 
inhibitor leads to decreased eicosanoid levels including DXA3  indicating that its 
generation depends on cPLA2 (Aldrovandi, unpublished; Riendeau et al. 1994; Brooke 
et al. 2014). To further caracterise this, I utilised platelets derived from a cPLA2α 
deficient patient and assessed their DXA3 generation in response to thrombin 
stimulation. In this patient a homozygous 4 bp deletion (155574_77delGTAA) within 
the cPLA2α gene suppresses expression of this enzyme. This abolishes TxA2 synthesis 
and impairs platelet aggregation. The reduced eicosanoid levels are thought to cause 
further systemic complications including severe peptic and upper small-intestinal 
ulceration, extensive small-intestinal stricturing, fibrosis and fistulae, and multiple 
severe extraintestinal complications (Brooke et al. 2014).  
Hydrolysed arachidonate can then be oxidised by COXs to generate PGH2, which is 
subsequently utilised by synthases to form prostanoids including PGE2 and TxA2 
(Marnett 2000). However, as described in 1.3.3.4, COXs also generate 11- and 15-
HETEs as side products (Xiao et al. 1997; M Hamberg & Samuelsson 1974). These 
form when the 11- and 15-hydroperoxyl radicals escape from the COX active site, 
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instead of finishing the catalytic cycle. Mutations within the catalytic domain of COX 
lead to enhanced formation of PGG2 and 15(S)-HETE (mutant V349L oPGHS-1) or 
11(R)-HETE (mutant V349A/W387F) (Thuresson et al. 2000; Harman et al. 2004). In 
Chapter 4, I proposed that the 11-hydroperoxyl radical is an intermediate in DXA3 
formation. Furthermore, the structure of DXA3 suggests that this lipid is unlikely to 
originate from PGH2 itself. Consequently, we reasoned that DXA3 formation occurs 
prior to PGH2 release. To determine whether DXA3 is formed from the escaping 11-
hydroperoxyl radical (thus, whether the dioxolane ring forms before or after radical 
escape), I will investigate DXA3 formation by wildtype (WT) COX-2 and the mutants 
V349A and W387F. If the 11-hydroperoxyl radical escapes and then becomes the 
dioxolane ring, then COX mutants predominantly generating 11(R)-HETE should yield 
greater DXA3 amounts than WT enzyme. 
Earlier, I showed that three DXA3 isomers form during in vitro generation, but not in 
platelets (Chapter 4) suggesting additional regulation of formation in these cells. 
Indeed, the formation of other platelet COX-1 products requires additional enzymatic 
control. For example, TxA2 (structure shown in Table 1.1), the most abundant COX 
product in platelets, is synthesised from PGH2, which is released by COX-1, by 
thromboxane synthase (TxS). In this chapter I will investigate whether additional 
enzymes are involved in DXA3 generation by targeting two enzymes in platelets that 
act downstream of COX-1 specifically peroxidases and TxS. Inhibition of peroxidases 
using iodoacetate decreases generation of 12-HHTrE (structure shown in Table 1.1), 
a product of COX-1 and TxS in platelets (Sutherland et al. 2001). This compound 
modifies cysteine residues preventing oxidation of SH side groups of glutathione and 
proteins. Consequently, it acts as a universal peroxidase inhibitor, likely through 
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removing reducing substrates. Separately, TxS will be inhibited by picotamide, a 
derivative of methoxy-isophtalic acid (Violi et al. 1988; Berrettini et al. 1990). 
 
5.1.1 AIMS 
 Examine DXA3 generation in human platelets derived from a cPLA2α deficient 
patient 
 Determine the role of TxS in DXA3 synthesis 
 Investigate the role of peroxidases in DXA3 generation 
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5.2 RESULTS 
In this chapter I investigated DXA3 formation by platelets, which were 
pharmacologically inhibited or showed a genetic deletion of cPLA2α, and using WT 
and mutant COX-2s in vitro. Eicosanoid generation was compared using LC/MS/MS 
and the ratios of the integrated peak area of DXA3, TxB2, PGE2, 11-HETE or 15-HETE 
compared to an IS. 
 
5.2.1 CPLA2Α DEFICIENT HUMAN PLATELETS ARE UNABLE TO GENERATE DXA3 
Platelets from a cPLA2α-deficient patient (Brooke et al. 2014) were isolated, activated 
using 0.2 U/ml thrombin and the lipids extracted and analysed using LC/MS/MS as 
described in 2.2.1.1, 2.2.1.3, 2.2.5.1 and 2.2.7.4. LC/MS/MS chromatograms of 
platelet lipid extracts indicate that DXA3 is generated by healthy donors following 
activation (Figure 5.1, Panels A and C) but not by platelets derived from a cPLA2α 
deficient patient (Figure 5.1, Panels B and D). 
 
5.2.1 LESS DXA3 IS GENERATED BY THE COX-2 MUTANTS V359A AND W387F 
Arachidonate was oxidised using WT and mutant COX-2 isoforms in vitro as described 
in 2.2.2. Lipids were extracted (2.2.5.1) and eicosanoid levels monitored using 
LC/MS/MS (2.2.7.4). As expected, 11-HETE formation is significantly increased in 
V359A and W387F (Figure 5.2, Panel A). In contrast, generation of 15-HETE was not 
affected (Figure 5.2, Panel D). Both DXA3 (Figure 5.2, Panel B) and PGE2  
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Figure 5.1. DXA3 generation by human platelets is cPLA2α dependent. Isolated 
human platelets (healthy donor and cPLA2α deficient) were activated for 30 min at 
37 oC using 0.2 U/ml thrombin as described in 2.2.1.1 and 2.2.1.3. Lipids were 
extracted and DXA3 (m/z 351.2 to 165.1) as well as PGE2-d4 (m/z 355.2 to 271.2, data 
not shown) monitored using LC/MS/MS as described in 2.2.5.1 and 2.2.7.4.  
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Figure 5.2. DXA3 generation is decreased in COX-2 mutants that predominantly 
generate 11-HETE. Arachidonate was oxidised using WT COX-2 or COX-2 mutants 
(V349A, W387F) as described in 2.2.2. Eicosanoids were analysed utilizing LC/MS/MS 
(2.2.7.4). Ratios (analyte/IS) and representative chromatograms of (A) 11-HETE and 
(B) DXA3, (C) PGE2, and (D) 15-HETE. In chromatograms black is W387A, green is 
V349A, and red is wt. n=5-7 ± SEM, ***p  0.005, one way ANOVA followed by 
Bonferroni multiple comparisons test. 
 139 
 
(Figure 5.2, Panel C) formation was significantly decreased in V359A and W387F 
compared to WT COX-2. 
 
5.2.2 TXS INHIBITION DOES NOT AFFECT DXA3 GENERATION BY PLATELETS 
To inhibit TxS, isolated platelets from three individual donors were treated with 50 μM 
of the TxS inhibitor picotamide prior to 0.2 U/ml thrombin (2.2.1.3). Extracted 
eicosanoids were analysed using LC/MS/MS (2.2.5.1, 2.2.7.4). DXA3 generation was not 
affected by picotamide (Figure 5.3, Panel A). In contrast, PGE2 formation was 
significantly increased and TxB2 generation decreased by about 50% (Figure 5.3, Panels 
B and C). 
 
5.2.3 PEROXIDASE INHIBITION DECREASES DXA3 GENERATION BY PLATELET  
Isolated platelets from three individual donors were treated with 1-10 mM iodoacetate 
prior to activation using 0.2 U/ml thrombin (2.2.1.3). TxB2 levels were decreased at 1 
mM inhibitor (Figure 5.4, Panel C). In contrast, DXA3 and PGE2 generation were 
decreased at higher inhibitor concentrations (Figure 5.4, Panels A and B). 
 
5.2.3.1 AN ADDITIONAL DXA3 ISOMERS IS FORMED FOLLOWING PEROXIDASE INHIBITION IN 
PLATELETS 
LC/MS/MS demonstrates that a single DXA3 isomer is formed by thrombin activated 
platelets (Figure 5.5, red). However, an additional isomer was seen to elute at 6.36 min 
in the chromatogram of iodoacetate-treated platelets (Figure 5.5, black).  
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Figure 5.3. DXA3 formation is not affected by TxS inhibition in platelets. Isolated human 
platelets were treated with 50 μM picotamide or ethanol (vehicle), then activated using 
0.2 U/ml thrombin as described in 2.2.1.1 and 2.2.1.3. Control: untreated platelets. 
Eicosanoids were analysed using LC/MS/MS as described in 2.2.7.4. (A) DXA3 (black), (B) 
PGE2 (grey) and (C) TxB2 (white). Thrombin activated platelets set as fold change 1. 
Triplicates of three donors ± SEM are shown. 
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Figure 5.4. Peroxidase activity is required for DXA3 formation. Isolated platelets were 
treated using 1-10 mM iodoacetate prior to activation using 0.2 U/ml thrombin (2.2.1.1, 
2.2.1.3). LC/MS/MS was utilised to analyse eicosanoid levels as described in 2.2.7.4. (A) 
DXA3 (black), (B) PGE2 (grey) and (C) TxB2 (white). Thrombin activated platelets set as 
fold change 1. Triplicates of three donors ± SEM are shown. 
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Figure 5.5. Isomers of DXA3 are formed in platelets following peroxidase inhibition. To 
inhibit peroxidases, isolated platelets were treated using 2 mM iodoacetate 10 min prior 
to activation using 0.2 U/ml thrombin (2.2.1.1, 2.2.1.3). DXA3 was monitored using 
LC/MS/MS as described in 2.2.7.4. LC/MS/MS chromatogram of DXA3 with (black) and 
without (red) inhibition of peroxidases using 2 mM iodoacetate. One donor as 
representative of three genetically unrelated donors, repeated at least three times. 
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5.3 DISCUSSION 
The rate-limiting step of eicosanoid synthesis is the hydrolysis of arachidonate from 
phospholipids by cPLA2 as described in 1.3.3.1. The genetic deficiency of the gene 
encoding for cPLA2α results in absence of the protein in the intestine causing 
inhibition of TxA2 formation and decreased platelet aggregation (Brooke et al. 2014). 
My data showed that DXA3 generation is blocked in platelets from a cPLA2α deficient 
patient (5.2.1). This indicates that DXA3 generation depends on cPLA2α in vivo and 
confirms results using cPLA2 inhibitors in vitro obtained prior to my PhD (Aldrovandi, 
unpublished). The major physiological importance of eicosanoids is demonstrated by 
the patients’ medical conditions that include small bowel ulceration, stenosis of 
unknown aetiology (cryptogenic multifocal ulcerous stenosing enteritis (CMUSE)), 
and failures in immune responses indicated by repeated infections by Candida 
albicans, Campylobacter, Salmonella, and Staphylococcus (Brooke et al. 2014). 
Indeed, cPLA2α is associated with efficient neutrophil-mediated bacterial killing and 
therefore, its deficiency may be responsible for these infections (Rubin et al. 2005). 
The biological function of DXA3 is yet to be fully understood. However, in Chapter 8 I 
will demonstrate that this lipid increases integrin expression on neutrophils 
suggesting a role of DXA3 in early immune responses and acute inflammation. 
Therefore, as DXA3 represents a cPLA2α dependent eicosanoid, its deficiency may 
play a role in the immune related medical conditions of the patient but this requires 
further investigation. 
Prior to my PhD it was demonstrated that the signalling pathway upstream of COX 
that activates DXA3 generation is the same as for other COX products (Aldrovandi, 
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unpublished). Thus, in this Chapter I investigated the enzymatic mechanism of COX 
that leads to the formation of this unique lipid, and the involvement of other 
enzymes that may act downstream of COX in platelets. My studies showed that, in 
comparison to other COX products, DXA3 formation is affected differently by COX 
mutations and inhibition of either TxS or peroxidases in platelets. Inhibition of TxS 
will lead to an increase in its substrate, PGH2. This could then non-enzymatic 
rearrange to PGE2 explaining the increase in its levels following TxS inhibition (Figure 
5.3, Figure 5.6, F). DXA3 formation was not inhibited by picotamide, indicating that 
TxS or PGH2 are not required for DXA3 generation. Peroxidase inhibition decreased 
DXA3 levels indicating that peroxidase function is required for its formation by 
platelets. In addition, I demonstrated that DXA3 isomers were formed during 
peroxidase inhibition (Figure 5.6, I). Isomers also form during DXA3 generation by 
COX-1 and 11-HpETE oxidation in vitro (4.2.4). Thus, the greater control of DXA3 
generation to form only one isomer in platelets may be facilitated by a peroxidase. 
As both oxidation and reduction is required to form DXA3 following C8 radical escape, 
an enzyme exhibiting both functions may account for DXA3 generation downstream 
of COX. Cytochrome P450s represent such enzymes and have been demonstrated to 
facilitate synthesis of certain prostanoids including TxA2 and PGI2 (Hecker & Ullrich 
1989; Brash 2009). Furthermore, P450 -derived products such as 8, 9-
epoxyeicosatrienoic acid (8,9-EET) and 14, 15-EET can be used by COX yielding epoxy-
hydroxy products and by LOX forming dioxolanes in vitro (Zhang et al. 1992; Teder et 
al. 2014). Thus, P450 enzymes are potential candidates for DXA3 synthase activity in 
platelets.  
 
 145 
 
 
 
Figure 5.6. Proposed formation of DXA3 by COXs. Oxidation of arachidonate by COX 
leads to PGH2 formation. Mutations within the COX active site result in decreased 
DXA3 and PGE2 levels, and increased 11(R)-HETE levels (G, green). TxS inhibition using 
picotamide does not affect DXA3 levels (H, purple). Inhibition of peroxidases using 
iodoacetate leads to decreased DXA3 levels and isomer formation (I, blue). A full 
description of this pathway is shown in 5.3. 
 
 146 
 
Last, studies were undertaken to investigate DXA3 generation by the COX-2 mutants 
V359A and W387F (Figure 5.2), which form greater levels of 11(R)-HETE than WT 
COX-2 as a result of increased 11-hydroperoxyl radical escape from the COX active 
site (Harman et al. 2004). My data showed that DXA3 levels generated by these 
mutants are significantly decreased compared to WT enzyme (Figure 5.2, Figure 5.6, 
G). This indicates that DXA3 formation does not involve the escape of the 11-
hydroperoxyl radical. COXs are known to facilitate endoperoxide ring closure 
between C9 and C11 during catalysis (Marnett 2000). Therefore, I propose that the 
dioxolane ring of DXA3 forms between C11 and C9 within the COX catalytic site, then 
the radical delocalises to C8 (Figure 5.6, B). As PGH2 may not be an intermediate 
during DXA3 generation (Figure 5.6, H), I suggest that this radical then escapes from 
the enzyme (Figure 5.6, C), rather than completing the COX catalytic cycle (Figure 5.6, 
F). Then, the C8 radical is further oxidised forming an 8-hydroperoxyl radical (Figure 
5.6, D). Finally, this radical is reduced, possibly by a peroxidase, to a hydroxyl group 
(Figure 5.6, E) forming 8-hydroxyl-9, 11-dioxolane eicosatrienoic acid (DXA3).  
As the C11 of the escaping 11-HETE has an (R) configuration, DXA3 would have the 
same stereochemistry at this position (Harman et al. 2004; Thuresson et al. 2000). 
Therefore, investigating the stereochemistry of DXA3 would further support my 
proposed structure. 
 
My proposed mechanism includes the escape of a carbon centred radical at C8. 
Previously described enzymatic mechanisms of COX show that this radical is 
delocalised to C15 when continuing the COX cycle and then oxidised at this position 
in order to form PGH2 (Marnett 2000). In addition, a carbon-carbon bond forms 
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between C8 and C12, which is not seen in my proposed DXA3 structure (Figure 5.6, 
F). Consequently, it is unlikely that DXA3 originates from an intermediate that is 
formed later than the C8 radical. As a novel mechanistic pathway proposed for COX, 
this requires further investigation that may include genetic mutations of the COX 
catalytic site aiming to increase escape of the C8 radical.  
 
In conclusion, in this chapter I confirmed that DXA3 generation requires cPLA2. Its 
formation by and/or downstream of COX is distinct to that of other prostanoids and 
suggests the potential involvement of a specific synthase with peroxidase activity.  
Eicosanoids represent a large group of lipid mediators present in several cell types 
and tissues. Therefore, in the following chapter I will investigate whether DXA3 is 
generated by leukocytes and detectable in human serum following clot induction in 
vitro.  
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6 CHAPTER SIX 
DXA3 IN HUMAN SERUM AND RAW246.7 CELLS 
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6.1 INTRODUCTION 
Platelets are important mediators of haemostasis and play a role in early immune 
responses. Under healthy conditions, platelets circulate in a resting state in the 
blood. As described in 1.2.3.1, platelet activation subsequently leads to thrombus 
formation in prevention of bleeding. Apart from this physiological role, thrombi 
also form on the surface of atherosclerotic plaque and their rupture is a high risk 
factor for coronary artery diseases (CAD) that include stable and unstable angina, 
myocardial infarction and sudden coronary death (Badimon & Vilahur 2014; Libby 
2005). At atherosclerotic lesions, activated platelets release bioactive mediators 
including growths factors and cytokines that lead to smooth-muscle proliferation 
and leukocyte recruitment promoting disease progression (Huo & Ley 2004). 
Furthermore, CAD and atherosclerosis are associated with elevated levels of 
activated platelets and eicosanoids including TxA2 (Theken et al. 2012; Simon et 
al. 1989; Baker et al. 1999; Belton et al. 2000; Furman et al. 1998; Trip et al. 1990). 
To determine whether DXA3 could play a role in thrombus formation, I will 
investigate its generation during blood clot formation in vitro. To determine 
whether DXA3 levels are altered in circulating platelets in atherosclerosis, its 
generation will be analysed in platelets of murine ApoE deficient mice, a murine 
strain that spontaneously develops this disease with age.  
Eicosanoids are not only involved in cardiovascular events, but also play an 
important role during inflammation. In leukocytes these lipids are predominantly 
generated by macrophages expressing COX-1 and COX-2 (Harizi et al. 2008). Prior 
to this study, it was shown that DXA3 is formed in vitro by both isoforms, COX-1 
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and COX-2 (Aldrovandi, unpublished). Therefore, in this chapter, I will investigate 
DXA3 formation in the macrophage cell line RAW264.7, which expresses COX-2 
upon LPS stimulation (Rouzer 2005).  
 
6.1.1 AIMS 
 Determine the presence of DXA3 in human serum and blood clots 
 Examine DXA3 generation by murine platelets and comparison of WT and 
ApoE deficient mice 
 Determine DXA3 formation in the macrophage cell line RAW264.7 
 
 
 151 
 
6.2 RESULTS 
In this chapter I investigated whether DXA3 can be detected in human serum and 
blood clots (6.2.1), murine platelets derived from WT and ApoE deficient mice 
(6.2.2), and stimulated RAW264.7 cells (6.2.3). These analyses were undertaken 
using LC/MS/MS and comparison of the obtained integrated peak areas ratios 
(lipid/IS). 
 
6.2.1 DXA3 IS PRESENT IN HUMAN SERUM DURING THROMBUS FORMATION 
During thrombus formation, platelets are activated leading to the release of 
bioactive mediators including eicosanoids. To determine whether DXA3 is formed 
during clotting, whole blood was incubated for 15 min at 37 oC without anti-
coagulant until a blood clot was formed. The serum was isolated and the lipids 
extracted from both, the blood clot and serum as described in 2.2.1.5 and 2.2.5.1. 
DXA3 was detected using LC/MS/MS and compared to an activated platelet 
sample as positive control (Figure 6.1, Panel A; Figure 6.2, Panel A). DXA3 was 
detected in serum (Figure 6.1, Panel C, E, G) and clot (Figure 6.2, Panel C) of three 
genetically unrelated donors.  
 
6.2.2 DXA3 LEVELS ARE IDENTICAL IN THROMBIN ACTIVATED PLATELETS DERIVED FROM 
WILDTYPE AND APOE DEFICIENT MICE 
Platelets of wildtype and ApoE deficient mice were isolated and activated using 
0.2 U/ml thrombin. Following lipid extraction DXA3, PGE2, TxB2 and 12-HETE were 
monitored using LC/MS/MS as described in2.2.1.2, 2.2.5.1 and 2.2.7.4.  
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Figure 6.1. DXA3 is detectable in human serum. Whole blood was incubated at 
37 oC for 15 min until a blood clot was formed. Serum was isolated using 
centrifugation. Isolated platelets were activated using 0.2 U/ml thrombin. Lipids 
were extracted and analysed using LC/MS/MS as described in 2.2.1.5, 2.2.5.1 and 
2.2.7.4. MS/MS chromatograms of DXA3 and PGE2-d4 in platelet (A) and serum (B-
D). Serum was obtained from three genetically unrelated donors. 
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Figure 6.2. DXA3 is detectable in human blood clot in vitro. Whole blood was 
incubated at 37 oC for 15 min until a blood clot was formed as described in 2.2.1.5. 
Isolated platelets were activated using 0.2 U/ml thrombin (2.2.1.1, 2.2.1.3). Lipids 
were analysed using LC/MS/MS as described in 2.2.5.1 and 2.2.7.4. MS/MS 
chromatograms of DXA3 or PGE2-d4 derived from platelets (A) and blood clot (B). 
Shown is one donor as representative of three genetically unrelated donors. 
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DXA3 was monitored in murine platelets (Figure 6.3). Its levels and that of PGE2, 12-
HETE and TxB2 were increased following thrombin activation (Figure 6.3 A-D). They 
did not differ between WT (black) and Apo E deficient (grey) mice. 
 
6.2.3 DXA3 IS GENERATED BY THE MACROPHAGE CELL LINE RAW264.7  
RAW264.7 cells were cultured to a confluence of 90% (2.2.1.8), activated with 200 
ng/ml LPS and/or 1 μM calcium ionophore A23187 (2.2.1.9) and the lipids extracted 
and analysed using LC/MS/MS (2.2.5.1, 2.2.7.4).  
Both PGE2 and DXA3 were absent in the culturing medium DMEM (Figure 6.4, Panel 
A). DXA3 was detected at low levels in untreated (control) and LPS treated cells 
(Figure 6.4, Panels B and D). Ionophore activation increased DXA3 (Figure 6.3, Panel 
D), but it was not further enhanced by LPS (Figure 6.4, D). In contrast, PGE2 was 
generated on treatment with LPS but not A23187 (Figure 6.4, Panels B, C, and D). LPS 
and A23187 also increased PGE2 compared to LPS alone (Figure 6.4, Panel E). PGD2 is 
detected in the same MS/MS chromatogram eluting at 4.05 min under basal 
conditions (Figure 6.4, Panel B). It increased following treatment with A23187 but 
not LPS (Figure 6.4, Panels C, D, and E). These data demonstrate that DXA3 formation 
requires A23187 but is unaffected by inflammatory stimulation. Therefore, 
generation of this lipid most likely to occurs via COX-1 but not COX-2 in RAW246.7 
cells. 
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Figure 6.3. Eicosanoid levels do not differ in platelets from WT and ApoE deficient 
mice. Isolated platelets from either WT or ApoE deficient mice were activated using 
0.2 U/ml thrombin, lipids extracted and analysed using LC/MS/MS as described in 
2.2.1.2, 2.2.5.1 and 2.2.7.4. (A) DXA3, (B) PGE2, (C) 12-HETE and (D) TxB2. Lipid levels 
are shown as ratios of integrated peak areas (lipids/IS).  
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Figure 6.4. DXA3 is generated by RAW264.7cells following calcium ionophore A23187 
activation. RAW264.7 cells were activated using 10 μM calcium ionophore A23187 for 
10 min at 37oC. In some experiments cells were stimulated using 200 ng/ml LPS for 24 
h at 37oC prior to A23187 treatment. LC/MS/MS chromatograms of lipid extracts 
derived from RAW264.74 cells of DXA3 (m/z 351.2 to 165.1) and PGE2 (m/z 351.2 to 
271.1) in (A) DMEM, (B) unstimulated cells, (C) A23187, (D) LPS and (E) both LPS and 
A23187 treated cells. Sample preparation and analysis as described in2.2.1.8, 2.2.1.9, 
2.2.5.1 and 2.2.7.4. 
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6.3 DISCUSSION 
In this chapter I demonstrated that DXA3 is detectable in human serum and blood clot 
during thrombus formation in vitro, in calcium ionophore A23187 activated RAW264.7 
cells and in murine platelets following thrombin activation.  
During thrombus formation circulating platelets rapidly adhere to the site of injury. 
Their interactions with exposed proteins such as von Willebrand factor (VWF) lead to 
activation. Adhesion induces intracellular signalling, which subsequently leads to 
synthesis and secretion of secondary platelet agonists such as TxA2, which promotes 
platelet aggregation and together with fibrinogen results in blood clot formation 
(Nieswandt et al. 2011; Savage et al. 1998). Serum and blood clot samples tested in 
this study were obtained from whole blood without anti-coagulant, following 
spontaneous platelet activation and eicosanoid formation as indicated by TxB2 
detected in serum (not shown). In addition to this, DXA3 (Figure 6.1) and PGE2 (not 
shown) were detected in both serum and blood clots. During clot formation, TxA2 
contributes to further platelet activation and aggregation in vivo (Paul et al. 1999; Kroll 
& Schafer 1989). Therefore, DXA3 may facilitate similar effects. However, this requires 
further investigation including determining the effect of DXA3 on platelet activation as 
discussed later in 9.6. 
Herein, I showed that DXA3 generation is conserved among two species. I also 
investigated whether DXA3 formation is altered in platelets derived from ApoE 
deficient compared to WT mice. Atherosclerotic lesions develop with age, and are 
larger and more advanced in female ApoE deficient mice than male (Caligiuri et al. 
1999; Paigen et al. 1987). Levels of 12-HETE, DXA3, TxB2 and PGE2 were not different in 
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activated platelets from WT and ApoE deficient mice (Figure 6.3) indicating similar 
eicosanoid generation and platelet reactivity in vitro in both strains. However, I have 
only investigated their generation ex vivo. In vivo, elevated TxB2 (and its metabolite 
2,3-dinor TxB2) levels have been detected in serum (or urine) of ApoE deficient mice 
compared to WT. These levels were decreased following aspirin treatment (Praticò et 
al. 2000). Therefore, eicosanoid generation including that of DXA3 may be different in 
vivo between both strains. To further investigate this, future studies may determine 
DXA3 levels in serum of ApoE deficient and WT mice. 
Data obtained prior to my PhD revealed that DXA3 is generated by both COX-1 and 
COX-2 in vitro (Aldrovandi, unpublished). To investigate its cellular generation by COX-
2, I analysed DXA3 formation by RAW264.7 cells. These express COX-2 following a 24 
hrs LPS stimulation (Rouzer 2005). COX-2 expression and its activation is coupled to 
increased PGE2 generation (Giroux & Descoteaux 2000). Indeed, I found that LPS 
stimulation led to generation of PGE2 indicating COX-2 upregulation. In contrast, DXA3 
was generated in A23187-activated RAW cells basally, and this was not elevated by 
LPS. This suggests a potential isoform-specific generation of this lipid in cells. To 
investigate this, future studies may investigate DXA3 generation in RAW264.7 cells 
upon selective COX-1 and COX-2 inhibition.  
 
In conclusion, my data suggests that DXA3 generation is a local response to platelet 
activation during clot formation in vitro. The lipid is also generated by COX-1 in a 
macrophage cell line. Therefore, further investigation may determine whether DXA3 
generation is cell, COX isotype, and stimulus specific. 
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To determine whether a DXA3 is likely to be biologically relevant, it is important to 
quantify its levels generated by human and murine platelets and compare them to the 
amounts of other platelet-derived eicosanoids. Therefore, in the next chapter I will 
develop a quantitative assay and quantify DXA3 as both free fatty acid and esterified 
to PE in thrombin activated platelets.  
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7 CHAPTER SEVEN 
QUANTIFICATION OF DXA3 GENERATED BY PLATELETS 
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7.1 INTRODUCTION 
DXA3 represents a novel COX-1 product, thus no synthetic standard or other reagents 
to quantify this lipid are currently available. To determine DXA3 levels generated by 
platelets and compare the amounts to other eicosanoids, I will develop a quantitative 
assay and assess the amounts of DXA3, PGE2, TxB2 and 12-HETE in human and murine 
platelets. 
Several methods are available for eicosanoid quantification including LC-UV, LC-MS, 
radioimmunoassay, and GC-MS (Schweer et al., 1985, Walenga et al., 1985, Kiyomiyaet 
al., 1986; Sweeney et al., 1987; Kurosawa et al., 1990, Miller and Weyker, 1990). 
However, synthetic standards are essential for all of these methods. In this study, I will 
generate a DXA3 standard curve utilising radiolabelled [14C]-arachidonate and quantify 
DXA3 in biological samples using LC/MS/MS (Bruins 1998; Deems et al. 2007; Margalit 
et al. 1996). Minor changes in extraction efficiencies and retention times of the LC/MS 
are corrected by adding an internal standard (IS) before lipid extraction. To allow 
accurate quantification, an IS should ideally be structurally and chemically identical to 
the lipid of interest (Ho et al. 2003). The simplest way to achieve this is by using stable 
isotope modified standards, e.g. PGE2-d4 for PGE2 (Murphy et al. 2005). However, when 
an isotope standard is not available, lipids with similar structure can be employed as 
ISs in combination with a primary unlabelled standard identical to the molecule of 
interest (Ho et al. 2003). Therefore, I generated DXA3 as primary standard, which was 
used to construct a standard curve with PGE2-d4 as IS as described in 7.2.3.  
As DXA3 can be esterified to four PE species (16:0p, 18:0p, 18:1p and 18:0a) following 
platelet activation, I will also quantify the esterified forms (Aldrovandi et al., 
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unpublished). To achieve this, I will quantify free DXA3 before and after hydrolysis of 
total platelet lipids as described in 7.2.4 and shown previously for PGE2-PE (Aldrovandi 
et al. 2013).  
 
7.1.1 AIMS 
 Establish a quantitative assay for DXA3 
 Determine the amounts of free and esterified DXA3 generated by isolated human 
platelets 
 Quantify the amount of free DXA3 generated by isolated murine platelets 
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7.2 RESULTS 
Currently, DXA3 is not available as a commercial standard. Therefore, I generated [14C]-
DXA3 by COX-1 oxidation of [14C]-arachidonate in vitro as described in 2.2.2. A [14C]-
DXA3 standard curve was generated and analysed using LC/MS/MS (7.2.2). This 
standard curve was then used to quantify unlabelled DXA3 also generated by COX-1 
oxidation, using LC/MS/MS. Finally, a standard curve was generated using unlabelled 
DXA3, with PGE2-d4 as the IS (7.2.3), for quantification of the lipid in biological samples 
(7.2.4 and 7.2.5).  
 
7.2.1 GENERATION OF A [14C]-ARACHIDONATE STANDARD CURVE 
In this approach the molar amounts of [14C]-arachidonate and [14C]-DXA3 are directly 
comparable since one mol [14C]-arachidonate is converted to one mol [14C]-DXA3: 
 
Therefore, [14C]-DXA3 can be quantified by radioactivity, using a [14C]-arachidonate 
standard curve. This was generated within the limit of detection of the LC 
radiochemical detector, equivalent to a maximum of 30 Bq [14C]-arachidonate. The 
integrated peak areas of varying [14C]-arachidonate activity amounts (6 - 30 Bq) were 
calculated and the resulting standard curve used for [14C]-DXA3 quantification (Figure 
7.1). 
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Figure 7.1. [14C]-arachidonate standard curve. A [14C]-arachidonate standard curve in 
the range of 6 - 30 Bq [14C] was monitored using a LC radioflow detector as described 
in 2.2.7.1. The integrated peak areas were calculated and plotted against the Bq values 
of [14C]-arachidonate. 
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7.2.2 GENERATION OF A [14C]-DXA3 STANDARD CURVE 
[14C]-DXA3 was generated by oxidation of [14C]-arachidonate by COX-1 in vitro as 
described in 2.2.2. Several peaks elute when monitoring [14C] in the lipid extract of this 
enzyme reaction (Figure 7.2). Fractions were collected at 30 second intervals and [14C]-
DXA3 identified using MS/MS monitoring m/z 353.2 to 165.1 eluting at 50.5 min on the 
LC-radiochemical system. Using the [14C]-arachidonate standard curve (Figure 7.1), the 
radioactivity of the [14C]-DXA3 peak was determined to be 25.5 Bq [14C]. As [14C]-DXA3 
amounts are directly comparable to that of [14C]-arachidonate, this equals 51.3 ng 
[14C]-DXA3. 
A [14C]-DXA3 standard curve was generated (0.01 – 10 ng) and analysed utilizing 
LC/MS/MS as described in 2.2.7.3. The lipid elutes at 49.5 min on the Q-Trap platform 
(Figure 7.3, Panels A and B). As MS analysis (2.2.7.2) of the substrate, [14C] 
arachidonate, revealed that only 66 % was radiolabelled (Figure 7.4), the [14C]-DXA3 
levels were corrected by this percentage resulting in a specific [14C]-DXA3 standard 
curve in the range of 0.06 – 6.6 ng (Figure 7.3, Panel C). This standard curve was 
employed to quantify unlabelled DXA3 also generated by COX-1 in vitro (7.2.3). Thus, 
the transition for [14C]-DXA3 at m/z 353.2 to 165.1 was directly compared for integrated 
area with that for cold DXA3, at m/z 351.2 to 165.1. 
 
7.2.3 GENERATION OF A DXA3 STANDARD CURVE 
Unlabelled DXA3 was generated using COX-1 in vitro (2.2.2) and analysed using 
LC/MS/MS (2.2.7.3). The DXA3 peak was integrated and quantified using the [14C]-DXA3 
standard curve. Then, a second DXA3 standard curve was generated with  
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Figure 7.2. [14C]-derived from COX-1 in vitro is detected when monitoring [14C] 
labelled lipids on an LC radioflow detector. [14C]-DXA3 was generated using COX-1 in 
vitro and analysed using LC with radioflow detection as described in 2.2.2 and 2.2.7.1. 
A chromatogram derived from the [14C] labelled lipid extract is shown. Fractions were 
collected every 30 sec and lipids identified using MS/MS on the 4000 QTrap as 
described in 2.2.7.3. The peak eluting at 50.5 min was identified as [14C] - DXA3. 
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Figure 7.3. LC/MS/MS analysis of the [14C]-DXA3 standard. [14C]-DXA3 was generated using 
COX-1 in vitro as described in 2.2.2. [14C]-DXA3 was quantified by comparing the 
radiochemical response to [14C]-arachidonate. (A) LC/MS/MS monitoring [14C]-DXA3 
eluting at 49.5 min. (B) MS/MS spectrum of [14C]-DXA3. (C) [14C]-DXA3 standard curve. 
Integrated peaks area of [14C]-DXA3 vs. [14C]-DXA3 amounts [ng]. LC/MS/MS analysis on 
the 4000 QTrap instrument as described in 2.2.7.3. 
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Figure 7.4. The majority of the [14C]-arachidonate standard is radiolabelled. To 
determine its radiolabelled content, the standard was analysed using a Q1 scan m/z 
100 - 400 following direct injection (2.2.7.2).  
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varying amounts of unlabelled DXA3 (0.01 - 10 ng) and constant PGE2-d4 (100 pg) 
(Figure 7.5). To shorten analysis times a 30 min chromatography method was 
employed as described in 2.2.7.4. 
 
7.2.4 HUMAN PLATELETS GENERATE NANOGRAM AMOUNTS OF FREE AND ESTERIFIED 
DXA3 FOLLOWING THROMBIN ACTIVATION 
Next, using the standard curve, I quantified free and esterified DXA3 in human 
platelets. Free DXA3 was undetectable basally until activation of platelets using 
thrombin. Following activation DXA3 levels rise rapidly within 10 min of 
stimulation and increase steadily thereafter up to 2 hrs. This trend is also observed 
for TXB2, 12-HETE and PGE2 as shown for three representative donors in Figure 
7.6. Eicosanoid synthesis was highly variable between genetically unrelated 
donors (Figure 7.7) with an average of 14.23 ± 3.33 ng DXA3, 60.3 ± 35.57 ng TxB2, 
683.55 ± 147.85 ng 12-HETE, and 8.45 ± 2.26 ng PGE2/2 x 108 platelets (n = 6 - 10, 
mean ± SEM) generated at 30 min post thrombin activation. For all donors DXA3 
levels generated were greater than those observed for PGE2, but lower than 12-
HETE. Interestingly, in two out of seven donors DXA3 levels were greater than TxB2 
levels. 
  
To quantify relative levels of esterified vs. free DXA3, lipid extracts from thrombin 
activated platelets were analysed before and after hydrolysis using snake venom 
cPLA2 as described in 2.2.1.2, 2.2.1.4 and 2.2.7.4. Simultaneously, the hydrolysis 
efficiency was calculated to be 83.8 % by monitoring the levels of all four DXA3- 
PE species remaining after hydrolysis using LC/MS/MS (2.2.7.5). 
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Figure 7.5. DXA3 standard curve. A standard curve was generated with varying 
amounts of DXA3 and integrated peak areas (DXA3/PGE2-d4) plotted.  
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Figure 7.6. DXA3 is generated in comparable amounts to other eicosanoids by 
human thrombin activated platelets. Isolated platelets were activated using 0.2 
U/ml thrombin for 0, 10, 30 or 120 min and the lipids extracted as described in 
2.2.1.1 and 2.2.1.3. DXA3, TxB2, 12-HETE and PGE2 were quantified using 
LC/MS/MS (Panels A, B and C), (three genetically unrelated donors, triplicates ± 
SEM). Analysis was undertaken on the 4000 QTrap (ABSciex) using a biogenic DXA3 
standard curve as described in 2.2.7.4.  
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Figure 7.7. Eicosanoid generation by thrombin activated platelets varies 
between donors. Isolated platelets from healthy donors (n=6 – 10) were activated 
using 0.2 U/ml thrombin for 30 min and the lipids extracted as described in 2.2.1.1 
and 2.2.1.3. (A) TxB2, and (B) 12-HETE, (C) DXA3 and (D) PGE2 were quantified using 
LC/MS/MS. Genetically unrelated donors ± SEM. One way Anova with Bonferroni 
post hoc test, **** p≤0.0001, *** p≤0.001. Analysis was undertaken on the 4000 
QTrap (ABSciex) using a biogenic DXA3 standard curve as described in 2.2.7.4.  
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This was used to correct DXA3 levels measured post-hydrolysis. Before hydrolysis 
7.3 ± 2.2 ng DXA3 / 2 x 108 platelets (n = 4, mean ± SEM) was detected. Following 
hydrolysis a total of 26.5 ± 6.8 ng DXA3 / 2 x 108 platelets was found (Figure 7.8). 
Taking the hydrolysis efficiency into consideration, 31.6 ± 8.1 ng DXA3 /2 x 108 
platelets were calculated to be esterified to PE. This indicates that the majority 
(77 %) of DXA3 is present in esterified form in activated human platelets. 
 
7.2.5 MURINE PLATELETS GENERATE DXA3 FOLLOWING THROMBIN ACTIVATION 
Both platelet 12-LOX and COX-1 utilise arachidonate after it is hydrolysed from PL 
(Holinstat et al. 2011). Therefore, when LOX is inhibited, then more arachidonate 
could be available for COX turnover. To determine the effect of LOX inhibition on 
its synthesis by murine platelets, DXA3, 12-HETE, PGE2 and TxB2 were quantified 
in murine C57BL/6J WT and 12-LOX deficient cells. Isolated murine platelets were 
activated using 0.2 U/ml thrombin and lipids extracted and analysed using 
LC/MS/MS as described in 2.2.1.2, 2.2.1.3 and 2.2.7.4. As for human platelets, WT 
platelets generated higher levels of DXA3 than PGE2, but the DXA3 amounts were 
lower than that of TxB2 or 12-HETE (Figure 7.9). 12-LOX deficient platelets 
generated higher levels of DXA3, TxB2 and PGE2 compared to WT (Figure 7.9, 
Panels A, C and D). As expected the absence of 12-LOX results in undetectable 12-
HETE in these platelets (Figure 7.9, Panel B). 
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Figure 7.8. Two-thirds of DXA3 are esterified to PE. DXA3 and DXA3-PE were 
generated by activation of platelets using 0.2 U/ml thrombin as described in 
2.2.1.1 and 2.2.1.3. Quantification of free DXA3 was undertaken using LC-MS/MS 
(2.2.7.4). Free DXA3 generated by platelets was quantified. Following hydrolysis of 
PLs using snake venom PLA2 (2.2.1.4), free DXA3 was quantified again. 
Simultaneously, PE was analysed using LC-MS/MS (2.2.7.5) and PE/DMPE ratios 
used for calculation of hydrolysis efficiency. Shown is the amount of free (black), 
esterified (white) and total (grey) DXA3 in ng / 2 x 108 platelets in four donors, for 
each donor triplicates, mean ± SEM.  
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Figure 7.9. Murine platelets generate DXA3. Isolated platelets from C57BL/6J WT 
(black) and 12-LOX deficient (white) mice were activated using 0.2 U/ml thrombin as 
described in. (A) DXA3, (B) 12-HETE, (C) TxB2 and (D) PGE2 were quantified in 
unactivated (control) or following 30 min thrombin activation. Eicosanoid amounts 
are shown in ng / 2 x 108 platelets of three WT or 12-LOX deficient mice (n = 3, mean 
± SEM), *** p < 0.005 using one way ANOVA followed by Bonferroni multiple 
comparisons test. 
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7.3 DISCUSSION 
In this chapter, I generated DXA3 standard using COX-1 in vitro and quantified free 
and esterified DXA3 in human and murine platelets using a standard curve.  
When an isotope standard is not available, lipids with similar structure can be 
employed as ISs, such as PGE2-d4 which is used as an IS for DXA3 throughout this 
thesis (Ho et al. 2003). PGE2-d4 is structurally related to DXA3, which is not 
commercially available, and elutes close to DXA3 in our 30 min LC method. Therefore, 
my quantification method accounts for ionisation differences as DXA3 was used as 
primary standard and possible retention time shifts. However, a disadvantage of this 
approach is that due to the structural differences that exist between PGE2-d4 and 
DXA3, it cannot account for differences in extraction efficiency. Therefore, stable 
isotope labelled DXA3 would be preferable for quantification, and generation of this 
will be a future goal.  
My assay enabled quantification of DXA3 in biological samples. The lipid was detected 
in ng amounts, and was higher than PGE2 and lower then 12-HETE. Interestingly, 
greater DXA3 levels than TxB2 were observed in two out of seven donors 30 min post 
thrombin activation. TxB2 is the stable metabolite of the pro-aggregatory TxA2, one 
of the most abundant COX products in platelets (Hamberg et al. 1975). Donor 
variability in COX products generation by platelets is well known. For example, the 
generation of 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT) is also 
donor-dependent with levels greater than that of TxB2 in some individuals 
(Matsunobu et al. 2013). This natural variation in eicosanoid generation may be due 
to different expression levels of COX, cPLA2, TxS and also receptor-dependent 
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signalling proteins in platelets. Both 12-HHT and TxA2 are physiologically important 
platelet lipids playing a role in haemostasis and immunity and signal at low 
nanomolar concentrations (Okuno et al. 2008; Hamberg et al. 1975). Although DXA3 
generation was as variable as that of 12-HHT, its concentration in vivo, target 
receptors and signalling pathways are yet to be identified. This will be further 
discussed in 8.3 and 9.5. 
In 12-LOX deficient platelets the enzymatic pathway of LOX is genetically absent. In 
theory, this could lead to increased arachidonate levels that would then be available 
for COX resulting in a higher turnover rate of this enzyme. In agreement with this 
idea, increased levels of COX products including PGE2, TxB2 and DXA3 were observed 
along with reduced 12-HETE as shown in Figure 7.8. This also indicates that DXA3 
generation is independent of 12-LOX function.  
Our group recently discovered eicosanoid-esterified PLs including DXA3-PE, PGE2-PE, 
12-HETE-PLs or 14-hydroxydocosahexaenoic acid (HDOHE)-PEs (Morgan et al. 2010; 
Thomas et al. 2010; Aldrovandi et al. 2013; Aldrovandi et al. unpublished). In contrast 
to DXA3, the majority of 12-HETE is generated as a free fatty acid (40 - 60 ng / 2 x 107 
platelets) rather than esterified to PLs (5 - 18 ng / 4 x 107 platelets) (Thomas et al. 
2010). Similar trends were recently described for PGE2 (3.8 ng / 2 x 108 platelet) and 
PGE2-PE (28 pg / 2 x 108 platelet) (Aldrovandi et al. 2013, and unpublished data). In 
contrast, I found that 77 % of DXA3 is formed esterified to PE following thrombin 
activation. A common characteristic of esterified eicosanoids including DXA3-PE is 
their membrane association (Aldrovandi et al. 2013; Aldrovandi et al, 
unpublished;Thomas et al.2010, Aldrovandi et al. unpublished). Oxidised PLs contain 
polar groups and can protrude from the membrane surface into the aqueous space 
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as described for non-enzymatically generated analogues in the “Lipid Whisker 
Hypothesis” that proposes localisation of oxidised fatty acids attached to PL at the 
extracellular space (Greenberg et al. 2008). Our proposed DXA3 structure (Chapter 3) 
suggests a high polarity of this lipid due its oxygenated functional groups. Thus, DXA3-
PE may protrude from the membrane surface, similar to other non-enzymatically-
generated oxidised PL. This may promote interactions with external proteins such as 
coagulation factors or leukocyte adhesion receptors, which associate with negatively 
charged surfaces on activated platelet (Hemker et al. 1983).  
 
In conclusion, data presented herein indicate that DXA3 generation is donor 
dependent but levels are comparable between murine and human platelets. 
Together with previous findings, which showed that DXA3 is generated using 
endogenous substrate and by platelet following activation with a physiological 
agonist, my data suggests that DXA3 is biologically relevant (Aldrovandi, unpublished; 
Chapter 4, discussed in Chapter 9.5). Thus, to investigate the role of DXA3 on 
leukocyte activation, in the next chapter I will determine the effect of this lipid on 
integrin expression by human neutrophils. 
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8 CHAPTER EIGHT 
DXA3 INCREASES AND PRIMES THE FMLP RESPONSE ON 
MAC-1 EXPRESSION BY NEUTROPHILS  
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8.1 INTRODUCTION 
Neutrophils are one of the first immune cells populations recruited to sites of 
infection and they play a key role in host defence in innate immunity. Basally, 
neutrophils patrol the circulation within blood vessels. During early infection they are 
recruited by activated, adherent platelets, which tether to circulating neutrophils via 
selectins (Scheme 8.1). This leads to neutrophil activation and integrin expression on 
their surface resulting in formation of platelet-neutrophil complexes (PNCs). These 
form via interactions of P-selectin and P-Selectin glycoprotein 1 (PGSL-1), 
glycoprotein Ibα (GPIbα) and Mac-1 (CD18/CD11b), as well as intracellular adhesion 
molecule-2 (ICAM-2) and LFA-1 (CD18/CD11a) (Scheme 8.1) (Weber & Springer 1997; 
Buttrum et al. 1993; Palabrica et al. 1992; Jungi et al. 1986; Hamburger & McEver 
1990; Page & Pitchford 2013; Diacovo et al. 1996). In the presence of activated 
platelets, neutrophil adhesion to endothelial cells is increased in vitro and in vivo 
indicating a priming effect of PNCs on neutrophil chemotaxis and the requirement of 
platelets for firm neutrophil adhesion to the endothelium (Kirschenbaum et al. 2004; 
Mine et al. 2001; Sreeramkumar et al. 2014). This reveals a pro-inflammatory role of 
activated platelets. The activated neutrophils can then migrate to the site of infection 
where they contribute to host defence, for example by producing reactive oxygen 
species (ROS) to eliminate pathogens (Itoh et al. 2006; Nimeri et al. 2003). Neutrophil 
recruitment by platelets is mediated by chemokines and cytokines (Cox et al. 2011; 
Deuel et al. 1981; Deuel et al. 1982; Page & Pitchford 2013). Furthermore, 
eicosanoids such as 12-HETE, LTB4 and PGE2 decrease or increase neutrophil 
chemotaxis in vitro and in vivo either  
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Scheme 8.1. Activated platelets bind to neutrophils forming platelet-neutrophil 
complexes. (A) Activated platelets tether to circulating neutrophils and bind via 
selectins. (B) This results in neutrophil activation and expression of integrins leading 
to the formation of platelet-neutrophil complexes. (C) These interactions enhance 
other neutrophil functions as shown. Modified from Page & Pitchford 2013. 
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directly via receptor binding or indirectly by altering the generation of 
chemoattractant cytokines (Armstrong 1995; Yu & Chadee 1998; Lemos et al. 2009; 
Gimbrone et al. 1984; Lindbom et al. 1982; Stenson & Parker 1980). However, a role 
for other COX-derived lipids on neutrophil chemotaxis is not known. Therefore, in 
this chapter I will investigate the ability of DXA3 to activate neutrophils. Specifically, I 
will examine neutrophil Mac-1 expression in response to DXA3 stimulation using flow 
cytometry. This integrin is expressed on activated neutrophils and required for firm 
adhesion to both platelets and endothelial cells, (Issekutz & Issekutz 1992; Osborn 
1990; Evangelista et al. 1996; Evangelista et al. 1999). 
 
8.1.1 AIM 
 Investigate the ability of DXA3 to activate human neutrophil Mac-1.  
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8.2 RESULTS 
DXA3 was generated using COX-1 in vitro as described in 2.2.2. Neutrophils were 
isolated from whole blood and treated with either DXA3 alone or in combination with 
fMLP as described in 2.2.1.6. The cells were stained using an anti-CD11b antibody 
(2.2.1.7), which recognises the active form of CD11b (Mac-1). 
 
8.2.1 GATING STRATEGY 
The gating strategy for this experiment was designed using untreated neutrophils, as 
shown in Figure 8.1. Isolated neutrophils were stained using anti-human CD11b 
AlexaFluor647 antibody, and analysed utilizing the CyAn ADP (Beckman). The live 
neutrophil population was gated, representing 94.8 % of the total cells (Figure 8.1, 
Panel A). In order to exclude neutrophil aggregates from the analysis, a doublet 
exclusion gate was applied plotting the FSC-H against FSC-W and the singlets gated 
as shown (Figure 8.1, Panel B). Using doublet discrimination, 99.5 % of the cells within 
the neutrophil gate are single cells. The singlets were then plotted as histograms 
showing Mac-1 fluorescent cells in modal mode (Figure 8.1, Panel C), which scales all 
channels as a percentage of the maximum count. Gates within the histogram were 
set as Mac-1 negative (Mac-1 neg) and Mac-1 positive (Mac-1 pos). 
. 
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Figure 8.1. Gating strategy for isolated neutrophils. Human neutrophils were 
isolated from whole blood and stained using anti-human CD11b AlexaFlour647 
antibody as described in 2.2.1.6 and 2.2.1.7. (A) Site scatter Log (SS Log) vs 
Forward Scatter Log (FS Log). 94.8 % of all cells are neutrophils. (B) Neutrophil 
singlets (99.5 %) were gated using FS Area vs. FS Lin. (C) Histogram of unstained 
neutrophils. Gates set as Mac-1 negative and positive. Flow cytometric analysis as 
described in 2.2.10. 
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8.2.2  DXA3 INCREASES MAC-1 EXPRESSION BY NEUTROPHILS 
Human neutrophils were incubated with 10 μM DXA3 or vehicle control and / or 10 
μM fMLP as described in 2.2.1.6 and 2.2.1.7.  
Basally approximately 12 % of neutrophils were positive for Mac-1 (Figure 8.2, Panel 
E, untreated). This increased significantly to 35 % following fMLP (Figure 8.2, Panels 
A and E) and 25 % following DXA3 treatment (Figure 8.2, Panels B and E). To 
investigate the effect of DXA3 upon the fMLP response, neutrophils were incubated 
with vehicle or 10 nM DXA3 10 min prior to fMLP. Treatment with vehicle control also 
enhanced the proportion of Mac-1 positive neutrophils (Figure 8.2, Panels C and E). 
However, treatment of neutrophils with DXA3 before fMLP significantly increased the 
proportion of Mac-1 positive neutrophils to 42 % compared to vehicle control (Figure 
8.2, Panels C, D and E).  
 
8.2.3 DXA3 PRIMES NEUTROPHIL RESPONSES TO FMLP 
To test whether DXA3 has a priming effect, isolated neutrophils were treated with 1 
- 10 nM DXA3 alone or prior to fMLP as described in 2.2.1.6 and 2.2.1.7. These 
concentrations of DXA3 alone did not increase Mac-1 expression (data not shown). 
When neutrophils were treated with 1 or 5 nM DXA3 prior to fMLP no difference in 
Mac-1 expression was observed compared to vehicle control (Figure 8.3, Panels A 
and B). In contrast, 10 nM DXA3 prior to fMLP increased Mac-1 expression 
demonstrating a priming effect upon the fMLP response (Figure 8.3). 
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Figure 8.2. 10 μM DXA3 increases Mac-1 expression by neutrophils. Isolated human 
neutrophils were treated with 10 μM DXA3 and / or 10 μM fMLP as described in 
2.2.1.6 and 2.2.1.7. Histograms of neutrophils following treatment with (A) 10 μM 
fMLP, (B) 10 μM DXA3, (C) vehicle and 10 μM fMLP and (D) 10 μM DXA3, then 10 μM 
fMLP. Treatments (scattered) compared to controls (grey). (E) Vehicle and 10 μM 
fMLP, isotype control (scattered) compared to anti-CD11b (grey). One donor shown 
as representative of three. Counts normalized to the maximum count. Gates set on 
the vehicle control. Flow cytometric analysis as described in 2.2.10. (F) Mac-1 positive 
neutrophils (%) following 10 μM fMLP, 10 μM DXA3 or 10 μM DXA3 prior to 10 μM 
fMLP. n = 3, three genetically unrelated donors (mean ± SEM). *** p < 0.005, using 
one way ANOVA followed by Bonferroni multiple comparisons test.   
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Figure 8.3. 10 nM DXA3 primes fMLP activation of human neutrophils. Isolated 
neutrophils were incubated with varying concentrations of DXA3 and 10 μM fMLP 
and analysed using flow cytometry as described in 2.2.1.6, 2.2.1.7 and 2.2.10 (A) 
Histogram of vehicle and fMLP treated neutrophils stained with either anti-CD11b 
antibody or isotype control. (C-D) Histograms showing Mac-1 positive human 
isolated neutrophils following treatment with 1 - 10 nM DXA3 prior to 10 μM fMLP. 
For all panels vehicle control and fMLP (grey) vs. DXA3 and fMLP (scattered).A 
representative donor is shown of three independent experiments. Histograms 
were normalized to the maximum count. Gates set on the vehicle control. Flow 
cytometric analysis as described in 2.2.10. (B) Percentage of Mac-1 positive 
neutrophils following treatment with vehicle or 10 nM DXA3 prior to 10 μM fMLP. 
n = 3, genetically unrelated donors (mean ± SEM). *** p < 0.005, using one way 
ANOVA followed by Bonferroni multiple comparisons test. 
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8.3 DISCUSSION 
In this chapter I demonstrated that DXA3 promotes Mac-1 expression on human 
neutrophils. DXA3 was generated using arachidonate oxidation by COX-1 in vitro 
yielding a total of 5 μg. Thus, functional studies were limited due to the very low DXA3 
amounts available.  
Eicosanoids are known to exert diverse effects upon neutrophils. For example, LTB4 
or 5-oxo EET signal via BLT1, BLT2 or the OXO receptor mediating Mac-1 expression 
on neutrophils associated with neutrophil adhesion to the endothelium and 
therefore chemotaxis (Crooks & Stockley 1998; Tager & Luster 2003; Powell & 
Rokach, 2005; Grant et al. 2009; Futosi et al. 2013). PGE2 affects several neutrophil 
functions via interactions with EP receptors expressed on the neutrophil surface such 
as inhibition of neutrophil chemotaxis via the EP2 receptor (Yamane et al. 2000; 
Armstrong 1995). It also mediates IL-23/IL-17-induced neutrophil migration by 
inhibiting IL-12 and IFNα generation in a murine model of rheumatoid arthritis 
suggesting distinct roles in health and disease (Lemos et al. 2009). In addition, PGE2 
inhibits superoxide generation, LTB4 release, TNFα production, and fMLP-induced 
aggregation but enhances IL-6 generation by neutrophils (Wise & Jones 1994; Wise 
1996; Wise 1998; Wheeldon & Vardey 1993; Talpain et al. 1995; Yamane et al. 2000). 
In this chapter, I demonstrated that DXA3 increases Mac-1 expression suggesting that 
this lipid regulates neutrophil functions. Therefore, DXA3 may mediate additional 
functions including ROS and NET formation, chemotaxis or chemokine production 
but this warrants further investigation. In addition, the signalling pathway and target 
receptor for DXA3 leading to Mac-1 expression is currently unknown. In order to aid 
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determination of whether DXA3 acts via receptor-dependent mechanisms, the 
concentration used herein can be compared to concentrations (Kd and EC50 or IC50 
values) of other eicosanoids required to mediate similar bioactivities in neutrophils. 
For example, LTB4 binds with high affinity to BLT1 (Kd = 0.39-1.5 nM) and low affinity 
to BLT2 (Kd = 22.7 nM) (Tager & Luster 2003). The latter is also a low affinity receptor 
for 12-HETE but and a high affinity one for 12-HHT (IC50 2.8 nM) (Okuno et al. 2008). 
Therefore, the DXA3 concentration used herein (10 nM) is similar to that which is 
bioactive for other eicosanoids supporting the idea that it could regulate neutrophil 
function in vivo. It is possible that DXA3 upregulates Mac-1 in neutrophils via a known 
receptor such as BLT1 or BLT2 (Futosi et al. 2013). This could be determined by 
pharmacological studies using receptor antagonists such as U-75302 (BLT-1) 
orLY255283 (BLT2) in combination with DXA3. 
Data presented herein demonstrated a priming effect of DXA3 upon the fMLP 
response. This finding suggests that DXA3 is an endogenous lipid mediator that alters 
the inflammatory response of neutrophils to exogenous stimuli.  
 
In conclusion, DXA3 increases Mac-1 expression at physiological concentrations, and 
thus, may promote the formation of PNCs and support neutrophil adhesion to the 
endothelium. However, further studies are necessary to identify target receptors, to 
understand the signalling pathway and to further investigate the effect of DXA3 upon 
neutrophil function.  
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9 CHAPTER NINE 
GENERAL DISCUSSION 
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In this thesis, I investigated the structure, enzymatic generation and biological 
actions of a novel COX product, which we termed DXA3. Structural elucidation 
demonstrated a unique structure for this lipid (Chapter 3), which is generated by 
COX-1 in activated platelets via an enzymatic pathway proposed to be distinct from 
other prostanoids (Chapters 4, 5 and 6). To directly quantify DXA3 generated by 
human and murine platelets in response to activation, a quantitative assay was 
developed which demonstrated that levels generated are comparable to other 
eicosanoids (Chapter 7). These lipids are important players in haemostasis and 
inflammation (Smith & Murphy 2002; Fahy 2005; Richardson et al. 2005; Semple et 
al. 2011; Giuliano & Warner 2002; Barrios-Rodiles et al. 1999; Caivano & Cohen 2000; 
Weller et al. 2007; Yu & Chadee 1998; Harris et al. 2002). Therefore, the ability of 
DXA3 to activate neutrophils was determined and showed that this lipid increases 
integrin expression on human neutrophils. This suggests a potential role in 
promoting early innate immune responses (Chapter 8). 
 
9.1 STRUCTURAL CHARACTERISATION 
Mass spectrometry represents an essential analytical tool in lipid research. Whilst 
GC/MS enabled the discovery of the first volatile eicosanoids during the 1960’s, the 
development of LC/MS during the 1980’s revolutionised the field of lipid biology 
(Hamberg & Samulsson 1967; Hamberg et al. 1975; Hamberg & Samuelsson 1967). 
Today the greater mass accuracy and sensitivity that LC/MS provides and the 
constant evolution of MS techniques including ionisation and precursor scanning has 
allowed the identification and structural characterisation of hundreds of non-volatile 
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lipids, including phospholipid-esterified eicosanoids and related lipids such as 
protectins and resolvins (Hong et al. 2007; Masoodi et al. 2008; Serhan et al. 2002; 
Schwab et al. 2007; Thomas et al. 2010; Maskrey et al. 2007; Morgan et al. 2009; 
Aldrovandi et al. 2013; O’Donnell et al. 2014; Murphy & Gaskell 2011; Perry et al. 
2008). Using extensive GC and LC/MS analysis, I proposed a covalent structure for 
DXA3 as described in Chapter 3. However, as LC/MS is unable to distinguish between 
enantiomeric structures, other techniques such as NMR will be required to fully 
characterise the stereochemistry of DXA3. Teder and colleagues recently used a 
similar multi-technique approach successfully for the structural elucidation of LOX-
derived dioxolanes (Teder et al. 2014). Preliminary LC-UV spectral data demonstrates 
a λmax at 238 nm, indicating the presence of conjugated dienes. This is comparable 
to the UV spectrum of a structurally similar dioxolane generated by purified LOX, and 
further supports the proposed structure (Teder et al 2014). To further determine the 
stereochemistry of this lipid, NMR studies are in progress in collaboration with Dr. 
Andy Watson (Bristol University, UK). However, NMR analysis requires μg to mg 
amounts of lipids; therefore, full characterisation is extremely challenging due to the 
current limited availability of DXA3.  
Levels of DXA3 generated by platelets are in the low ng range. Thus, in collaboration 
with Dr. Larry Marnett (Vanderbilt University, USA) I sought to establish an in vitro 
approach to generate greater quantities. Using ovine COX-1 isolated from seminal 
vesicles I was able to generate 5 μg of lipid. Whilst this was sufficient for the 
structural and functional data presented herein, to achieve full NMR analysis, high 
yield pure DXA3 is required. In association with Cayman Chemicals (Ann Arbor) and 
Prof. Alan Brash (Vanderbilt University, TN, USA) we are attempting to produce DXA3 
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enzymatically through the oxidation of 8, 9-EET by coral 8-LOX, which generates 
other dioxolanes from EETs (Teder et al. 2014). To maximize the likelihood of 
generating high-yield pure DXA3 we are also setting up a total synthesis approach in 
collaboration with Dr. Andy Watson and Prof. Varinder Aggarwal (Bristol University). 
Whilst these studies are challenging, the efficient and reproducible generation of a 
pure DXA3 standard would greatly enhance our ability to characterise its 
stereochemistry and biological functions.  
 
9.2 DIOXOLANES AS NOVEL LIPID MEDIATORS 
Arachidonate-derived dioxolanes were first discovered as products of cholesteryl 
arachidonate oxidation in vitro (Havrilla et al. 2000). However, to date no biological 
roles have been ascribed to these unusual lipids. A recent study by Teder et al. (2014) 
demonstrated that dioxolanes could be enzymatically generated via LOX in vitro but 
their formation in cells was not shown. Therefore, DXA3 represents the first 
dioxolane reported to be generated by both enzymatic and non-enzymatic 
arachidonate oxidation in vitro and in cells. In contrast to COX-1 and 11-HpETE 
oxidation where three isomers were generated, DXA3 is formed as a single isomer in 
platelets (4.2.4). In addition, the serial cyclic products observed by Havrilla et al. 
which contain more than one dioxolane ring, and are formed as additional oxidation 
products in vitro (Scheme 1.5), were not observed to be generated by platelets or 
COX in vitro (data not shown). This suggests a controlled generation of DXA3 by 
agonist activated platelets, whereby it is formed enzymatically and is consistent with 
our idea that DXA3 may play signaling physiological roles in innate immunity. Thus, 
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further studies are now required to investigate the generation and biological 
significance of this and other members of this lipid class during inflammation and 
innate immunity in cells and in vivo (Teder et al., 2014). 
 
9.3 ENZYMOLOGY OF DXA3 GENERATION 
Oxidation of arachidonate by COXs yields predominantly PGH2, whilst 11- and 15-
HETE are generated as side products via radical escape from the catalytic site 
(Marnett 2000; Harman et al. 2004; Thuresson et al. 2000). My studies suggest that 
DXA3 formation also includes a radical escape. However, my proposed mechanistic 
pathway is different to other COX products (5.2.2). I also demonstrated that DXA3 
generation requires peroxidase turnover (5.2.3). This may be mediated by a DXA3 
specific enzyme or by COX peroxidase itself. This is consistent with other prostanoids, 
which require specific synthases such as TxS downstream of COX, and requires 
further study to determine the enzymes that may be involved.  
Herein, I proposed a mechanism for COX -mediated dioxolane formation (Chapter 5). 
Teder and colleagues (2014) also described dioxolane generation via a mechanism in 
which P450-derived EETs are oxidised by LOX. Together, these studies change our 
current understanding of enzymatic eicosanoid generation and will stimulate further 
investigations into the enzymatic mechanism of dioxolane synthesis both in cells and 
in vitro. 
COX inhibition by NSAIDs is globally used to prevent cardiovascular events and 
dampen inflammation. Additionally, COX-1 selective NSAIDs plays an emerging role 
in the prevention of cancer metastasis (Rothwell et al. 2012; Algra & Rothwell 2012; 
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Rothwell et al. 2012). Therefore, determining both the enzymology of DXA3 
generation and its biological function could be of major future pharmacological 
interest. 
 
9.4 TISSUE DISTRIBUTION OF DXA3 
Eicosanoids represent a large group of bioactive lipids generated by a variety of cells 
and tissues. Their synthesis is catalysed by several enzymes including PLA2s, COXs, 
LOXs, as well as specific synthases such as TxS and PGIS (Smith & Murphy 2002; 
Hecker & Ullrich 1989; Naraba et al. 1998; Tramposch et al. 1994). Numerous studies 
have shown that eicosanoid generation is cell type dependent as it is regulated by 
the co-expression and (in)activation of their synthetising enzymes. Their synthesis is 
also controlled by the activating stimuli (Bos et al. 2004; Caughey et al. 2001; Ueno 
et al. 2001). For example, stimulation of rat peritoneal macrophages with A23187, a 
non-specific stimulant resulting in increased intracellular calcium levels, leads to 
preferential generation of TxB2 vs. PGE2. This is due to coupling of cPLA2, COX-1, and 
TxS. In contrast, LPS stimulation, which increases COX-2 expression, of these cells 
predominantly results in PGE2 synthesis via cPLA2, COX-2, and PGES (Naraba et al. 
1998; Matsumoto et al. 1997). Preliminary results showed that a mixed population 
of calcium ionophore A23187 activated leukocytes did not generate DXA3 but PGE2 
(data not shown) suggesting that its synthesis could be similarly controlled. To 
further determine this, future studies could investigate its synthesis by individual 
leukocyte populations following treatment using a series of reagents such as 
cytokines or TLR agonists. A stimulus specific synthesis of DXA3 would provide 
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insights into the signalling pathway that leads to generation of this lipid. As levels of 
certain eicosanoids are elevated during biological events, such as PGE2 during 
inflammation and TxA2 during haemostasis, identifying cells that synthesise DXA3 and 
stimuli that activate its generation would help to determine when its synthesis may 
be biologically relevant (Kurland & Bockman 1978; Yu & Heinen et al. 1986; Chadee 
1998; Nakayama et al. 2006; Wang & Lau 2006; Hamberg et al. 1975).  
 
9.5 DXA3 QUANTIFICATION 
In order to determine whether sufficient levels of DXA3 are generated to trigger 
receptor-dependent signaling, the lipid needs to be quantified and compared to 
other known lipid mediators. Different approaches can be used for this, including 
either calculated estimation or direct lipid quantification. Calculated estimation is 
based either on the amount of initial substrate used or on the detection of the total 
products generated (Podrez et al. 2002). However, this approach is less precise than 
direct quantification. Fatty acids can be directly quantified either as esterified methyl 
esters (FAME) using GC/MS or as free fatty acids using UV or LC/MS/MS (Dodds et al. 
2005; Le Faouder et al. 2013; Guarrasi et al. 2010; Carvalho et al. 2012). However, 
the limitation of these approaches is that they require pure lipid standards, which 
are not yet commercially available for DXA3. Alternatively, radiolabeled standards 
can be utilised which are synthesised de novo (Dreon et al. 2002; Nare et al. 1999; 
Rapoport 2005; Ho et al. 2016). Based on this approach I developed a quantification 
assay using [14C]-DXA3 derived from oxidation of [14C]-arachidonate by COX-1 
(Chapter 7). Although this enabled the quantification of DXA3 in biological samples, 
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it has minor limitations in its accuracy due to PGE2-d4 being used as an IS. Therefore, 
once DXA3 and its stable isotope analogue are synthetised, a new standard curve will 
be generated allowing a greater accuracy of quantification.  
Herein, I demonstrated that agonist activated platelets generate 14.23 ± 3.33 ng 
DXA3 / 2 x 108 platelets (n = 10 ± SEM, Chapter 7). As this is the average cell number 
per ml blood, it would in theory equal to 0.04 nmol DXA3/ml blood, if all the platelets 
were activated, and is equivalent to an approximate concentration of 40.4 nM (Thon 
et al. 2012). Although this concentration remains theoretical, it allows comparison 
with concentrations of other eicosanoids known to be required for receptor 
signaling. TxA2 mimetics and 12-HETE mediate their signaling functions, such as 
platelet activation and neutrophil chemotaxis with receptor dependent affinities 
(ranging between low-high nanomolar concentrations) (Hamberg et al. 1975; Ko et 
al. 1995; Burch et al. 1985; Dorn et al. 1997; Armstrong et al. 1993; Paul et al. 1999; 
Ohkubo et al. 1996; Goetzl et al. 1980; Reynaud & Pace-Asciak 1997; Guo et al. 2011; 
Herbertsson et al. 1999). In addition, 12-HHT activates the leukotriene receptor 
BLT2, expressed by neutrophils, at an IC50 of 2.8 nM (Okuno et al. 2008; Matsunobu 
et al. 2013). This suggests that DXA3 will be generated at sufficient concentrations to 
mediate receptor-dependent signaling in vivo.  
Eicosanoid esterified PLs can be indirectly quantified using LC/MS/MS (Morgan et al. 
2009; Aldrovandi et al. 2013; Maskrey et al. 2007; A. H. Morgan et al. 2010). For this, 
the fatty acid, which is esterified to the PL, is hydrolysed from the lipid and 
subsequently quantified (Morgan et al. 2009; Aldrovandi et al. 2013; Maskrey et al. 
2007). For example, PGE2-PE levels generated by activated platelets were 
determined by quantification of PGE2 before and after lipid hydrolysis using snake 
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venom cPLA2 (Aldrovandi et al. 2013). An identical approach was used herein to 
quantify DXA3-PE. To increase accuracy, future experiments could include de novo 
synthesis of deuterated DXA3-PE as a standard. This may be generated via 
esterification of deuterated DXA3 into lyso-PE using rat liver microsomes, which 
contain a set of enzymes involved in fatty acid metabolism including long chain fatty 
acyl-CoA synthetase (LC-FACS) and lysophospholipid acytransferase (LPAT), as shown 
for arachidonate-d8 esterified to PE (Shindou et al. 2013; Suzuki et al. 1990; 
Aldrovandi, PhD thesis, 2013). However, as a pure deuterated DXA3 standard is yet 
to be synthesised, this would be part of further studies. 
 
9.6 NEUTROPHIL ACTIVATION 
Prostanoids play important roles in inflammation and haemostasis (Smith & Murphy 
2002; Fahy 2005; Richardson et al. 2005; Semple et al. 2011; Giuliano & Warner 2002; 
Barrios-Rodiles et al. 1999; Caivano & Cohen 2000; Weller et al. 2007; Yu & Chadee 
1998; Harris et al. 2002). To investigate their biological effects, pure lipid standards 
are required. These enable functional assays to be undertaken, either on isolated 
cells and tissues in vitro or in vivo. Although arachidonate oxidation by COX-1 in vitro 
was used to yield higher amounts of DXA3 than generated by platelets, the overall 
quantity synthesised was too low to enable a full functional characterisation of the 
role of the lipid in vivo. 
Herein, I investigated the effect of DXA3 on leukocyte activation by determining the 
ability of DXA3 to upregulate integrin expression by neutrophils (Chapter 8). This is a 
major event in response to activation of leukocytes and is required for the formation 
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of PNCs and neutrophil adhesion to the endothelium (Page & Pitchford 2013). 
Specifically, upon activation, neutrophils express the intergrin Mac-1 (CD11b/CD18), 
which is responsible for their binding to both platelet and endothelial cells (Pitchford 
et al. 2005; Kirton & Nash 2000; Konstantopoulos et al. 1998; Evangelista et al. 1996). 
In my studies, I found that DXA3 stimulates and primes Mac-1 expression by 
neutrophils in vitro (8.2.2 and 8.2.3). Further studies are warranted to determine 
whether DXA3 only increases Mac-1 expression, or if it mediates a similar effect upon 
other integrin family members such as PSGL-1 (Moore et al. 1995; Xiao et al. 2006; 
Schmidtke & Diamond 2000).  
DXA3 was found to be generated by activated platelets (Aldrovandi, unpublished; 
Chapter 4). These can recruit and activate neutrophils at a site of injury leading to 
increases in neutrophil adhesion to the endothelium, transendothelial migration, 
NET formation and ROS production (Dole et al. 2012; Singbartl et al. 2001; 
Miedzobrodzki et al. 2008; Suzuki et al. 2001; Caudrillier et al. 2012; Clark et al. 2007; 
Lam et al. 2011; Carestia et al. 2016). The aformentioned studies identified that 
platelet surface receptors such as TLR4 or P-selectin play a role in these activities. 
However, the involvement of eicosanoids in platelet-neutrophil interactions remains 
poorly understood. NET formation and ROS production are activated by free and 
esterified 5-HETE (Clark et al. 2011). However, effects of COX products on neutrophil 
functions are unknown. Since DXA3 activates integrin expression, it may also mediate 
further neutrophil functions, which could be investigated in future studies. For 
example, the ability of DXA3 to modulate neutrophil migration could be examined by 
determining the expression of adhesion molecules such as JAM-A and PECAM-1 
(Woodfin et al. 2007; Ostermann et al. 2002).  
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The formation of PNCs is thought to be a key event in inflammation, with platelets 
promoting neutrophil adhesion and migration. These interactions also have been 
observed in atherosclerosis, asthma, various bacterial infections, sepsis and sickle 
cell disease (Ott et al. 1996; Pamuk et al. 2006; Asaduzzaman et al. 2009; Pitchford 
et al. 2003; Zarbock et al. 2006; Gawaz et al. 1995; Polanowska-Grabowska et al. 
2010; Langer et al. 2012; Setianto et al. 2010; Johansson et al. 2011, Sreeramkumar 
et al. 2014, Lievens et al. 2010). Thus, determining the role that DXA3 may play in 
chronic diseases warrants further study. This could include in vivo studies to examine 
the effect of DXA3 on leukocyte recruitment in murine models of inflammatory 
disease such as atherosclerosis and infection. 
In pilot studies not presented herein, I examined the ability of DXA3 to activate 
platelets. Preliminary data suggested that it can increase P-selectin expression (data 
not shown). However, due to the low amounts of DXA3 available, these studies could 
not be repeated. Consequently, once synthetic DXA3 is available, future work will 
include investigating the role of DXA3 in platelet activation and aggregation.  
It is important to investigate both the effects of DXA3 on receptor expression and its 
signalling via target receptors. Therefore, once sufficient lipid is available, 
pharmacological studies will investigate whether DXA3 signals via known eicosanoid 
receptors such as for BLT2, which is known to be activated by eicosanoids including 
LTB4, 12- and 15-HETE, 12-HpETE, and 12-HHT (Tager & Luster 2003; Yokomizo et al. 
2001; Toshiaki Okuno et al. 2008; Okuno et al. 2015; Matsunobu et al. 2013).  
9.7 Summary 
To summarise, I have demonstrated that DXA3 is a new COX-derived lipid of likely 
physiological importance. Due to its activation of integrin expression on neutrophils, 
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I propose that DXA3 potentially facilitates pro-inflammatory signaling in vivo. This will 
be followed up in future studies on its generation and role in inflammatory vascular 
disorders such as atherosclerosis. In particular, if DXA3 is a pro-inflammatory 
eicosanoid, then it could represent a potential therapeutic target for chronic 
inflammatory disease.  
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